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Abbreviations
Units
k = 103 
n = 109
m = 10'3
p = 1012
-611 = 10 
f = 1015
bp = base pairs
A = Amperes
A = Angstroms
° C = degrees centrigrade
M = molar
h = hours
sec = seconds
cps = counts per seconds
ppm = parts per million
kb = kilo base pairs 
V = Volts 
Ci = Curies 
g = grammes 
m = metres 
mol = moles
rpm = revolutions per minute 
cpm = counts per minutes
Chemicals/Reagents
Ac20  = acetic anhydride
AcOH = acetic acid
APS = ammonium persulfate
ATP = adenosine triphosphate
dNTP = deoxynucleoside triphosphate
DMAP = 4-(dimethylamino)pyridine
DCC = N, V-dicycylohexylcarbodiimide
DMF = dimethyl formamide
DNBSC1 = 2, 4-dinitrobenzene sulfenyl chloride
DNP = 2, 4-dinitrophenyl
DTT = dithiothreitol
EDTA = ethylenediaminetetraaceticacid (disodium salt) 
FDNB - l-fluoro-2, 4-dinitrobenzene
IAF = 4(5)-(iodoacetamido)-fluorescein
IPTG = isopropyl-p-D-thiogalactopyranoside
KOAc = potassium acetate
MeCN = acetonitrile
NaSH -= sodium hydrosulfide
PMSF = Phenylmethylsulfonyl fluoride
sec-BuLi = secondary butyllithium
SDS = sodium dodecyl sulfate
TEMED = N, N, N', N'- tetramethylethylenediamine
THF = tetrahydrofuran
Tris = rm-(hydroxymethyl)aminoethane
8 = chemical shift (ppm)
The abbreviations used in the experimental section (Chapter 2) are routinely used 
in Organic Chemistry.
Other terms
ori = origin of replication 
Xr = resistance to X 
IR = infrared 
Rf = relative fraction 
J = coupling constant 
m/z = mass/charge ratio 
8 = extinction coefficient
PAGE = polyacrylamide gel electrophoresis
NMR = nuclear magnetic resonance
M+ = molecular ion
mp = melting point
vmax = maximum absorption
tic = thin layer chromatography
\nax = maximum wavelength of absorption
Km = resistant to kanamycin Tc = resistant to tetracycline
Cm = resistant to chloramphenicol Ap = resistant to ampicillin
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Summary
A new method for site-specific protein-DNA crosslinking was developed. There 
is a need for new, improved and more efficient methods because existing 
strategies generally give very low yield of crosslinked complexes, or are very 
unselective.
The chosen strategy involved the formation of disulfide bonds between the 
protein and DNA. This required creation of a thiol at a specific base in the DNA 
and a cysteine thiol at a specific residue in the protein. Nucleotide analogues with 
a thiol at the C-5 position of the pyrimidine ring were made as the 
phosphoramidite derivative. This allowed the thiol-containing analogue to be 
incorporated into oligonucleotides.
The crosslinking strategy was tested by attempting to crosslink the site-specific 
recombinase Tn3 resolvase to its DNA binding site. An X-ray structure of Tn3 
resolvase bound to DNA has been solved, making it a good model on which to 
test the method. Cysteine mutants of the Tn3 resolvase DNA binding domain 
were created, at residues predicted to be close to the modifiable thymidine 
residues at the binding site. The mutations did not abolish binding and 
recombination by the protein.
Binding analysis of the cysteine mutants with the oligonucleotides did indicate 
that the binding affinity of the proteins was reduced. Some crosslinked complexes 
to the thiol-containing oligonucleotides were observed, albeit in much lower yield 
than had originally been hoped for.
The stereochemical course of the strand exchange reaction catalysed by Tni 
resolvase was investigated by a strategy involving a phosphorothioate linkage 
placed at the point of resolvase-catalysed DNA strand cleavage.
ix
Chapter 1: Introduction
1.1 The crosslinking of proteins to DNA
Protein/DNA interactions play a crucial role in many important biological 
functions. The cellular process of transcription and replication rely on proteins 
and DNA interacting, forming nucleoprotein complexes. A way of studying 
protein/DNA interactions is to crosslink two interacting species together. The 
requirements for the formation of crosslinks between proteins and DNA are that 
there are chemically reactive sites in the protein and similar sites in the DNA that 
can come close enough to each other so that a chemical reaction can occur, 
leading to a covalent bond being formed between the two entities.
The crosslinking of proteins and DNA plays an important role in the analysis of 
biological processes. There are many different ways of forming covalent bonds 
between DNA and the proteins that bind to it, and many different ways to analyse 
the protein-DNA complexes that are formed (reviewed in Welsh and Cantor,
1984; Meisenheimer and Koch, 1997; Williams and Konigsberg, 1991).
Classical protein/protein crosslinking makes use of sites in proteins that are 
chemically reactive, for example cysteine thiols and lysines which are good 
nucleophiles. A problem with protein/DNA crosslinking is the lack of 
functionality within DNA. The amine groups of the bases tend to be chemically 
unreactive, although most of the bases within DNA have aromatic character and 
can be activated with UV light at wavelengths of 260 nm.
The first crosslinking between protein and DNA involved irradiation with UV 
light at 260 nm, which activates the pyrimidine rings, causing a Michael addition 
reaction between a nucleophilic protein side chain and the pyrimidine ring. It is 
very difficult to predict the amount and position of crosslinking as many bases in 
the DNA are activated by this wavelength of light, and protein degradation can 
occur due to activation of the aromatic amino acids, leading to multiple crosslinks 
being formed between the protein and DNA.
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In some cases the random introduction of a specific type of reactive nucleotide 
has led to discovery of the sites in DNA that contact the protein (or not). Where 
there is crystallographic data available for the protein and/or the protein/DNA 
complex the crosslinking agents can be targeted to the sites which are known to 
interact, as with the Tn3 resolvase system.
Protein/DNA crosslinking can be analysed using Edman degradation, a technique 
used to determine the amino acid sequence of proteins. Once the crosslinking has 
been carried out and the protein/DNA complex is degraded, the point at which the 
reaction fails is the site where the amino acid is crosslinked to the DNA. Another 
method used to detect the presence of crosslinking is by using polyacrylamide gel 
electrophoresis (PAGE). The crosslinking reaction is run out on a gel containing 
SDS, which will abolish all protein-protein interactions, leaving only crosslinked 
protein-DNA species visible on the gel. Mass spectrometry can also be used to 
identify protein-DNA crosslinks. The crosslinked complex is first subjected to 
proteolysis. The fragment containing the crosslink is identified by PAGE, excised 
from the gel, and then analysed using electrospray mass spectroscopy (Wong et 
al, 1998).
Here a new method of inducing covalent, site-specific crosslinking between 
protein and DNA will be developed. Specific sites in the DNA will be modified 
with nucleotide analogues containing thiol groups, which will be targeted to 
engineered cysteine residues in the protein, and disulfides will be formed between 
the two.
1.2 Photochemical methods for protein/DNA crosslinking
The simplest way to crosslink a protein to DNA is to use UV irradiation of the 
DNA-protein binding complex. This leads to photochemical activation of the 
pyrimidine rings such that a nucleophilic amino acid can attack the 5 or 6 position 
of the ring. Using this method, with enough material and extensive purification of 
the product, identification of protein-DNA contacts has been made by Edman
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degradation. The advantages of using natural DNA for photocrosslinking are that 
since no modifications need to be made to the DNA, no structural perturbations 
of the nucleoprotein complex will occur. However the irradiation below 300 nm 
will lead to absorption by other chromophores in the system, leading to 
photochemical damage which could lower the yield of crosslinked complex and 
hinder analysis of the products. Multiple activations will lead to difficulties when 
trying to identify the site of crosslinking, and both the protein and the nucleic acid 
need to be sequenced to identify the crosslink. A way to activate the DNA 
towards crosslinking is to increase the chemical reactivity by introducing 
functional groups that can be activated easily and with more specificity.
Examples of some commonly used photoactivatible nucleotide analogues are 
shown in Figure 1.1.
Photoactivatible nucleotide analogues such as 4-thiothymidine, azides and 
halogenated nucleotide analogues have been used, many of which are 
commercially available. Upon UV irradiation at over 300 nm, these molecules 
form reactive radical species which will rapidly crosslink to amino acid side 
chains in the protein that are in close enough proximity to the modified base. 
Lasers have been used to induce crosslinks and have several advantages over 
conventional light sources (for review see Pashev et al., 1991) in that the rapid 
formation of crosslinks will minimise the likelihood that structural re­
arrangements will occur.
A more selective method is to synthesise an oligonucleotide which contains a 
functionality at a specific nucleotide that can be activated directly using UV 
irradiation or can be used to attach a photoreactive agent. This approach reduces 
purification requirements, since only one crosslinked product is produced. This 
product is then subject to Edman degradation and the point at which the 
degradation fails is taken as the point of crosslink formation.
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Figure 1.1 Some photoactivatible nucleotide analogues
Illustration of some photoactivatible analogues, which have been used 
for protein-DNA crosslinking. (1) 4-thio-2'-deoxyuridine, (2) 5- 
bromo/iodo-2'-deoxyuridine, (3) 5-bromo/iodo-2'-deoxycytidine, (4) 5- 
(phenylthiomethyl)-2'-deoxyuridine and (5) 5-[4-3-(trifluoromethyl)- 
3H-diazirin-3-yl)phenyl]-2'-deoxyuridine.
5-Bromo-2'-deoxyuridine (5BrdU; Figure 1.1, compound 2) is an analogue of 
thymidine that is activated at 308 nm, thus photochemical damage is minimised. 
In addition 5BrdU is very similar in size to the thymidine C-5 methyl group 
which has a Van der Waals radius of 2.0 A; the 5BrdU radius is 1.95 A, making it 
a good isosteric analogue. Therefore there are minimal structural perturbations to 
protein-DNA complexes and the binding affinities of DNA containing 5-BrdU 
are similar to the natural DNA. Incorporation of 5BrdU in vivo into the DNA has 
also been used. The analogue is a substrate for the polymerase enzymes and can 
be incorporated at multiple sites in the DNA, leading to higher yields of 
crosslinking upon UV irradiation. For example, the archaebacterial chromosomal 
protein MCI was crosslinked using 5BrdU-enriched DNA (Katouzian-Safadi et 
al, 1991), as was the lac repressor (Barbier et al., 1984.) Protein-DNA contacts 
have been identified using crosslinking with 5BrdU. The oncogene product Myc 
is a sequence-specific DNA-binding protein. DNA fragments were systematically 
modified with 5BrdU and crosslinking identified regions of the protein that came 
into close contact with the DNA by tryptic digest followed by peptide sequencing 
(Dong et al., 1994). Points of contact between the Rel transcription factors and its 
target DNA were identified using 5BrdU crosslinking (Liu et al, 1994). The 
bacteriophage R17 coat protein was crosslinked using 5-bromouracil, and the 
products were analysed by SDS PAGE (Willis et al., 1994).
5-Iodo-2'-deoxyuridine (5IdU; Figure 1.1, compound 2) is an another analogue of 
thymidine that can be activated by UV irradiation at 308 nm. In addition, 5IdU is 
very similar in size to natural thymidine, with a Van der Waals radius for the 
iodine atom of 2.15 A (see above). 5-Iodouracil has been used to crosslink both 
RNA and DNA to proteins (Willis et al, 1993) generally with greater efficiency 
than the equivalent brominated analogue. A yield of 40% crosslinking of 
bacteriophage R17 coat protein to its substrate DNA was reported. 5IdU was used 
to crosslink DNA-EcoRI DNA methyltransferase complexes (Wong et al., 1998). 
High yields of 60% crosslinked complex were obtained, and the products were 
further analysed using electrospray mass spectrometry. The MutS DNA mismatch
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repair protein was crosslinked to heteroduplex DNA containing 5-iodo-2'- 
deoxyuridine (Maikov et al, 1997). A technique was developed that used 5IdU in 
RNA ligands to identify high affinity proteins that bind to these ligands (Jensen et 
al, 1995).
Vaccinia topoisomerase I enzyme binds and cleaves duplex DNA at sites 
containing a specific recognition sequence. The enzyme was crosslinked to its 
target DNA, using 5-bromo-2'-deoxycytidine (5BrdC; Figure 1.1, compound 3) 
placed at the specific recognition sequence of the enzyme. The crosslinking 
efficiency was 15%. Following isolation and sequencing of peptide-DNA 
photoadducts it was possible to propose a model for the protein-DNA interface, 
and in conjunction with the crystal structure of the N-terminal fragment to 
speculate on the possible roles of important residues at the interface (Sekiguchi et 
a l , 1996).
A photoreactive diazirine analogue 5-[4-(3-(trifluoromethyl)-3H-diazirin-3- 
yl)phenyl]-2'-deoxyuridine (Figure 1.1, compound 5) was crosslinked to ZlcoRII 
and Mval restriction/modification enzymes (Topin et al, 1998).
Transcription complexes of yeast RNA polymerase III were studied using four 
different photoreactive reagents (Tate et al, 1998). These included aryl azide, 
benzophenone (Figure 1.2, compound 1), perfluorinated aryl azide (Figure 1.2, 
compound 2) and diazirine (Figure 1.1, compound 3). The last two reagents 
giving the highest levels of crosslinking.
Yeast transcription complexes were assembled and crosslinked using the 
photoactive 4-thiodeoxythymidine 5'-triphosphate (S-dTTP; Figure 1.3, 
compound 1) (Bartholomew et al, 1994) and 5-[V-(p-azidobenzoyl)-3- 
aminoally 1]-deoxyuridine triphosphate (N3RdUTP; Figure 1.3, compound 2). This 
reagent resulted in higher yields of crosslinked complexes, 40-45%, compared to 
5IdU and 5BrdU (Bartholomew et al, 1990). This reagent was also used to study
5
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Figure 1.2 Longer distance photoreactive analogues
These longer length crosslinkers were used to crosslink transcription 
complexes. A comparative study using the above modified nucleotides 
showed that the choice of photoreactive group used in photoaffinity 
labelling is crucial for identifying protein-DNA contacts (Tate et al., 
1998). (1) 5-[A-(4-benzoylphenyl)-3-aminoallyl]-dUTP, (2) 5-[A-(4- 
azido-2, 3, 5, 6-tetrafluorobenzoyl)-3-aminoallyl]-dUTP and (3) 5-[A-(4- 
(3-(trifluoromethyl)diazirin-3-yl)benzoyl)- 3-aminoallyl]-dUTP.
( 1) HN‘
O ^ N
(p o 3)3— o-
OH OH
SdTTP
(2)
(P 03)3 O
N3RdUTP
Figure 1.3 Photoreactive analogues that were used to study yeast transcription 
complexes
(1)is 4-thiodeoxythymidine 5'-triphosphate (S-dTTP) and (2) is 5-[N-(p-
(2) azidobenzoyl)-3-aminoallyl]-deoxyuridine triphosphate (N3RdUTP) 
Within the transcription complexes more crosslinking was obtained using 
the 'zero-distance' SdTTP than with the longer reaching N3RdUMP 
(Batholomew et al., 1990 and 1994).
the tracking of viral, bacterial and eukaryotic proteins along DNA (Tinker et al, 
1994).
1.3 Phosphorothioates and Azidophenacyl bromide
This methodology involves the synthesis of DNA substrates containing 
phosphorothioates at specific positions in the backbone. Phosphorothioates have a 
sulfur atom replacing the non-bridging oxygen in the DNA backbone (see 
Chapter 6). The phosphorothioate was then modified with azidophenacyl 
bromide, that places a photoactivatible azide group in the DNA (Figure 1.4.1). 
This method was used to crosslink Integration Host Factor (IHF) to its target 
DNA (Yang and Nash, 1994), TATA nucleoprotein complex to DNA (Lagrange 
et al., 1996), Human T-cell Leukemia Virus Type I Tax protein (Kimzey and 
Dynan, 1998), bacterial ribonuclease P (Harris et al, 1994) and bacterial RNA 
polymerase and its promoter (Naryshkin et al, 2000).
Phosphorothioates within oligonucleotides have been crosslinked using platinum 
complexes (Figure 1.5). These reagents have been used to crosslink 
complementary oligonucleotides together (Gruff and Orgel, 1991) and 
transcription factors to their target DNA (Chu and Orgel, 1992).
1.4 Cysteines and Azidophenacyl bromide
A way to modify proteins with crosslinking agents is to introduce cysteine 
residues at specific regions of the protein, modify these cysteines with 
azidophenacyl bromide, then irradiate this with UV light to induce crosslinks to 
the target DNA (Figure 1.4.2). This technique has been used to study the LexA 
DNA-binding motif on operator DNA (Dumoulin et al, 1993), bacteriophage X 
Cro (Chen and Ebright, 1993), histone H2A (Lee and Hayes, 1997), LexA 
Repressor (Dumoulin et al, 1996), transcription activator protein Oct-1 (Cleary et 
al, 1997) and CAP (Pendergrast et al, 1992).
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Figure 1.4 Azidophenacyl bromide modifications
In (1) a phosphorothioate in the DNA is modified with azidophenacyl 
bromide and (2) a protein cysteine thiol is alkylated.
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Figure 1.5 Cisplatin crosslinking
Illustration of cisplatin crosslinking of a DNA phosphorothioate and a 
protein lysine residue (cysteine thiols also react).
1.5 Sulfur-containing LTV crosslinking agents
4-thio-2’deoxyuridine (4SdU; Figure 1.1, compound 1) has the oxygen atom at 
position 4 of the pyrimidine ring replaced with sulfur, rendering it 
photoactivatible with UV light above 300 nm. 4SdU has been incorporated into 
DNA substrates for EcoKV endonuclease and EcoKV methyltransferase enzymes 
(Nikiforov and Connolly, 1992). Combinations of different thymidines in the 
GATATC target sequence for EcoKV were replaced with 4SdU and crosslinking 
was induced using UV irradiation at 310 nm. Yields of only 6% were 
accomplished. An RNA phosphoramidite of 4SU that has the 2'-OH protected 
with a l-(2-fluorophenyl)-4-methoxypiperidin-4-yl function was used to crosslink 
the Rev protein of HIV-1 (McGregor et al., 1996).
The analogue 5-(phenylthiomethyl)-2'-deoxyuridine (Figure 1.1.4) is a 
photoreactive nucleobase that is activated at 260 nm (Romieu et al, 2000). It 
cannot be used for the specific crosslinking because it is activated at 260 nm.
5-Mercaptouridine triphosphate/azidophenacyl (5-SH UTP/APAS; Figure 1.6) 
was incorporated into RNA utilising E.coli and T7 RNA polymerases and yeast 
RNA polymerases I and III. These analogues can be transcribed into segments of 
DNA in a site-specific manner. The nucleotide analogue 5-[(4- 
azidophenacyl)thio]uridine 5'-triphosphate was synthesised (Hanna etal., 1989) 
and used to study RNA polymerases. 5-mercapto-UTP (5-SH-UTP) has been 
used to study protein-RNA interactions (He et al, 1995). The same methodology 
was used to synthesise 5-[(4-azidophenacyl)thio] cytidine 5'-triphosphate (Hanna 
et al, 1993), also shown to be useful for crosslinking to E.coli and T7 RNA 
polymerases.
1.6 Chemical methods for protein/DNA crosslinking 
Non-specific chemical cross-linking
Formaldehyde and glutaraldehyde are examples of "non-specific" chemical 
crosslinkers. Formaldehyde reacts with several amino acid side chains producing
7
Figure 1.6 Nucleotide analogues that are substrates for polymerase enzymes
Illustration of 5-mercapto-UTP (5-SH-UTP) and 5-[(4azidophenacyl)thio] 
uridine 5'-triphosphate 5 [4-APAS]UTP. Used to crosslink E. coli and 
T7 polymerases (Hanna et al., 1989).
aldehyde | R R
OH
S ch iff  baseM
gluteraldehyde =
O
Figure 1.7 Crosslinking with dialdehydes
Illustration of crosslinking between an aldehyde (e.g. glutaraldehyde) 
and the primary amine group of lysine, forming a Schiff base crosslink. 
This method has been used to crosslink the RNA polymerase-/«cUV5 
promoter complex (McGhee and von Hippel, 1975).
Rn i  Q
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Figure 1.8 Illustration of disulfide bond fomation in nucleotide analogues
The synthesis of the thiol tether (step 1), and the reaction that forms 
the disulfide between a cysteine in HIV-1 reverse transcriptase and the 
thiol tether in the template DNA (step 2).
a methylol (hydroxymethyl) derivative which can then react further with DNA at 
amino and imino groups. Glutaraldehyde is a bifunctional aldehyde that forms a 
Schiff base with primary amines (Figure 1.7).
1.7 Disulfide crosslinking
The convertible nucleotide analogue approach has been used to successfully 
incorporate thiol-containing bases at specific positions within oligonucleotides 
(MacMillan and Verdine, 1991). The oligonucleotide is site-specifically modified 
to carry a tethered nucleophile. The nucleophile is then reacted with a ligand 
electrophile, usually an amine or a thiol disulfide (see Figure 1.8). The above 
approach was used to crosslink HIV-1 reverse transcriptase to its template DNA 
via a disulfide (Huang et al, 1998). The cysteine thiol formed a disulfide with a 
thiol group in the minor groove of the DNA (activated as a mixed disulfide), 
which was tethered to the N-2 of a dG in the template:primer. The positions of 
the thiols were systematically varied in both protein and template. Defined cycles 
of polymerisation were carried out with the reacting thiol partners such that 
different combinations of dNTPs and ddNTPs moved the enzyme a fixed distance 
along its substrate. When the DNA template was positioned so that the thiol 
tether and the engineered cysteine were close enough, a disulfide crosslink was 
formed, that prevents dissociation of the product, yielding a stalled complex. 
Disulfide crosslinking has been used to study DNA hairpins (Glick, 1991) that 
were stabilised by introducing disulfide crosslinks at the terminal bases.
Other reagents that have created a disulfide bond between an oligonucleotide and 
an enzyme (Chu and Orgel, 1988) have involved modification of the 
oligonucleotide at the 5' end of the oligonucleotide, which is not suitable for the 
study of Tni resolvase.
1.8 Crosslinking of Tn3 resolvase
To date the crosslinking agents that have been used to study protein-DNA 
interactions have had limited efficiency and thus usefulness. With most
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photoactivatible analogues low yields of crosslinked complex are usually 
obtained, thus lots of material is required in the reactions. For the study of Tn3 
resolvase and other proteins that interact with segments of DNA, e.g. 
transcription factors or replication machinery, it is important that the 
modifications do not cause any structural perturbations in the system. One of the 
most popular crosslinking agents, azidophenacyl bromide, introduces a bulky 
group at the site of crosslinking, so efficiency of binding of proteins would be 
effected. Thiols placed at the C-5 position of a pyrimidine (as a thymidine 
analogue) cause minimal structural perturbations, and so should not affect protein 
binding. 4SdU and 5IdU are commercially available nucleotide analogues that 
have been used previously to crosslink Tn3 resolvase to DNA (Mclllwraith,
1995).
4-Thiothymidine (Section 1.5; Figure 1.1, compound 1) has also been 
incorporated into DNA substrates for Tn3 resolvase (Mcllwraith, 1995) with high 
levels of crosslinking to linear DNA of 13%. It was however found to be 
unsuitable for the intended experiments, as the structure of the DNA duplex was 
altered in the supercoiled substrate. The 0-4 is required for the formation of the 
Watson and Crick base pairings that are critical for maintaining the helix in the 
correct conformation. The replacement of this oxygen with sulfur caused changes 
in the helix structure that affected the binding of the resolvase. Other 
photoreactive bases, including azidophenacyl bromide could also not be used to 
study Tn3 resolvase due to the introduction of a sterically bulky group which 
would cause unnatural conformations of the DNA duplex and so disrupt resolvase 
binding and synaptic complex formation.
Replacement of thymine with 5-iodouracil (Section 1.2; Figure 1.1, compound 2) 
has previously been used to study the interactions between Tn3 resolvase and its 
substrate DNA. Photocrosslinking experiments have showed that at least one of 
the four resolvase monomers bound at the crossover site must remain physically 
attached to the same DNA half site before and after recombination (Mcllwraith et
9
al., 1996). The crosslinking utilised 5IdU, substituted for thymidines in the TGT 
binding motif in a synthetic res subsite I (Figure 1.9.2), incorporated into a 
supercoiled substrate, and targeted towards Tyrl76 in the resolvase recognition 
helix. The crosslinking was between the phenolic ring of tyrosine and the uridyl 
radical. The best results obtained using this reagent yielded crosslinked product 
between 7 and 15% of the total substrate. However, for some useful mechanistic 
studies to be done would require more than one modification, so the initial yield 
would have to be as high as possible.
Convertible nucleotide analogue strategy for disulfide crosslinking (Section 1.7) 
is not suitable for crosslinking Tn3 resolvase to its target DNA. Although these 
analogues can be positioned in a site-specific manner, the thiol group is at the end 
of a two carbon tether. The strategy used here prefers the thiol to be similar to the 
5BrU analogues, that is, not too structurally different from the natural 
nucleotides. The longer tether would place give the thiols a greater degree of 
flexibility but may cause structural perturbations in the resolvase/DNA complex. 
The crosslinking agents developed in this study will be tested in the TnJ 
resolvase/DNA system. A co-crystal structure of the closely related y8 resolvase 
(Yang and Steitz, 1995) enables us to look closely at the points of interaction 
between the protein and DNA and so predict possible points of contact that could 
be crosslinked together. Tn3 resolvase is coded by the transposon Tn3 and carries 
out a process called site-specific recombination (Section 1.10).
1.9 Use of modified oligonucleotides in Tn3 resolvase
Modified oligonucleotides for all of the res subsites can be made and 
incorporated into supercoiled plasmids (Section 3.36), the natural substrate for 
T ni resolvase. This enables site-specific replacement of bases in the resolvase 
binding sites with photoactivatible or thiol-containing nucleotide analogues. 
Modified bases can be incorporated into oligonucleotides, that can be synthesised 
by the phosphoramidite method (Section 3.25). In order to determine the 
functions of the individual resolvase subunits, a new method of making covalent
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bonds (crosslinks) between one or more subunits and the DNA at specific 
sequence positions was developed (Chapter 5). Unlike generic 'crosslinking 
agents' the crosslinking approach used here targets sites in the DNA that are 
known to interact with the protein, rendering them 'affinity reagents'.
To perturb the catalytic steps involved in strand exchange, a phosphate in the 
DNA backbone will be made chiral, at the site where the strand is broken by Tn3 
resolvase (Figure 1.9.2; Chapter 6).
1.10 Site-specific recombination
Site-specific recombination is a process where DNA strands are cut 
enzymatically, and rejoined in a different configuration. Tn3 is a bacterial 
transposon that uses site-specific recombination. Transposons are DNA 
sequences that can jump from their original site on the genome to other sites 
within it. These 'jumping' genes allow for the horizontal transfer of genetic 
information.
Site-specific recombination of DNA plays a major role in many biological 
processes in prokaryotes and eukaryotes. During conservative site-specific 
recombination a DNA molecule is cut in both strands at two specific positions 
and the ends are rejoined to new partners in a series of precise catalytic steps. 
During the process there is no DNA synthesis or degradation involved, or 
hydrolysis of the phosphodiesters. Site-specific recombination differs from 
homologous recombination in that extensive homology within the region of 
strand exchange is not required. The only sequence homology required is at the 
site where the DNA is broken, i.e. the "overlap" region.
All site-specific recombination systems require a recombinase enzyme that binds 
to a specific site in the DNA, cleaves it and exchanges both strands in a controlled 
way to give a recombinant configuration. There are many different types of
11
recombination systems that require one (or more) recombinase enzyme(s) and 
specific binding sites for these enzymes on one (or more) pieces of DNA.
1.11 Functions of site-specific recombination
The functions of site-specific recombination vary in nature. Many organisms have 
one or more recombination systems. These systems are also associated with 
phages and plasmids. The recombinational apparatus of phage X controls the 
integration and excision of the phage to and from the host chromosome. Thus 
recombination plays an essential role in the life cycle of the phage. In the 
transposon Tn3, the process of recombination resolves the co-integrate DNA 
intermediate structures that arise as a result of the transposition of the transposon 
to another DNA site (Section 1.13).
In yeast, the copy number of the 2p plasmid is regulated by the recombination 
reactions of the Flp recombinase which inverts a segment of DNA resulting in 
switching of the direction of replication fork in that region. The invertases Cre of 
the phage PI and Hin from phage Mu both use recombination to alter the 
expression of genes. The Hin invertase of phage Mu has almost 30% homology 
with Tn3 resolvase. In response to the host environment, recombination occurs 
inverting the segment of DNA that carries promoters for expressing surface 
antigens, which will help the bacteria to evade host factors. XerC/D 
recombination systems in E.coli aid DNA stability by maintaining circular DNA 
replicons in a monomeric state. In humans, V(D)J recombination creates diversity 
of the immunoglobulin genes.
In S. cerevisiae and D. Melanogaster sequences corresponding to integrated 
proviruses have been found, the Ty elements of yeast and copia elements from 
flies have coding sequences with homology to reverse transcriptase which 
mobilise via an RNA form but have no infectious properties. Another important 
transposable element in D. Melanogaster is the P element that determines the 
fertility in progeny. Males carrying P elements crossed with females lacking the
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elements have progeny which are infertile (hydrid dysgenesis). The LINES (long 
interspersed sequences) are derived from transcripts of RNA polymerase II and 
are found on multiple sites throughout mammalian genomes. LINES LI belongs 
to the viral superfamily of retrotransposons like Ty and copia. Mammalian 
genomes also contain SINES (short interspersed sequences) that are from the 
non-viral class of retrotransposons and are derived from transcripts of RNA 
polymerase III. Site-specific recombination shares many common features with 
other processes where DNA strands are cut and rejoined at specific sites, 
especially transposition.
The work in this thesis focuses on components of the bacterial transposon Tn3 
and the mechanism of the proteins that are coded by it.
1.12 The recombinases
Two distinct families classified by amino acid sequence and by similarities in 
their recombination enzymes and recombination sites are the integrase and the 
resol vase/in vertase family. The integrases family known as the 'tyrosine 
recombinases' have a catalytic tyrosine residue which attacks the DNA 
phosphodiester backbone, whereas the resolvase family, the 'serine recombinases' 
have a catalytic serine. In the resolvase family all four strands are broken before 
the strand exchange takes place, whereas in the integrase family sequential single 
strand cleavage occurs, the first two cleavages giving rise to formation of a 
Holliday junction intermediate, which is then resolved into the recombinant 
configuration after the second pair of strand exchanges (Reviewed in Stark et al., 
1992). Sometimes proteins and/or binding sites within the same family are 
interchangeable. The y8 resolvase can act at Tn3 binding sites and vice versa.
Tn1000 (y8) shares 90% sequence homology with Tn3.
1.13 The Tn3 transposon
Tn3 is a bacterial transposon (illustrated in Figure 1.9.1) that carries all the 
components required for its survival and propagation. It is 4957 bp long and
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(1) Illustration of the Tn3 transposon. The arrows at the ends show the 
38 bp sequence where the transposase binds (2) Diagram of res. The 
regions of the DNA strands that are broken during the reaction are 
shown in red. The sites where the resolvase binds are shown by black 
triangles at the ends of each site.
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Figure 1.10 The transposition of Tn3
Illustration of the transposition of Tn3. The transposase proteins bring 
about the co-integrate structure that is resolved by the resolvase protein 
into two circles, each of which contains a copy of the transposon.
carries genes encoding the transposase enzyme (tnpA) and the resolvase enzyme 
(tnpR). Between these two genes is a sequence where the resolvase enzyme acts 
called res. The sites where the transposase acts are the 38 bp inverted repeats that 
flank the transposon. Tn3 also encodes a protein (Bla) that confers resistance to 
antibiotics that contain a (3-lactam ring in E.coli. (Sherratt, 1989). Tni belongs to 
a group of P-lactamase encoding plasmids isolated from a range of enteric 
bacteria. It is likely that all these transposons have interchangeable functions, as 
they share more than 90% sequence similarity (reviewed in Sherratt, 1989).
Transposons of the Tn3 family move in two steps as illustrated in Figure 1.10.
The first step requires the transposase (tnpA gene product) and involves fusion of 
the transposon-carrying molecule (the donor) with the site to where it is jumping 
(the recipient), to form a co-integrate structure. This co-integrate separates the 
donor and recipient molecules by directly repeated copies of the replicated 
transposon at each end (Gill et al., 1979). The second step requires the resolvase 
(tnpR gene product) whereby it binds to the two res sites within each copy of the 
transposon and carries out a resolution reaction. The result of this is a segregation 
of the co-integrate into two molecules, each carrying a copy of the transposon.
In the case of y8 and Tn3, the res site is located between the divergently 
transcribed tnpA and tnpR genes, and the promoters for these genes are situated 
within res. In addition to its role in recombination, resolvase acts as a repressor of 
its own transcription and that of the transposase protein.
1.14 The recombination site, res
res is a region of DNA 114 bp in length (see Figure 1.9.2). It contains three 
binding sites, I, II and III that each bind a dimer of resolvase. Each binding site is 
flanked by inverted repeats of an imperfectly conserved 9 bp sequence 
(consensus: T G T C Py Pu T T A). These binding sites are not evenly spaced, 
and their lengths differ because the spacing between the inverted repeats in each
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binding site is not identical. The 9 bp inverted repeats span a central spacer of 10 
bp in site I, 16 bp in site II and 7 bp in site III.
The structure of the res site is such that there are 53 bp or 5 helical turns between 
the centre of sites I and II, and around 3.3 turns of the helix between sites II and 
III. The importance of the helical phasing is such that the altering of the spacing 
between binding sites I and II can inhibit the recombination reaction, and most 
natural res sites have an integral number of helical turns between sites I and II 
(Hatfull and Grindley, 1988).
1.15 Tn3 resolvase
Tn3 resolvase family is 185 amino acids long (20.5 kDa). It has two functional 
domains identified by chymotryptic digest (Abdel-Meguid, 1984) to be an N- 
terminal catalytic domain comprising residues 1-140 (15 kDa), and a C-terminal 
DNA-binding domain from residues 141-183 (5 kDa). An extended arm region at 
residues 121-147 connects the main parts of the two domains and binds the DNA 
in the minor groove (Yang and Steitz, 1995).
The crystal structure of the N-terminal chymotrypsin fragment (residues 1-140) 
has been solved at 2.3 A (Sanderson et al, 1990). The C-terminal domain was 
disordered 'a crystal' of the whole protein. The N-terminal domain contains the 
residues essential for catalysis and the residues involved in higher-order 
interactions between resolvase dimers (Hughes et a l, 1990 and 1993). It 
comprises a central 5-stranded p-pleated sheet surrounded by five a-helices. 
Serine 10 is a catalytic residue situated in an unusual environment for an active 
site residue, as it is exposed on a protruding part of the protein structure, not 
buried in a pocket.
The C-terminal chymotryptic fragment contains a helix-turn-helix motif that 
binds in a specific way to the 12 bp consensus sequence in adjacent major and 
minor grooves, observed by footprinting studies (Abdel-Meguid et al., 1984; 
Rimphanitchayakit et al, 1989).
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During the site-specific recombination reaction, resolvase cuts and religates the 
DNA within a region of perfect dyad symmetry at the centre of res sub-site I 
(Figure 9.1.2). This staggered double break in the centre of site I is the site where 
resolvase covalently attaches itself via a 5'-phosphoserine linkage (Reed and 
Moser, 1984). Binding sites II and III are known as the accessory sites which are 
responsible for bringing the two site Is into correct alignment during synapsis 
(Bednarz et al., 1990).
1.16 The yS-resolvase-site I co-crystal structure
The co-crystal structure of y8 resolvase bound to a 34 bp oligonucleotides of site I 
is shown in Figure 1.11. Resolvase binds to site I as a 1, 2 dimer and induces a 
sharp bend of 60 ° at the centre of the DNA, towards the major groove. The 
catalytic residue was identified as serine at position 10 (Reed and Moser, 1984), 
and the equivalent serine at position 9 of the related recombinase Gin (Klippel et 
al., 1988). The phosphates of the two DNA strands that become covalently linked 
to serine-10 lie approximately 13 A apart across the minor groove of standard B- 
form DNA, whereas the a-carbon atoms of the serine-10 in the 1,2 dimer are 30 
A apart. From the co-crystal structure the hydroxyl groups of the serines are 17 
and 11 A away from the scissile phosphates. Thus a large conformational change 
is required to bring the serines close enough to the DNA before the phosphoserine 
bonds can be formed.
The region neighbouring serine-10 consists of conserved polar and positively 
charged amino acids, Tyr-6, Arg-8, Gln-14, Gln-19, Arg-68 and Arg-71,. 
Mutations in these residues abolished recombination (Hughes et al., 1990), 
though reduced activity was present in some of the mutants. Therefore these 
residues are important for the formation of the active site or are directly involved 
in catalysis. In Tn3 resolvase there is a highly conserved tyrosine Y6 thought to 
be important for active site function. However the tyrosine hydroxyl group is not 
required for cleaving and rejoining (Leschziner et al., 1995).
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Figure 1.12 The in vitro reaction catalysed by Tn3 resolvase
Illustration of the resolution of pMM5 by resolvase. The product is a -2 
catenane.
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The main difficulty in relating the crystal structure of the site I-resolvase complex 
to the mechanism of strand cleavage is the position of the catalytic serines in 
relation to the phosphodiester bonds that are to be cut and covalently linked to the 
protein. The solution structure of the N-terminal domains indicated the presence 
of two kinds of crystallographic dimers, the 1,2 dimer and the 2, 3 dimer 
(Sanderson et al, 1990). In the 1,2 dimer, which is thought to exist in solution 
(Hughes et al, 1993), the catalytic serines are approximately 13 A away from the 
phosphate backbone. The distance from the DNA is only known for the 1,2 dimer 
in the crystal structure bound to site I (Yang and Steitz, 1995). The catalytic 
serine residues in the 2,3 dimer are 17 and 11 A from the DNA. One could 
envisage that during the course of the reaction the dimers bound at the crossover 
site change conformation from the 1,2 to the 2,3 dimer in order to facilitate strand 
cleavage via the catalytic serines. Or it could be that the bound resolvase dimers 
maintain the 1,2 dimer conformation, and gross conformational changes of the 
1,2 dimer itself bring about strand cleavage. To date there is no biochemical 
evidence to support either theory; however the covalent fixing of subunits could 
perhaps make the problem clearer.
1.17 Binding properties of Tn3 resolvase
Site I of res is occupied by a dimer of y8 resolvase in the form of a 1, 2 dimer 
(Yang and Steitz, 1995). In yS resolvase the protein binds to each binding site as 
dimers in a highly co-operative manner and the protein is thought to exist as a 
dimer in solution. In Tn3 resolvase, binding is dimer-dependent and occurs in a 
co-operative manner (Blake et al, 1995). The binding interaction occurs 
primarily through residues 153-183 which constitute the C-terminal DNA- 
binding domain. This region has been mapped through footprinting (Abdel- 
Meguid et a l, 1984) and ethylation interference analysis (Rimphanitchayakit et 
a l,  1989). The DNA-binding domain will be discussed further in Section 4.2.
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1.18 In vitro reaction catalysed by Tn3 resolvase
The in vitro system requires only a simple buffer, a supercoiled substrate 
containing two res sites in direct repeat and the resolvase enzyme (Reed and 
Grindley, 1981). DNA cleavage, strand exchange and re-ligation all occur at the 
centre of site I. Double strand cleavage results in a 2 bp overhang at the central 
AT nucleotide, resolvase being attached to the recessed 5' end by a phosphoserine 
bond (Reed and Moser, 1984). Once the strand exchange occurs, the 
phosphoserine bonds are broken to form the recombinant product. The product of 
the in vitro reaction is a (-2) catenane (Figure 1.12). The two circles are thought 
to be unlinked in vivo by a type II topoisomerase (Bliska et al., 1991).
Three negative intra-dominal nodes are trapped between the res sites in the 
synaptic complex, and strand exchange is equivalent to 180° rotation in a right- 
handed sense (Figure 1.14). A linkage change of +4 occurs during resolution. The 
reverse is true of the reverse reaction (fusion) where the linkage change is -4  
(Boocock et al, 1987; Stark et al., 1989; Stark et al., 1991). The linkage change 
concurs with the sites being wrapped plectonomically around the protein, and 
strand exchange occurring by a simple rotation mechanism. Further topological 
analysis confirmed this result (Stark and Boocock, 1995).
1.19 Formation and functions of the synaptic complex
Models for the way the synaptic complex is formed and for its structure have 
been proposed (reviewed in Stark and Boocock, 1995).
The topological filter or 'two-step synapsis' model explains the requirements for 
synapsis in terms of the possible productive and non-productive ways the DNA 
sites and the proteins bound to them can come together (Figure 1.13).
Here the res sites come together by random collision. However, for an active 
synapse to form which leads to recombination, the II and III accessory sites must
18
Figure 1.14 Models of Strand Exchange
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(3) N-terminal domain rotation model
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intertwine in a defined way so that subsites I come into alignment, a process 
assisted by negative supercoiling. Incorrect synapsis structures involving the 
entanglement of DNA (such as from sites in inverted repeat orientation) would be 
energetically costly and would dissociate, allowing productive synapses to form. 
Analysis of synaptic structures of various substrates has provided support for this 
model (Watson et a l, 1996). Synapsis can occur with plasmids with sites inverted 
repeat orientation and with nicked substrates, although the overall yield of 
synaptic complex is much lower.
Resolvase dimers bound to all three subsites of res must come together, or 
synapse, before strand exchange can occur. Sites II and III form two tetramer 
cores that interwrap the DNA, trapping three negative nodes. This wrapping also 
brings the site I, with attached dimers, into alignment, a necessary accessory site 
function (Bednarz et a l, 1990). The site II/III component of the synaptic complex 
is thought to be involved in activation of the catalytic tetramer at site I. It is 
unclear if the activation is by protein-protein contacts between tetramers at II/III 
and I, or whether it is purely architectural, depending on the conformations of 
tetramers at II/III or I, relative to each other. Therefore the accessory sites, and 
the dimers bound to them, play an important role in the synaptic complex, being 
involved in topology, alignment and activation.
1.20 Models for Strand Exchange
An illustration of the current models are shown in Figure 1.14.
Subunit rotation (Figure 1.14.1)
The fact that the linkage change during resolution is +4 suggests a model in 
which the DNA is situated on the outside of the complex and the two resolvase 
monomers interact via their N-terminal domains on the inside. At strand 
exchange, two protein monomers rotate by 180° in a right-handed motion. A 
difficulty with subunit rotation is how the four cut DNA half-sites could be held 
together while rotation is occurring. This model would also require dissociation
of all four half sites. Experiments with mismatched substrates have shown that 
multiple rounds of recombination can occur, which fits well with this model. By 
using a substrate containing a mis-matched overlap in the 2 bp central 
dinucleotide, it has been shown that two rounds of recombination can take place 
without rejoining of the DNA strands in the intermediate recombinant form 
(Mcllwraith et al, 1997). Indeed multiple rounds of recombination (Figure 1.15) 
can occur, which is explained very well by subunit rotation.
DNA-mediated strand exchange (Figure 1.14.2)
The two copies of the subsite I are brought into close proximity at the centre of a 
catalytic complex, with the bound protein dimers on the outside. This mechanism 
involves minimum movement of both protein and DNA during strand exchange. 
After resolvase-induced unwinding of the crossover site DNA, strand exchange is 
proposed to occur via movement only of the free 3’ hydroxyls generated by 
cleavage, rather than by subunit exchange. It is difficult to imagine the four ends 
of DNA within the proteins being held together and coming together in the 
correct conformation. In addition, this theory does not explain iterative or
! multiple rounds of recombination since the DNA would become too tangled
i
| without a resetting mechanism.
I
j N-terminal domain rotation model (Figure 1.14.3)
(
I Mutants at resolvase positions 101-103 have been identified, that can resolve
substrates lacking accessory sites II and III (Arnold, 1996). These "hyper-active"
, mutants can carry out resolution reactions on a plasmid containing two site Is
only. This region might be a flexible hinge between the arm region (E-helix) and 
the N-terminal domain, allowing rotation of the N-terminal domains without 
dissociation of the 1,2 dimer. Strand exchange would occur by rotation of the N- 
terminal catalytic domains by 180°. The arm region (residues 121-147) 
interactions remain intact. During domain rotation, the DNA-binding domain of 
one monomer in each dimer needs to dissociate to allow the DNA to escape. The
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reaction can only proceed for two rounds of recombination without dissociation, 
unless there is a reset mechanism.
In view of the biochemical and topological evidence it is not clear which model is 
the true one. However the subunit rotation looks the most likely. The fact that it 
can account for the minor iterative products that appear in low amounts in 
addition to the two noded catenane shows that multiple rounds of rotation can 
occur without a re-ligated intermediate which would reset the dimers into a 
catalytic conformation. It has long been accepted that the strand exchange is 
equivalent to an 180 ° clockwise rotation, within the context of a synaptic 
complex that traps three negative nodes giving the unique major topological 
product of the -2 catenane. An expansion of this 180 ° rotation was to use 
mismatched substrates to induce two rounds of strand exchange yielding the 
predicted 4-noded knot. The observed 360 ° rotation, without a ligated 
intermediate (Mcllwraith et al, 1997) could easily be explained by subunit 
rotation, whereas the DNA-mediated model would be very unlikely as the DNA 
would have a full turn of the helix between the dimers bound at site I, causing 
great structural anomalies. The catalytically-active conformation of the dimers 
after one round of N-terminal domain-mediated rotation is lost after one round of 
strand exchange, so it is unlikely that a second round would occur. Thus subunit 
rotation accounts nicely for the observed product topologies, but how the 
resolvase structure would allow subunit rotation to occur is still unclear.
1.21 The mechanism/chemistry of strand exchange
Strand exchange (Figure 1.16) involves nucleophilic attack of Ser-10 residues on 
the two strands of the DNA duplex and two transesterification reactions, giving 
rise to a covalent resolvase-DNA complex, wherein the protein is attached to the 
5'-recessed ends, giving rise to free 3' hydroxyls on each strand. Strand exchange 
then takes place and these 3'-hydroxyls attack the serine-DNA phosphodiesters 
which results in the phosphate backbone rejoining, releasing the resolvase. In the 
reverse of the cleavage step (i.e. rejoining), the attacking hydroxyl group can be 
from the same DNA strand, giving a non-recombinant product, or from the
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Figure 1.16 The chemistry of resolvase-mediated strand exchange
Illustration of the series of nucleophilic attacks that give rise to the 
covalent protein-DNA intermediate (Shown in one strand only). 
Enz=the recombinase subunit; B=base and X=hydroxyl.
corresponding strand of the other cleaved site, giving a recombinant product. In 
Figure 1.16 only one strand of DNA is shown.
No Holliday junction intermediates have ever been isolated from Tn3 resolvase 
reaction, and it is thought that all four strands must be cleaved before strand 
exchange takes place. The exact order of cleavage events of all four strands is 
unclear at the moment. The popular theory is that all four strands are cleaved in a 
concerted array. However this type of concerted double-stranded cleavage would 
required a large conformational change of the catalytic dimer bound at the 
crossover site to bring the serine 10 nucleophiles closer to the scissile phosphates.
It was determined that the resolvase that is bound to each end of site I, i.e. site I 
left and site I right, is responsible for cleaving the half site to which it is bound 
(cis cleavage). This is in contrast to the Flp recombinase that cleaves the opposite 
strand to which the protein is bound (trans cleavage). It has also been shown that 
the top strand is preferentially cleaved before the bottom strand (Boocock et al, 
1995), although all four strands must be cut before the strand exchange reaction 
can proceed. A difficulty with subunit rotation is how to imagine the mechanism 
whereby all four cleaved DNA ends are held together after cleavage and 
immediately prior to strand exchange. If the DNA strands are cleaved in sequence 
(i.e. top strand before bottom), then this may provide a means for concerted 
cleavage, so that only when the last strand was cut could rotation commence.
In light of the crystal structures and biochemical evidence to date, most has been 
learned about the mechanism of resolvase from the topological analysis of the 
products. A mechanism for the production of a -2 catenane was derived from a 
model whereby the least energetically costly synaptic structure was formed, and 
following a 180 ° clockwise rotation the -2 catenane was formed. The least 
energy requirements and minimal DNA entanglement were from a synaptic 
structure that trapped three negative nodes.
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The topology of the synaptic structure was confirmed when experiments were 
carries out with loxP sites substituted for res site I. Addition of resolvase formed 
the expected synaptic structure at sites II and III trapping three negative nodes. 
Addition of the Cre invertase which cleaved at the loxP sites, gave the predicted 
topological products for an inversion reaction in the context of a synapse with 
three negative nodes (Kilbride et al., 1999).
1.22 Crosslinking techniques to study binding/synapsis and strand exchange
Using a combination of the data obtained from crystallographic, mutational and 
biochemical analysis of the recombinational apparatus, quite a lot of information 
can be deduced about the regions of the protein that come into close contact with 
the DNA during recombination. Residues that are important for catalysis have 
been identified through mutational analysis, and similarly residues essential for 
binding have been identified.
Site-specific crosslinking as a method of analysis of the recombination reaction is 
unique in that physical constraints can be imposed on the protein-DNA 
interaction that can allow us to "fix" the interacting components. The formation 
of covalent linkages between the protein and the DNA it associates with is a 
powerful technique for structural and functional studies. Photocrosslinking 
experiments (Mcllwraith et al., 1996) have shown that at least one of the four 
resolvase monomers bound at the crossover site can remain physically attached to 
the same DNA half site before and after recombination.
If high yields of crosslinking are obtained, a similar experiment to the above 
could be carried out involving the crosslinking of two protein monomers to 
binding site I. If the recombination reaction is inhibited by the covalent 
attachment of both ends of site I, it would suggest that protein dissociation from 
these sites is a requirement for recombination. Therefore the N-terminal domain 
rotation model would look more probable. However, if the recombination 
reaction worked with both sides covalently attached, then subunit rotation would
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be validated, as a double round of strand exchange would only be consistent with 
subunit rotation (not with the DNA-mediated model).
If a reaction where a covalently attached mis-matched substrate was crosslinked 
at both ends of site I underwent strand exchange, this would also validate subunit 
rotation and that the presence of a re-ligated intermediate was not required. 
Additional experiments could be performed that crosslink site II and III to 
targeted accessory site resolvases. Experiments analogous to those of Murley and 
Grindley, 1998 could be used to confirm current results about the requirements in 
the protomers bound to res, for all aspects of synapsis and recombination.
Site-specific crosslinking of components of the synaptic complex could provide 
useful information about the contacts that are made and indeed maintained during 
synapsis. Essential contacts could be identified by crosslinking the DNA at 
specific residues within the synaptic complex and direct inferences about the 
architecture of the components involved could be made.
1.23 Aims of research
In order to investigate the mechanism of strand exchange, two different 
approaches were adopted. The first involved developing a methodology of 
crosslinking the protein to its binding site, by modifying the DNA-binding site at 
points where it is known to form close interactions with specific residues in the 
DNA-binding domain of the protein. Once a covalent DNA-protein binding 
complex is formed, the different modes of strand exchange could be tested by 
introducing other inter-subunit crosslinks at different positions. This approach 
was to be tested on resolvase, but, if successful, would be applicable to many 
other experimental systems involving proteins that interact with DNA.
The second approach involves introducing a chemical modification at the point 
where the resolvase cleaves. By placing a chiral phosphorus atom at the point 
where the strand breakage occurs, it should be possible to determine the number 
of catalytic steps by relating to the stereochemistry of the phosphorus atom before
and after cleavage and strand exchange. The work of this thesis is directed
towards these aims, and the following steps will be described:
1. The chemical synthesis of thiol-containing phosphoramidite reagents.
2. Incorporation of these reagents into synthetic oligonucleotides that code for the 
binding sites of Tn3 resolvase.
3. Construction of expression vectors containing the DNA-binding domain of Tn3 
resolvase as a removable cassette.
4. Expression and purification of novel cysteine mutants of Tni resolvase.
5. Crosslinking via forming disulfides between protein cysteine thiols and the 
thiol-containing oligonucleotides.
6. Synthesis of synthetic site I oligonucleotides with a phosphorothioate 
modification at the phosphorus atom that becomes covalently linked to the 
resolvase nucleophile during the cleavage of the DNA strands.
7. Incorporation of these modified site Is into supercoiled substrates and assaying 
them with resolvase protein.
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Chapter 2: Synthesis of thiol-containing nucleotide 
analogues
2.1 Introduction
All of the nucleotide analogues that were to be used in crosslinking experiments 
carry the crosslinking group at the C-5 position of the pyrimidine ring. This 
position is not involved in the formation of Watson and Crick base pairs (Yuriev 
et al, 1999). These compounds are structural analogues of the natural base 
thymine, which contains a methyl group at the C-5 position.
Two types of modification were to be made. One involves the incorporation of a 
photoactivatible group at the C-5 position, whereas the other introduces thiol 
moieties at C-5.
These analogues were to be incorporated into oligonucleotides and then activated 
to crosslink Tni resolvase (Chapter 5). The photochemical target (Figure 2.1.1) 
can be activated with long wave UV light; the thiol-containing nucleotides are 
designed to crosslink via the formation of disulfide bonds. The latter strategy 
required the creation of novel cysteine mutants of Tn5 resolvase (Chapter 4), in 
regions where it is known to form close interactions with the DNA.
There are potentially two different ways to make nucleotide analogues. The first 
is to modify the nucleotide directly. The second is to modify the base, then couple 
it to the sugar portion (Wilson et al., 1995). These coupling reactions usually give 
two anomeric nucleotide products, the a  and (3 forms. Through modification and 
optimisation of the reaction conditions it is usually possible to favour one anomer 
over the other, although their separation is often difficult. It was preferred to use 
the nucleotides that already contain the desired anomeric conformation. The 
starting materials for the synthetic targets (Figure 2.1) were thymidine and 2'- 
deoxy uridine.
For crosslinking, the nucleotide analogues must be incorporated into 
oligonucleotides (Chapter 4). The phosphoramidite analogues can be incorporated 
into the oligonucleotides site-specifically. The phosphoramidite-protected thiols
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Figure 2.1 Illustration of synthetic targets
The three phosphoramidite targets. (1) is photoactivatible, whereas (2) and 
(3), once deprotected and incorporated into oligonucleotides, should form 
disulfides with engineered cysteine residues in the protein.
and diazirine analogues shown in Figure 2.1 were to be made and tested as 
crosslinking agents.
The diazirine-modified nucleotide has the advantage of being activated by UV 
light at wavelengths between 350-380 nm. This is well above the wavelength at 
which the groups in proteins and DNA are activated (260 nm). Diazirines, upon 
UV irradiation form a highly reactive carbene radical (with the release of N2), that 
can form stable adducts with most amino acids groups in proteins (Lui, 1986), so 
it should be easy to induce crosslinking at any chosen position. The diazirine 
groups are quite small, therefore should cause minimal unfavourable structural 
changes within the protein/DNA complex.
Thiols are potentially excellent site-specific crosslinking agents. The thiol- 
disulfide interchange proceeds readily under physiological conditions, and is 
reversible and selective. Two reactant thiols can be encouraged to form disulfides 
using a variety of oxidising agents. Thiols in the DNA substrates can be 
positioned close to engineered cysteine residues in proteins (Chapter 4).
The thiols require suitable protecting groups, as they are very nucleophilic and 
hence reactive. The protecting group must be stable enough to survive the 
conditions of the DNA synthesis, and must be stable to oxidising/reducing agents. 
It should also be relatively easy to remove once it is incorporated into the 
oligonucleotides. The protecting group chosen for the thiols was 2,4- 
dinitrophenyl (Meyer and Hanna, 1996), as it fulfils the above criteria. The effect 
of the structure and stability of DNA hybrids containing the analogue 5-[S-(2,4- 
dinitrophenyl-thio]-2'deoxyuridine have been studied (Yuriev et al., 1999).
2.2 Synthesis of the diazirine-containing nucleotide analogue
Diazirines can be synthesised from ketones in a two-step process (Church and 
Weiss, 1970; Figure 2.2.1). Treatment of the ketone with ammonia and 
hydroxylamine-O-sulfonic acid yields the diaziridine which can be oxidised to
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Figure 2.2 Illustration of the diazirine reactions
(1) Synthesis of the diazirine of levulinic acid and (2) proposed diazirine 
of 2'- deoxyuridine.
the diazirine using iodine and triethylamine. To make the diazirine target, it was 
necessary to first make the 5-acetyl derivative of 2'-deoxyuridine (Figure 2.2.2). 
An important precursor to the keto-compound is the hydroxymethyl compound, 
obtained by treating 2'-deoxyuridine with paraformaldehyde in the presence of 
base (Shiau et al., 1980), by formaldehyde addition. The 5-hydroxymethyl-2'- 
deoxyuridine was oxidised to the 5-formyluracil nucleoside using activated 
manganese dioxide (Matulic-Adamic and Watanabe, 1988).
2.3 Thiol-containing pyrimidine compounds
Reactions incorporating sulfur at the C-5 position of the pyrimidine ring were 
initially carried out on uracils. 5-Mercaptouracil and other S-substituted 
derivatives were synthesised (Bardos et al, 1955; Figure 2.3.1). 5-Aminouracil 
was diazotised and using an alkaline solution of sodium disulfide, the 5-uracilyl 
disulfide was produced. This was reduced to the free mercaptan using zinc 
reduction. 5-Mercaptomethyluracil was also synthesised (Giner-Sorolla and 
Medrek, 1966 and 1978; Figure 2.3.2). The 5-hydroxy methyl compound of uracil 
was first halogenated, then reacted with thioacetamide in dimethyl formamide, 
yielding 5-acetiminothiomethyluracil hydrochloride. This was heated in methanol 
yielding 5-mercaptomethyl uracil.
Coupling reactions of thiol-containing bases (and other modified bases) to the 
sugar group are reviewed in Wilson et al., 1995; Figure 2.4. The coupling of 5- 
mercaptouracil bis-O-trimethylsilyl derivatives to halogenated ribose compounds 
yielded anomeric 5-mercapto-2'-deoxyuridines (Bardos et al., 1966). The desired 
p-anomer was isolated in 37.5% yield, although yields in excess of 70% (Dinan et 
al., 1982) were also reported. The same methodology was also used to synthesise 
5-mercaptomethyl 2'-deoxyuridine (Gupta et al., 1975), and the desired P-anomer 
was obtained in 13-15% yield. Due to the difficulty in separating the anomers in 
these reactions, and the low yields of products, these reactions were omitted from 
this study.
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Figure 2.3 Reactions yielding sulfur-containing uracils
Scheme (1) shows the synthesis of 5-mercaptouracil from 5-aminouracil 
(Bardos et al, 1955) and (2) illustrates the synthesis of 5-mercaptomethyl 
uracil from uracil (Giner-Sorolla and Medrek, 1966).
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Figure 2.4 Coupling of sulfur-containing pyrimidines using glycosylation
Illustration of the synthesis of the 5-mercapto-2’ -deoxyuridine derivative 
(Bardos et a l, 1966). The equivalent coupling was carried out on the 5- 
mercaptomethyl derivative (Gupta et al., 1975).
1. CH3OBr/NaS2
2. NaBH4
3. azidophenacyl bromide
Figure 2.5 Illustration of the synthesis of 5-[(4-azidophenacyl)thio]uridine 5'- 
triphosphate
Diagram showing the synthesis of this photoactivatible nucleotide 
analogue (Hanna et al, 1989).
The nucleotide analogue 5-[(4-azidophenacyl)thio]uridine 5'-triphosphate was 
synthesised (Hanna et al., 1989; Figure 2.5) using a different strategy. The 5- 
mercapto-UTP (5-SH-UTP) was synthesised by treating the triphosphate with 
methylhypobromide and sodium disulfide, resulting in the disulfide being formed. 
Following treatment of the disulfide with sodium borohydride, the thiol was 
obtained, which was subsequently alkylated with azidophenacyl bromide. The 
same methodology was used to synthesise 5-[(4-azidophenacyl)thio]cytidine 5'- 
triphosphate (Hanna et al, 1993).
2.4 Direct Thioarylation Methods
These methods allow for the direct attachment of functional groups to the C-5 
position of pyrimidine nucleotides. These syntheses are potentially useful, as they 
would shorten the phosphoramidite route by allowing direct introduction of the 
protected sulfur moiety on the pyrimidine ring.
For these syntheses it was necessary to synthesise Z?z5’-(2,4-dinitrophenyl) 
disulfide. Reacting 2,4-dinitrobenzenesulphenyl chloride with acetic acid, 
followed by aqueous work up resulted in the disulfide (Kharasch et al., 1955).
The disulfide can be reduced to 2,4-dinitrothiophenol by mild reduction with 
glucose and base (Bordwell and Andersen, 1953). This monomer unit would be 
useful as it could react with a halide and be used in the synthesis of target B, as a 
way of introducing the protected thiol group directly on the pyrimidine ring. The 
thiol reagent 2,4-dinitrobenzene sulfenyl chloride can be used as a source of the 
protecting group in these methods.
The use of silver reagents to catalyse the addition of arylthiols to the C-5 position 
was reported (Lee and Kim, 1991; Figure 2.6.1). This thioarylation reaction has 
been used on a range of uridines and 2'-deoxyuridines. The reaction of triacetyl- 
protected uridine with AgOCOCF3 and benzene sulfenyl chloride resulted in C-5 
arylation at 98% yield (Lee and Kim, 1991). The analogous reaction with 3',5'-0- 
diacetyl-2'-deoxyuridine will be used as a method of direct incorporation of the
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Figure 2.6 5-Thioarylation using silver reagents
In (1) above the triacetyl derivative is thioarylated as shown and (2) is 
the proposed reaction for the diacetyl derivative.
protected thiol moiety (Figure 2.6.2). Higher yields of product were reported 
when AgOCOCF, was used instead of AgBF4 for the 3',5'-G-diacetyl-2'- 
deoxyuridine derivative.
Another way of introducing functionality at the C-5 position of the pyrimidine 
ring is to make the lithium salt of the base, then quench it with different 
electrophiles. This reaction allows the electrophiles to be added in a 
regioselective way. Very high selectivity of C-5 over C-6 incorporation was 
observed when bulky lithium bases and J-butyldimethylsilyl protecting groups on 
the sugar hydroxyls of 2'- deoxyuridine were used (Ogilvie et al, 1978; 
Armstrong et al, 1989; Figure 2.7.1). The lithiation reaction on 3',5'-bis -0-(t- 
butyldimethylsilyl)-2'-deoxyuridine was quenched with different disulfides and 
electrophiles. When &A(phenyl)disulfide was used to quench the lithium salt, a 
58% yield was found (Armstrong et al, 1989). A l3C-methyl labelled thymidine 
was synthesised from 2’-deoxyuridine (Ahmadian and Bergstrom, 1998). The 
lithiation reaction was used in this work as it reduced the synthesis of the 
phoshoramidite targets by three steps. The lithium salt was quenched with either 
Z?A-(2,4-dinitrophenyl)disulfide or 2, 4-dintrobenzenesulfenyl chloride (Figure 
2.7.2).
Another way of introducing functionality at the C-5 position of pyrimidines is by 
palladium cross-coupling reactions, using mercurated nucleosides with organic 
disulfides, acid and allyl chlorides (Bergstrom et al, 1991; Figure 2.8.1). When 
aromatic disulfides were used, i.e. fr/s(phenyl)disulfide, the incorporation at C-5 
was 52%. This reaction could potentially be used for introducing the protected 
thiol group in one step (Figure 2.8.2). A four atom linker was introduced using 
the coupling of allyl chloride using palladium, followed by oxidation, followed 
by thiol synthesis (Goodwin and Click, 1993; Figure 2.8.3). The starting material 
in these reactions is a very toxic mercuric salt, and the bis-(2,4- 
dinitrophenyl)disulfide is not soluble in the solvents required for the reaction, so 
this reaction was omitted from this study.
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Figure 2.7 Illustration of lithiation reactions
Diagram showing the lithiation of protected deoxyuridine and 
quenching with various electrophiles. (1) shows quenching with 
disulfide reagents, and (2) illustrates the proposed reaction where the 
sulfenyl chloride is the electrophilic species.
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Figure 2.8 Palladium catalysed thioarylation
In (1) the thioaryl group is added to the pyrimidine ring (Chang and 
Mertes, 1987; Bergstrom et a l, 1991); (2) shows the proposed reaction 
with £/s(2,4-dinitrophenyl)disulfide and (3) shows the synthesis of a three 
atom alkylthiol-tether (Goodwin and Glick, 1993).
2.5 Indirect methods of thiol incorporation
Introduction of thiol moieties at the C-5 position of pyrimidine rings can be 
achieved via thiocyanation. A thiocyanation reaction with 2'-deoxyuridine yielded 
the 5-thiocyanato derivative (Nagamachi et al., 1972; Torrence et al., 1978). The 
analogous reaction with the 5', 3'-diacetyl-2'-deoxyuridine (Nagamachi et al.,
1974, Meyer and Hanna, 1996) resulted in much higher yields of the product. The 
reaction is an electrophilic substitution reaction of the pyrimidine ring using 
thiocyanogen chloride (Angus and Bacon, 1958). The electrophilic reagent is 
generated in situ using potassium thiocyanate and chlorine gas in anhydrous 
glacial acetic acid. An important factor in the reaction is that a stoichiometric 
amount of thiocyanogen chloride is reacted with the pyrimidine ring. This can be 
determined by titration of the chlorine solution with sodium thiosulfate solution 
(Flascha et al., 1969). The reaction has also been carried out using lead 
thiocyanate as the source of thiocyanate (Bradley and Hanna, 1992).
For the synthesis of the 5-mercaptomethyl-2'-deoxyuridine analogue, it was 
necessary to try a number of different methods (see Section 2.9). The 5- 
thiocyanato, thioacetyl and mercaptomethyl derivatives of 2'-deoxyuridine have 
been made (Barwolff and Langen, 1975). These were made from the 5- 
bromomethyl precursor (Shiau et al., 1980, Sergiev et al., 1997), from reactions 
of the desired nucleophiles by simple SN2 reactions in dimethyl formamide.
2.6 Phosphoramidite Synthesis
For use in the DNA synthesiser, nucleotide analogues require specific protecting 
groups on the sugar hydroxyl groups. The 5'-primary hydroxyl on the sugar must 
be protected as a 4,4'-dimethoxytrityl (DMT) ether. These DMT groups are acid 
labile and thus easily removed during the DNA synthesis cycle, thus releasing the 
5'-OH for the coupling step. 5-[S-(2,4-Dinitrophenyl)thio]-2'-deoxyuridine is 
treated with 4,4'-dimethoxytrityl chloride in pyridine (Bradley and Hanna, 1992). 
An increase in efficiency of incorporation of the DMT group was reported
(Bleasdale et al., 1990) when the trityl tetrafluoroborate salt was used for the 
protection step.
There are a number of methods for carrying out phosphitylation of the 3'- 
hydroxyl of pyrimidines. These use different phosphorus reagents and different 
activators. The activated phosphoramidite, 2-cyanoethyl-A, A'-diisopropylchloro 
phosphine (Sinha et al, 1983) when reacted with the alcohol in the presence of 
diisopropylethylamine, yields the phosphoramidite. Another source of the 
phosphoramidite is the dimer, 2-cyanoethyl-A, N, N', 7V-tetraisopropyl 
phosphorodiamidite. It can be activated with tetrazole (Zhao and Landry, 1993; 
Meyer and Hanna, 1996) or tetrazole diisopropyl ammonium salt (Picken, pers. 
comm.). A method of phosphitylation using 2-cyanoethyl-A, N, N', N - 
tetraisopropyl phosphorodiamidite and pyridinium trifluoroacetate as the 
activator, has been developed (Sanghvi et al., 2000). Phosphoramidites are 
extremely reactive species and are very sensitive to air oxidation; the Pm species 
are easily oxidised to Pv.
Three different methods of making the phosphoramidite were used to determine 
which method was the most efficient and yielded the purest product. Method A 
(Meyer and Hanna, 1996) used tetrazole as the activator in the presence of 2- 
cyanoethyl tetraisopropylphosphorodiamidite in a 1:1 ratio, added in two separate 
portions to prevent over-activation. Method B (Picken, pers. comm.) used 2- 
cyanoethyl tetraisopropylphosphorodiamidite with 0.3 equivalents of the activator 
tetrazole diisopropyl ammonium salt. Method C (Sinha et al, 1983) used the 
phosphoramidite reagent 2-cyanoethyl-A, A'-diisopropylchloro phosphine with 2 
equivalents of diisopropylethylamine.
2.7 Synthetic routes to thiol targets
The compounds shown in Figure 2.1 are the synthetic targets. Requirements for 
the DNA synthesis are a trityl-protected primary alcohol (5'-OH) and a 
cyanoethyl phosphoramidite at the secondary hydroxyl (3'-OH) of the sugar.
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Figure 2.9 Synthetic route to target A
Illustration of the route used to synthesise the 5-DNP-protected thiol 
phosphoramidite
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Figure 2.10 Synthetic route to B
Illustration of the synthesis of the 5-mercaptomethyl derivative, starting 
from thymidine.
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Figure 2.11 'Proposed' synthetic route to B
Diagram showing the protection and the phosphoramidation of the 5- 
mercaptomethyl derivative.
These protecting groups are easily removed during DNA synthesis, and allow for 
propagation of the oligonucleotide chain.
The route to target A (Figure 2.1.2) is shown in Figure 2.9 (Meyer and Hanna, 
1996) and the proposed route to target B (Figure 2.1.3) is Shown in Figure 2.10 
and Figure 2.11.
2.8 Experimental
Reagents were purchased from Aldrich Chemical Company (Gillingham, UK), 
Avocado Synthesis (UK) or Lancaster Synthesis (UK) and were used without 
further purification. Organic solvents were obtained from Rhone-Poulenc-Rorer 
and were dried, where necessary, using the procedures described by Leonard et 
al., 1989. Melting points were recorded in open capillaries using a Gallenkamp
i napparatus and are uncorrected. H and C NMR spectra were recorded for 
solutions in CDC13 with tetramethylsilane as an internal standard on a Bruker
DPX/400 spectrometer operating at 400 and 100 MHz respectively, unless
notherwise stated. C NMR spectra were assigned with the aid of Distortionless 
Enhancement by Polarisation Transfer (DEPT)-edited spectra. All coupling 
constants are measured in Hz. Thin layer chromatography was performed using 
Merck aluminium-backed silica plates of 0.25 mm thickness. Chromatograms 
were visualised using UV illumination at 254 nm, staining with iodine or using a 
variety of common stains prepared by the methods described in Leonard et al, 
1989. Column chromatography was carried out on silica gel (particle size 70-230 
mesh). Mass spectra (MS) were recorded on AEI MS 12 or MS902 spectrometers 
using the electron-impact ionisation (El) mode or, if stated, chemical ionisation 
(Cl) or fast atom bombardment (FAB) modes. Infra-red (IR) spectra were 
recorded on a Perkin Elmer PU 9800 FT-IR spectrometer. Combustion analysis 
was carried out on a Carlo-Erba 1106 elemental analyser.
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4, 4-Azopentanoic acid SH PI (Church and Weiss, 1970)
l = N
A solution of 4-ketopentanoic acid (3.17 g, 27.2 mmol) in liquid ammonia (40 
ml) was stirred for 5 h at reflux. The solution was cooled to -78 °C using an 
acetone/dry C 02 bath, and a suspension of hydroxylamine-O-sulphonic acid (3.8 
g, 33.6 mmol) in dry methanol (10 ml) was added over a period of 30 min. The 
mixture was stirred at reflux for 1 h, the ammonia was then evaporated overnight. 
The resulting slurry was filtered and the solid washed with methanol ( 5 x 1 0  ml). 
All washings were combined with the original filtrate and the solution was 
concentrated in vacuo to about 10 ml. Excess ammonia was removed using an oil 
pump (< 0.1 mmHg) until no odour was detected. The crude methanolic solution 
of 4,4-hydrazipentanoic acid was diluted with dry methanol (20 ml), cooled in an 
ice bath and treated with triethylamine (3.46 ml, 24.8 mmol) and solid iodine (3.6 
g, 14.2 mmol) was added over 1 h. After all the iodine was added, a red colour of 
excess iodine persisted. The solution was concentrated in vacuo to 20 ml and then 
diluted with brine (50 ml). The solution was extracted with diethyl ether (3 x 50 
ml), and the combined extracts were dried using MgS04, filtered and 
concentrated in vacuo yielding the title compound as a brown oil (509.7 mg, 
14.6%). The residue was rigorously dried using an oil pump (< 0.1 mmHg).
New data: (Found C, 46.88; N, 21.78; H, 6.38. C5H8N20 2 requires C, 46.89; N, 
21.86; H, 6.25%); v„,„ (liquid film, NaCl plates)/cm' 2928m (OH), 1715s (CO), 
1585s (N=N); 8„ (CDC1,) 0.97 (3H, s, CH,-5), 1.63 (2H, t, J=7.8, CH,-3), 2.16 
(2H, t, J=7.8, CH2-2), 7.19 (1H, s, OH); 5C (CDC13) 18.7 (CH3-5), 27.6 (CH2-3),
28.3 (CH2-2), 44.5 (C-4), 177.3 (CO); m/z (CI+) 129.0664 (M+H)+ C5H9N20 2 
requires 129.0663; m/z (%) 129.11 (32), 101.1 (100), 83 (85).
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4,4-Azopentanoyl chloride SH P2 (Church and Weiss, 1970)
l = N
A solution of 4,4 azopentanoic acid (235 mg, 1.83 mmol) and oxalyl chloride 
(0.192 ml, 2.20 mmol) was stirred for 16 h under nitrogen. The excess oxalyl 
chloride was removed in vacuo yielding the title compound as an oil (88%) which 
was difficult to purify. It was difficult to get rid of the excess oxalyl compound as 
the product is too volatile and viscous to purify by vacuum distillation.
p-Nitrophenyl 4,4-azopentanoate SH P3 (Endo et al., 1982)
l = N
N02
A solution of 4,4-azopentanoic acid (234.8 mg, 1.83 mmol), DCC (0.49 g, 2.38 
mmol), DMAP (43.9 mg, 0.36 mmol) and 4-nitrophenol (0.25 g, 1.83 mmol) in 
dichloromethane (5 ml) was stirred overnight at room temperature. Solvents were 
removed in vacuo yielding a yellow solid that was further purified using silica 
chromatography eluting with chloroform. The product was collected and 
concentrated in vacuo yielding a clear gum, (40 mg, 8.7%).
New data: Rf = 0.47 (chloroform); vmax (liquid film, NaCl plates)/cm1 2925s 
(CH), 1765s (CO), 1592s (N=N), 1347s (NOJ and 864s (Ar-H); 8U (CDC1 ) 1.03
2 H 3
(3H, s, H-5), 1.80 (2H, t, J = 7.4, CH3-3), 2.40 (2H, t, J = 7.4, CH2-2), 7.22 (2H, 
m, HI' and H2'), 8.20 (2H, m, H3' and H4'); 5C (CDC13) 20.1 (CH3-5), 29.3 (CH2- 
3), 29.7 (CH2-2), 60.7 (C-4), 122.7 (CH-3' and CH-4'), 125.6 (CH-1' and CH-2’),
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138.5 (C-0), 155.6 (C-N02) and 170.3 (CO); m/z (CI+) 250.0829 (M+H)+ 
Ci2Hi2N3°4 recluires 250.0823; m/z (%) 250.1 (100), 222.1 (55), 140 (30).
5-Hydroxymethyl-2'deoxyuridine SH P4 (Shiau et a l, 1980)
HN OH
HO
OH
Paraformaldehyde (260 mg, 8.9 mmol) was added to a solution of 2'-deoxyuridine 
(200 mg, 0.87 mmol) in potassium hydroxide (0.5 M; 5 ml). The solution was 
heated to 60 °C for 6 d. After 1 and 3 d the pH of the solution was adjusted to 11 
using potassium hydroxide (0.5M, 2 ml). The reaction mixture was cooled and 
neutralised using freshly activated Dowex 50WX8(H+) resin for 1 h. The solution 
was filtered and concentrated in vacuo yielding the crude product that was 
purified using column chromatography on silica, eluting with 4:1 
chloroforrmmethanol. The title compound was obtained as white prisms (18 mg, 
7.9%); mp = 177-180 °C (Shiau et a l, mp = 179-180 °C); Rf = 0.28 (4:1 
chloroform:methanol); (Found C, 46.15; H, 5.32; N, 10.93. C10H14N2O6 requires 
C, 46.53; H, 5.42; N, 10.85%); (CDC1,) 2.51 (1H, m, H-2'), 2.50 (1H, m, H-
2"), 3.55 (1H, dd, J= 11.9 and 3.3, H5'), 3.56 (1H, dd, J = 11.9 and 3.3, H5"), 3.84 
(1H, m, H-4'), 4.12 (2H, m, CH2-5), 4.30 (1H, dd, J = 3.9 and 1.9, H-3’), 4.95 
(1H, m, CH2OH), 5.25 (1H, m, OH-5'), 5.40 (1H, d, J = 5.4, OH-3'), 5.80 (1H, dd, 
J = 5.8, H-l'), 7.45 (1H, s, J = 7.89, H-6), 11.40 (1H, br. s, NH); m/z (CI+)
259.2325 (M+H)+ C10H15N2O6 requires 259.2310; m/z (%) 259.2 (14), 201.1 (8) 
and 81.0 (100).
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New data: vmax(KBr discycm"1 3506s (OH), 3045w (CH), 1775s and 1690s (CO) 
and 1600s (C=C); 6C (CDC13) 56.3 (CH2-2'), 61.4 (CH2-7), 63.2 (CH2-5'), 70.4 
(CH-4’), 73.6 (CH-3’), 89.7 (CH-1'), 114.5 (C-5), 137.4 (C-6), 151.0 (CO), 162.9 
(CO).
2',3',5'-Bis -0-(r-butyldimethylsilyl)-uridine SH P5 (Ogilvie et al., 1978)
HIM'
— $iO
A solution of uridine (0.50 g, 2.04 mmol), ferf-butyldimethylsilylchloride (2.16 g,
14.3 mmol) and imidazole (1.95 g, 28.5 mmol) in dry dimethylformamide (5 ml) 
was stirred for 8 h at room temperature. The solvent was removed in vacuo, the 
residue dissolved in a minimum amount of chloroform, and purified using 
column chromatography on silica, eluting with 2:1 ether:hexane. The relevant 
fractions were pooled yielding the title compound as a white gum (1.12 g,
93.0%).
New data: mp=76.2-78.4 °C; Rf= 0.56 (2:1 ether:hexane); (Found C, 54.60; H, 
9.27; N, 4.74. C27H54N20 6Si3 requires C, 55.28; H, 9.20; N, 4.77%); vmax (KBr 
disc)/cm-1 2955 and 2930w (CH), 1695s (CO), 1274s (SiC), 836s (SiO); 5U 
(CDC13) -0.03, -0.02, 0.00 and 0.01 (18H, 6 x s, 6 x SiMe), 0.78 and 0.81 (27H,
3 x s, 3 x r-butyl), 3.67 (1H, d, J = 11.5, H-5'), 3.90 (1H, d, J = 11.5, H-5"), 3.98 
(1H, d, J = 3.0, H-31), 3.99 (1H, m, H-4’), 4.00 (1H, d, J = 3.4, H-2’), 5.59 (1H, d, 
J = 8.1Hz, H-5), 5.77 (1H, m, H-l'), 7.79 (1H, d, J = 8.1, H-6), 8.89 (1H, br. s, 
NH).SC (CDC13) -5.2 to -3.8 (6 x SiMe), 18.3, 18.4 and 18.8 (3 x qC), 26.1, 26.2 
and 26.3 (3 x r- butyl CH3), 62.1 (C-5), 71.1 (C-4), 76.5 (C-2), 84.8 (C-3), 89.3
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(C-l), 102.2 (C-5), 140.7 (C-6), 150.5 (CO) and 163.6 (CO); m/z (CI+) 587.3373
(M+ H)+ C27H54N20 6Si3 requires 587.3368 m/z (%) 587.7 (100), 529.2 (40), 343.2 
(30).
3',5'-Bis -(9-(r-butyldimethylsilyl)-2'-deoxyuridine SH P6 (Ogilvie et al., 1978; 
Ahmadian and Bergstrom, 1998)
HN
A solution of 2'-deoxyuridine (0.20 g, 0.87 mmol); terr-butyldimethylsilyl- 
chloride (0.92 g, 6.13 mmol) and imidazole (0.83 g, 12.2 mmol) in dry 
dimethylformamide (3 ml) was stirred for 8 h at room temperature. The solvent 
was removed in vacuo and the residue was dissolved in a minimum amount of 
chloroform, then purified using silica chromatography with 2:1 ethenhexane as 
eluant. The relevant fractions were pooled yielding the title compound as a white 
gum (0.38 g, 95.0%); (Found C, 54.87; H, 8.88; N, 5.80. C21H40N2O5Si2 requires 
C, 55.26; H, 8.76; N, 6.13%); vmax (KBr discycin1 2955 and 2929w (CH), 1704s 
(CO), 1277s (SiC), 837s (SiO); SH (CDC13) -0.03, -0.02, 0.00 and 0.01 (12H, 4 x 
s, 4 x SiMe), 0.78 and 0.81 (18H, 2 x s, 2 x f-butyl), 1.95 (1H, m, H-2’), 2.22 (1H, 
m, H-2"), 3.64 (1H, m, H-4'), 3.81 (3H, m, H-4' and H-5’), 4.31 (1H, m, H-3'),
5.57 (1H, d, J = 8.1Hz, H-5), 6.18 (1H, m, H-l'), 7.79 (1H, d, J = 8.1), 8.28 (1H, 
br. s, NH).
New data: mp=l 10-112 °C; Rf= 0.41 (2:1 ethenhexane); (Found C, 54.87; H, 
8.88; N, 5.80. C21H40N2O5Si2 requires C, 55.26; H, 8.76; N, 6.13%); 5C (CDC13) -
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5.2 to -4.2 (4 x SiMe), 18.3, 18.7 (2 x qC), 26.0 and 26.2 (2 x r- butyl CH3), 42.3 
(CH2-2'), 62.8 (CH2-5'), 71.5 (CH-4’), 85.5 (CH-3'), 88.1 (CH-1'), 102.4 (CH-5),
140.5 (CH-6), 150.3 (CO) and 163.3 (CO); m/z (CI+) 457.2555 (M+ H)+ 
C21H4]N20 5Si2 requires 457.2556 m/z (%) 457.5 (100), 213.3 (22), 145.3 (44).
b/s-(2,4-dinitrophenyl)disulfide SH P7 (Kharasch et al., 1955)
,N02
o 2n- n o 2
o 2n
A solution of 2,4-dinitrobenzenesulfenyl chloride (1 g, 4.26 mmol) in glacial 
acetic acid (14.7 ml) was warmed until complete dissolution occurred, then 
allowed to stir for a further 5 min. After the addition of water (9.8 ml), a yellow 
precipitate ensued. Further water (14.7 ml) was added to the reaction vessel, and 
the mixture was stirred for 20 min. The yellow solid was collected by vacuum 
filtration, and dried overnight in vacuo using P20 5. The crude yellow solid was 
heated at reflux in freshly dried (distilled from CaH2) benzene (20 ml). The 
insoluble material was collected by filtration, washed with diethyl ether and dried 
over P2Os in vacuo yielding the title compound as a pale yellow solid (1.43 g, 
84.3%); mp = 235-239 °C (dec.) (Kharasch et al., 1955, mp = 240-280 °C).
New data: Rf = 0.56 (2:1 ether:hexane); vmax (KBr )/cm 1 1598 (Ar), 1535 and 
1350 (N 02) stretch and 809 (p-disubstituted Ar); 5H (DMSO) 7.20 (2H, d, J = 8.4, 
H-l and H-l'), 8.24 (2H, dD, J = 1.2,8.4, H-2 and H-2') and 8.87 (2H, d, J = 1.2,
H-3 and H-3'); m/z (EI+) 397.9625 (M+) C12H6N4S2 requires 397.9630; m/z (%)
398.0 (12), 199.0 (100), 95.0 (52) and 63.0 (87).
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2,4-Dinitrobenzenethiol SH P8 (Bordwell and Andersen, 1953; Kharasch and 
Parker, 1959)
,n o 2
o 2n- SH
The disulfide SH P7 (4.26 g, 10.7 mmol) and glucose.H20  (5.94 g, 30 mmol) in 
ethanol (15 ml) was heated to 60 °C. Once the temperature was reached, NaOH 
(2.4 g, 60 mmol) in H20  (6 ml) was added dropwise. The mixture was kept at 60 
°C for 15 min, then the reaction was diluted with H20  (to 100 ml) and filtered 
into HC1 and ice (10 ml). The mixture was kept on ice until a orange-brown 
precipitate appeared. The solid was collected by filtration, dissolved in water and 
extracted with chloroform. The organic layer was dried with M gS04, and 
concentrated in vacuo yielding the crude product (530 mg, 24.7%). This was 
purified using column chromatography on silica eluting with 4:1 
chloroform:methanol yielding the title compound as a red solid (70 mg, 13.2% 
from crude); mp = 132-134 °C (Kharasch and Parker, 1959, mp = 128-130 °C).
New data; Rf = 0.27 (4:1 chloroforrmmethanol); vmax (KBr )/cm ' 2253 (SH), 
1598 (Ar), 1529 and 1342 (N02) stretch and 898 (p-disubstituted Ar); 8h 
(DMSO) 7.56 (1H, d, J = 8.7, H-l), 8.20 (1H, dd, J = 8.7, 2.4, H-2) and 9.05 (1H,
d, J = 2.4, H-3)\m/z (EI+) 199.9893 (M+) C6H3N2S requires 199.9892; m/z (%) 
199.98 (30), 149.0 (15), 106.0 (15) and 82.9 (100).
3',5'-0-Diacetyl-2,-deoxyuridine SH P9 (Lin and Gao, 1983)
HN
AcO-
OAc
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2’-Deoxyuridine (2.2 g, 9.6 mmol) was evaporated three times with anhydrous 
pyridine (3 x 10 ml) then re-dissolved in pyridine (20 ml) and freshly distilled 
acetic anhydride (10.7 ml, 96.9 mmol) and imidazole (1.86 g, 13.6 mmol) were 
added. The reaction was stirred overnight at 40 °C. The pyridine was removed in 
vacuo and the residue was azeotroped with toluene (3x15  ml). The resulting oil 
was recrystallised from ethanol yielding the product as white needles (2.51 g, 
82.3%); mp = 126-128 °C (Lin and Gao, 1983, mp = 106-108 °C); 5H(CDC13)
2.05 and 2.04 (3H, 2 x s, OCH3-5’ and OCH3-3’), 2.11 (1H, m, H-2’), 2.48 (1H, 
ddd, J = 14.2, 5.6 and 1.9, H-2” ), 4.20 (1H, ddd, J = 6.7, 5.9 and 3.9, H-4’), 4.29 
(1H, dd, J=  12.1 and 4.2, H-5’) and 4.30 (1H, dd, J=  12.1 and 4.2, H-5” ), 5.15 
(1H, dd, J = 6.4 and 6.4, H-3’), 5.72 (1H, d, J = 8.2, H-5), 6.22 (1H, dd, J = 5.6 
and 5.6, H -l’), 7.43 (1H, d, J = 8.2, H-6) and 9.58 (1H, br. s, NH).
New data: Rf= 0.7 (4:1 CHCl3:MeOH); (Found C, 49.99; H, 5.12; N, 8.93. 
C13H16N20 7 requires C, 50.02; H, 5.13; N, 8.97%); vmax(KBr discVcm'1 3183m 
(NH), 3062w (CH), 1745s and 1689s (CO) and 1624s (C=C); 6c(CDC13) 21.2 
(OCH3-5’ and OCH3-3’), 38.2 (CH2-2’), 64.1 (CH2-5’), 74.4 (CH-4’), 82.7 (CH- 
3’), 85.7 (CH-1’), 103.3 (CH-5), 139.2 (CH-6), 150.7 (CO), 163.5 (CO), 170.6 
and 170.7 (OCCH3-5’ and OCCH3-3’); m/z (EI+) 312.0956 (M+) C13H16N20 7 
requires 312.0965; m/z (%) 312.1 (10), 201.1 (20) and 81.0 (100).
3', 5'-0-Diacetyl-5-(thiocyanato)-2'-deoxyuridine SH P10 (Meyer and Hanna, 
1996)
SCN
HN'
AcO-
OAc
Anhydrous glacial acetic (65 ml) was placed in a three-necked flask with a 
bubbler delivering dry Cl2 gas. The gas was bubbled through until a deep yellow
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colour persisted after which time a 5 ml aliquot was removed and titrated against 
a known standard of sodium thiosulfate. To this solution of Cl2 (3.68 g, 51.9 
mmol) was added potassium thiocyanate (5.57 g, 57.4 mmol) which had been 
dried overnight at 100 °C. The reaction mixture was stirred at room temperature 
for 30 min, then 3', 5'-diacetyl-2'-deoxyuridine (1.61 g, 5.18 mmol) SH P9 was 
added. The mixture was then stirred for a further 90 min before cyclohexene (10 
ml) was added to remove any unreacted Cl2. After stirring for 15 min, the reaction 
mixture was filtered and the filtrate was concentrated in vacuo at > 40 °C. 
Residual glacial acetic acid was removed azeotropically with toluene and the 
residue was triturated overnight with 40-60° petroleum ether. The ether was 
decanted and the residue was dried briefly on a rotary evaporator. The crude mix 
was further purified using column chromatography on silica eluting with 20:1 
ethyl acetate:acetone yielding the title compound as an off-white solid which was 
recrystallised from ethanol (1.41 g, 73.5%); mp = 151-152 °C (Meyer and Hanna,
1996, mp = 154-156 °C); vm„ (KBr disc)/cm'' 3083m (NH), 2161s (SCN), 1730s 
and 1690s (CO) and 1619s (C=C); 8U (CDC1,) 2.06 and 2.11 (3H, 2 x s, OCH -5'
H 3 3
and OCH3-3'), 2.16 (1H, m, H-2’) and 2.56 (1H, ddd, J = 14.2, 5.7 and 2.1, H-2"), 
4.27 (1H, ddd, J = 6.7, 5.9 and 3.9, H-4'), 4.39 (1H, dd, J = 12.1 and 4.2, H-5'), 
4.40 (1H, dd, J = 12.1 and 4.2, H-5”), 5.16 (1H, ddd, J = 6.4, 4.2 and 2.1, H-3'), 
6.16 (1H, dd, J = 5.7 and 7.8Hz, H-l'), 8.08 (1H, s, H-6), and 9.38 (1H, br. s,
NH).
New data: Rf= 0.65 (20:1 ethyl acetate:acetone); (Found C, 45.35; H, 4.18; N,
11.27. C]4H15N30 7S requires C, 45.55; H, 4.06; N, 11.37%); UV (MeOH) Xmax = 
268 nm, 8 = 17,500 1 m ol1 cm 1; 5C (CDCI3) 21.2 and 21.3 (OCH3-5’ and OCH3- 
3'), 38.9 (CH2-2*), 63.9 (CH2-5'), 74.2 (CH-4'), 83.5 (CH-3'), 86.8 (CH-1'), 109.3 
(C-5), 138.5 (qCN), 144.7 (CH-6), 149.5 (CO), 159.6 (CO), 170.6 and 170.7 
(0 0 1 ,-5 ' and OCH3-3’); m/z (CI+) 387.0972 (M+NH4)+ C]4H]9N4 0 ?S requires 
387.0978; m/z (%) 387.1 (100), 217.1 (45) and 200.1 (11).
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3',5'-0-Diacetyl-5-mercapto-2'-deoxyuridine SH P l l  (Meyer and Hanna, 1996)
SH
HN
AcO'
OAc
Ethylenediaminetetraacetic acid (EDTA) disodium salt (169 ml, 0.1M, pH 7.7) 
and dithiothreitol (2.0 g, 12.9 mmol) were added to a solution of the thiocyanate 
SH P10 (1.41 g, 3.8 mmol) in methanol (200 ml). The reaction mixture was 
stirred at room temperature for 35 min and then filtered. The filtrate was reduced 
to half volume by rotary evaporation, acidified with 10% (v/v) H2S 04 and 
extracted with dichloromethane (3 x 50 ml). The organic extract was then 
concentrated in vacuo and the residue was triturated with water providing the title 
compound as a white crumbly solid, (0.98 g, 75.3 %); mp = 153-154 °C (Meyer
and Hanna, 1996, mp = 159-163 °C); vmax (KBr disc)/cm' 3013m (NH), 2527s 
(SH), 1744s and 1696s (CO), 1625s (C=C); 5h (CDC13) 2.05 and 2.12 (3H, 2 x s, 
OCH3-5' and OCH3-3'), 2.13 (1H, m, H-2') and 2.44 (1H, ddd, J = 14.2, 5.7 and 
2.1, H-2"), 3.55 (1H, br.s, SH), 4.21 (1H, dd, J = 5.9 and 3.0, H-4'), 4.30 (1H, 
ddd, J = 12.2, 3.4 and 3.0, H-5'), 4.31 (1H, ddd, J = 12.2, 3.4 and 3.0, H-5"), 5.16 
(1H, ddd, J = 6.4, 4.6 and 2.2, H-3'), 6.25 (1H, dd, J = 8.1 and 5.7, H -l’), 7.60 
(1H, s, H-6), and 8.90 (1H, br. s, NH).
New data: Rf = 0.26 (20:1 chloroform:methanol); (Found C, 45.39; H, 4.72; N, 
7.95 Cl3Hl6N20 7S requires C, 45.37; H, 4.65; N, 8.14%); UV (MeOH) Xmax = 260 
nm, £ = 16,500 1 m ol1 cm'1 and 320 nm £ = 21,000 1 mol'1 cm'1; 8C (CDC13) 21.2 
and 21.3 (OCH3-5' and OCH3-3’), 38.3 (CH2-2'), 64.2 (CH2-5')f 74.4 (CH-4'), 82.8 
(CH-3'), 85.6 (CH-1’), 106.3 (C-5), 138.5 (CH-6), 149.9 (CO), 161.1 (CO), 170.6 
and 170.7 (OCH3-5' and 001 ,-3 '); m/z (EI+) 344.0681 (M+) C]3H]6N20 7S requires 
344.0972; m/z (%) 344.1 (8), 201.1 (10), 144.0 (12) and 81.0 (100).
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3',5'-0-Diacetyl-5-[S-(2,4-dinitrophenyl)thio]-2'-deoxyuridine SH P12 (Meyer
and Hanna, 1996)
no2
HN
AcO'
OAc
2,4-Dinitrofluorobenzene (134 mg, 0.73 mmol) and triethylamine (486 pi) were 
added to a solution of the mercaptan SH P ll  (200 mg, 0.58 mmol) in anhydrous 
acetonitrile (24 ml). The reaction mixture was stirred for 90 min at room 
temperature after which time the solvent was removed in vacuo. The crude 
material was purified using column chromatography on silica eluting with 1:1 
hexane:ethyl acetate. The title compound was obtained as shiny yellow flakes
(186 mg, 62.8%); vmax (KBr disc)/cm' 3447m (NH), 1700s and 1695s (CO), 
1616s (C=C), 1560 and 1340 (NOz); 5H (CDC13) 2.00 and 2.04 (3H, 2 x s, OCH3- 
5' and OCH3-3’), 2.24 (1H, m, H-2') and 2.53 (1H, ddd, J = 14.4, 5.8 and 2.4, H- 
2"), 4.20 (1H, d, J = 2.9, H-4'), 4.30 (1H, ddd, J = 11.0, 3.6 and 2.7, H-5'), 4.31 
(1H, ddd, J = 11.0, 3.6 and 2.7, H-5"), 5.15 (1H, dd, J = 6.5 and 3.2, H-3'), 6.18 
(1H, dd, J = 7.2 and 6.2, H -l’), 7.27 (1H, d, J = 9.8, H-8), 8.16 (1H, s, H-6), 8.17 
(1H, dd, J = 9.9 and 2.4, H-9) and 8.95 (1H, d, J = 2.4, H-l 1).
New data: mp = 85-87 °C (dec.); Rf = 0.20 (1:1 hexane:ethyl acetate; (Found C, 
44.40; H, 3.78; N, 10.46 C19HlgN4OnS requires C, 44.72; H, 3.53; N, 10.97%); 
UV (MeOH) Xmax = 260 nm, £ = 17,300 1 mol'1 cm'1 and 319 nm £ = 24,500 1 mol"1 
cm'1; 6C (CDC13) 19.8 and 20.0 (OCH3-5’ and OCH3-3'), 37.2(CH2-2'), 62.5 (CH2- 
5'), 72.6 (CH-4'), 81.8 (CH-3'), 85.1 (CH-1'), 102.1 (C-5), 120.6 (CH-8), 126.2 
(CH-9), 127.6 (CH-11), 143.4 (C-10), 143.5 (C-12), 144.0 (C-7), 146.2 (CH-6),
148.7 (CO), 159.6 (CO), 169.2 and 169.4 (OCH3-5' and OCH3-3’); m/z (EI+)
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510.0690 (M+) C]9H]8N4OnS requires 510.0695; m/z (%) 510.1 (8), 201.1 (12) 
and 81.0 (100).
5-[1S-(2,4-Dinitrophenyl)thio]-2'-deoxyuridine SH P13 (Meyer and Hanna, 1996)
no2
HN
HO-
OH
Sodium metal (25 mg, 1.08 mmol) in anhydrous methanol (2 ml) was added to 
the diacetate SH P12 (208 mg, 0.408 mmol) in anhydrous methanol (12 ml). The 
mixture was stirred at room temperature for 2 h, then neutralised with freshly 
washed Dowex 50WX4 and filtered. The filtrate was concentrated in vacuo and 
the crude product was purified by column chromatography on silica, eluting with 
ethyl acetate. The title compound was obtained as a yellow solid (150 mg,
86.3%); vmax (KBr disc)/cm'' 3436m (OH), 1686s (CO), 1596s (Ar), 1521s and 
1341s (NO,) and 1048s (C-OH); 8U (MeOD) 2.26 (1H, m, H-2'), 2.27 (1H, m, H-
2 H
2"), 3.60 (1H, dd, J= 12 and 3, H5’), 3.69 (1H, dd, J = 12 and 3, H5"), 3.84 (1H, d, 
J = 3.1, H-4'), 4.30 (1H, dd, J = 3.9 and 1.9, H-3'), 6.14 (1H, dd, J = 6.2 and 6.2, 
H-l'), 7.45 (1H, d, J = 8.9, H-8), 8.20 (1H, dd, J = 8.9 and 2.2, H-9), 8.64 (1H, s, 
H-6) and 8.87 (1H, d, J = 2.4, H-l 1).
New data: mp = 124-126 °C (dec.), Rf = 0.19 (ethyl acetate); UV(MeOH) Xmax = 
267 nm, e = 16,800 1 mol' 1 cm' 1 and 325 nm £ = 27,500 1 mol' 1 cm'1; 8C (MeOD)
42.4 (CH2-2'), 62.7 (CH2 -5'), 72.1 (CH-41), 88.0 (CH-3'), 89.7 (CH-1'), 103.3 (C- 
5), 122.6 (CH-8), 128.6 (CH-9), 130.7 (CH-11), 146.2 (C-10), 146.6 (C-12),
147.1 (C-7), 151.0 (CH-6), 152.2 (CO), 163.9 (CO); m/z (FAB) 427.0568 (M+H)+
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Ci5Hi5N4° 9S re9uires 427.0550; m/z (%) 426.9 (14), 306.9 (55), 288.9 (30) and 
153.9(100).
5'0-(Dimethoxytrityl)-5-[,5'-(2,4-dinitrophenyl)-thio]-2,-deoxyuridine SH P14 
(Meyer and Hanna, 1996; D. Picken, pers.comm.)
OMe
n o 2
o 2n
OH
OMe
The dihydroxy compound SH P13 (493 mg, 1.16 mmol) was thoroughly dried 
using an oil pump then azeotroped with anhydrous pyridine (2 x 5  ml). To the 
reaction flask was added 4,4'-dimethoxytrityl chloride (471 mg, 1.39 mmol) and 
anhydrous pyridine (15 ml). The mixture was stirred overnight at room 
temperature under argon. The reaction was monitored by tic and after 48 h 
stirring, methanol was added to destroy any excess trityl chloride. The solution 
was concentrated in vacuo, yielding a gum which was dissolved in 
dichloromethane (50 ml) and washed with saturated sodium hydrogen carbonate 
(30 ml) and brine (30 ml). The organic layer was dried using magnesium sulphate 
and concentrated in vacuo, yielding material which was purified using column 
chromatography eluting with 9:1 dichloromethane: methanol (and 0.5% 
triethylamine), yielding the title compound as a yellow gum (710 mg, 84.0%); 
5U(CDC1 ) 2.32 (1H, m, H-2'), 2.51 (1H, m, H-2"), 3.27 (1H, m, H5'), 3.28 (1H,
H 3
m, H4"), 3.71 (6H, s, 2 x OMe), 4.01 (1H, m, H-5'), 4.03 (1H, m, H-5"), 4.56 (1H, 
m, H-3’), 6.32 (1H, dd, J = 7.5 and 5.8, H-l'), 6.75 (1H, d, J = 8.9, H-8), 6.99-7.61
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i
(13H,m, trityl group), 7.97 (1H, dd, J = 8.9 and 2.4, H-9), 8.34 (1H, s, H-6) and 
8.94 (1H, d, J = 2.4, H -ll); m/z (FAB) 728.1784 (M+H)+ C3fiH32N4OnS requires 
728.1790; m/z (%) 727.9 (10), 303.0 (100), 153.9 (15) and 102.4 (32).
New data: mp =134-138 °C; Rf = 0.71 (9:1 dichloromethane:methanol, 0.5%
triethylamine); vmax (KBr disc)/cm' 3436m (OH), 2853w (O-Me), 1695s (CO), 
1596s (CO), 1508s and 1340s (N 02) and 734s (trityl); 6C (CDC13) 45.6 (CH2-2'),
63.8 (CH2-5'), 73.0 (CH-4'), 86.5 (CH-3'), 87.3 (C-31), 87.5 (CH-1’), 103.3 (CH- 
5), 113.5 (CH-15, CH-17, CH-27 and 29), 121.8 (CH-8), 127.2 (CH-22), 128.3 
(CH-20, CH-21, CH-23 and CH-24), 128.7 (CH-9), 129.5 (CH-11), 130.0 (CH- 
14, CH-18, CH-26 and CH-30), 138.5 (C-12), 139.8 (C-10), 144.2 (C-13 and C- 
25), 144.9 (CH-19), 145.9 (C-7), 148.1 (CH-6), 151.5 (C-19), 158.8 (C-16), 158.9 
(C-28)and 162.1 (CO).
4,4'-Dimethoxytrityl Alcohol SH P15 (Bleasdale et al., 1989)
OH
4,4'-Dimethoxytrityl chloride (3.38 g, 10 mmol) in tetrahydrofuran-0.5M aqueous 
sodium hydroxide (40 ml, 1:1, v/v) was stirred at room temperature for 30 min. 
The mixture was then extracted with dichloromethane (80 ml), dried using 
sodium sulfate, filtered and concentrated in vacuo. The crude material was 
purified by column chromatography on silica, eluting with 9:1
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dichloromethane:methanol, yielding the title compound as an orange oil which 
was precipitated from ether-pet.ether (2.36 g, 73.7%); mp = 75-76 °C (Bleasdale 
e ta l, 1990, mp = 75-77 °C); 8H (DMSO) 3.71 (6H, s, 2 x OCH3), 6.22 (1H, s, 
OH), 6.83 and 7.08 (8H, 2 x AA'BB' Ar ring A and B protons) and 7.25 (5H, m, 
ring C protons).
New data: Rf = 0.32 (dichloromethane); (Found C, 77.78 and H, 6.34 C2]H2Q0 3
requires C, 77.76 and H, 6.24%); vmax (KBr disc)/cm' 3506s (OH), 2932m (CH) 
and 1508 and 830 (ArH); 5C (DMSO) 55.3 (CH3-3 and CH3-16), 80.2 (C-19),
113.1 (C-2, 4, 15 and 17), 126.8 (C-10), 127.7 (C-9 and 11), 127.9 (C-8 and 12),
129.2 (C-l, 5, 14 and 18), 140.5 (C-6 and 13), 148.6 (C-7), 158.1 (C-3 and 16);
m/z (CI+) 320.1416 (M+ H)+ C2]H2]0 3 requires 320.1413; m/z (%) 320.1 (45),
243.1 (100), 213.1 (30), 135 0 (63).
4,4'-Dimethoxytrityl Tetrafluoroborate SH P16 (Bleasdale et al., 1989)
C4 BF4
SH P15 (0.99 g, 3.08 mmol) was dissolved in warm acetic anhydride (6.04 ml, 64 
mmol). The solution was allowed to cool, and 40% aqueous tetrafluoroboric acid 
(1.08 ml, 14.6 mmol) was added at such a rate that the temperature of the reaction 
mixture did not rise above 25 °C (over 1 h), at which time a dark red solution had , 
formed. Addition of dry ether (100 ml) caused the product to precipitate as deep
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orange crystals. These were dried in vacuo on a rotary evaporator (20 mm Hg) 
for 1 h, then using an oil pump (< 0.1 mm Hg) for 2 h to give the title compound 
as crimson needles, (1.15 g, 96.2%); mp = 165-168 °C (Bleasdale et al., 1990, mp 
= 193-196 °C); 5H (DMSO) 4.08 (6H, s, 2 x OCH3), 7.20-7.66 (13H, m, rings A,
B and C protons); m/z (EI+) 303.1385 (M+ -BF4 ) C2]H19BF40 2 requires 303.1385; 
m/z (%) 303.1 (100), 257.1 (26), 129.1 (28).
New data; Rf = 0.29 (dichloromethane); vmax (KBr disc)/cm ' 3402s (OH), 2925m 
(CH) and 1508s and 829s (ArH); 5C (DMSO) 57.9 (CH3-3 and CH3-16), 80.2 (C- 
19), 117.8 (C-2, 4, 15 and 17), 121.3 (C-10), 122.4 (C-9 and 11), 129.8 (C8 and 
12), 130.9 (C-l, 5, 14 and 18), 139.3 (C-6 and 13), 144.8 (C-7), 172.8 (C-3 and 
16).
Phosphoramidite Method A (Meyer and Hanna, 1996) 
5'-0-(Dimethoxytrityl)-5-[S-(2,4-dinitrophenyl)-thio]-2'-deoxyuridine-3'-(9-(2- 
A,A"-cyanoethyl diisopropylphosphoramidite SH P17
OMe
N02
o 2n
OMe
NO
The trityl-protected nucleotide SH P13 (100 mg, 0.14 mmol) was rigorously 
dried using an oil pump and kept under dry nitrogen. To the reaction flask was 
added 2-cyanoethyl tetraisopropylphosphorodiamidite (43 pi, 0.13 mmol) and 
tetrazole (10 mg, 0.13 mmol) in dry acetonitrile (2 ml). The mixture was stirred at
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room temperature for 30 min before adding further 2-cyanoethyl-A( N, N', N1- 
tetraisopropylphosphorodiamidite (18 pi, 0.05 mmol) and tetrazole (5 mg, 0.06 
mmol) in dry acetonitrile (1 ml), and the mixture was stirred for a further 30 min. 
The reaction was then poured into dichloromethane (20 ml) and 5% (w/v) sodium 
bicarbonate (15 ml) was added. The organic layer was removed and washed with 
water, dried with sodium sulfate, filtered and concentrated in vacuo yielding a 
yellow semi-solid. This was further purified using column chromatography on 
silica eluting with 9:1 dichloromethane: methanol (containing 0.5% triethyl amine) 
yielding the title compound as a yellow gum (41.0 mg, 32.3%).
New data: Rf = 0.75 (9:1 dichloromethane:methanol); 8H (CDC13) 1.20 (12H, m, 4 
x iPr), 2.32 (1H, m, H-2'), 2.56 (1H, m, H-2"), 2.68 (4H, dt, J = 5.9 and J = 2.3, 
H-31 and H-32), 3.29 (1H, m, H-5’), 3.30 (1H, m, H-5"), 3.62 (6H, s, 2 x OCH3),
4.01 (1H, m, H-4'), 4.09 (2H, sept, H-33 and H-34), 4.62 (1H, m, H-3’), 6.33 (1H, 
dd, J = 7.5 and 5.8, H -l’), 6.75 (1H, d, J = 8.9, H-8), 7.00-7.24 (13H, m, trityl 
group), 8.00 (1H, dd, J = 8.9 and 2.4, H-9), 8.39 (1H, s, H-6) and 8.92 (1H, d, J =
2.4, H-l 1).
Phosphoramidite Method B (D. Picken, pers.commun)
5,-(9-(Dimethoxytrityl)-5-[5'-(2,4-dinitrophenyl)-thio]-2,-deoxyuridine-3,-0-(2- 
7V,7V"-cyanoethyl diisopropylphosphoramidite SH P17
The trityl-protected nucleoside SH P13 (554 mg, 0.73 mmol) was dried in vacuo 
with dry acetonitrile (3 x 10 ml). It was then dissolved in dichloromethane (10 
ml) and 2-cyanoethyl-A( N, N', iV'-tetraisopropylphosphorodiamidite (288 pi, 0.91 
mmol) and tetrazole diisopropylammonium salt (64 mg, 0.36 mmol) was added. 
The solution was stirred under nitrogen overnight at room temparature. Once the 
tic had shown that the starting material had been converted into two slower 
moving species (corresponding to the diastereoisomers about phosphorus), the 
reaction was worked up by adding saturated sodium hydrogen carbonate (10 ml). 
The organic layer was separated and washed with brine (2 x 1 0  ml). The organic 
layer was then dried with sodium sulfate and evaporated in vacuo to an oil. To
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precipitate the product, hexane (100 ml) was added to the oil. The precipitate was 
left to settle and the solvent was decanted. The precipitate was re-dissolved in 
ethyl acetate (5 ml) and precipitated by adding hexane (50 ml).
The precipitate was re-dissolved in ethyl acetate (1-2 ml) and purified using 
column chromatography on silica, eluting with ethyl acetate, yielding the 
phosphoramidite as a yellow oil. The oil was dissolved in anhydrous acetonitrile, 
then filtered through a 0.22 pm filter to ensure any small particles were removed. 
Once filtered, the solution was evaporated and dried by acetonitrile co­
evaporation (x 2). The oil obtained was placed under high vacuum, yielding the 
product as a yellow foam (372 mg, 54.4%).
New data: Rf = 0.75 (9:1 dichloromethane :methanol); 8H (CDC13) 1.10 (12H, m, 
4 x iPr), 2.42 (1H, t, J = 6.2, CH2CN), 2.48 (1H, dd, J = 6.8 and 13.6, H-2'), 2.64 
(1H, dd, J = 5.9 and 13.6 Hz, H-2"), 3.35 (2H, m, H-5’ and H-5”), 3.52 (2H, m, 
CHiPr), 3.62 -3.72 (8H, m, 2 x OCH3 and CH2OP ), 4.19 (1H, m, H-4'), 4.73 (1H, 
m, H-3’), 6.26 (1H, dd, J = 6.5 and 6.5, H-l'), 6.60-7.20 (13H,m, trityl group), 
7.33 (1H, s, H-6), 8.03 (1H, ddd, J = 11.4 and 2.4, H-9), 8.42 (1H, d, J = 10.8) 
and 8.93 (1H, d, J = 2.4, H-l 1); m/z (FAB) 929.2937 (M+H)+ C^H^NgO^PS 
requires 929.2948; m/z (%) 929.1 (8), 711.0 (6), 619.1 (12). 406.9 (42) and 303.0 
(100); 5P (81 MHz, CDC13) 148.7, 148.9.
Phosphoramidite Method C SH P17 (Sinha et al, 1983)
The trityl-protected nucleoside SH P13 (50 mg, 0.07 mmol) was dried in vacuo 
with dry tetrahydrofuran (5 ml). It was then dissolved in tetrahydrofuran (5 ml) 
and 2-cyanoethyl-A, A'-diisopropylchlorophosphorodiamidite (23 pi, 0.10 mmol) 
and diisopropylethylamine (47 pi, 0.27 mmol) were added. The solution was 
stirred at room temperature for 4 h, then poured into ethyl acetate (10 ml, pre­
treated with 1 x 10 ml and 3 x 10 ml brine washes). The product was precipitated 
by adding hexane (100 ml). The supernatant was decanted off and the product 
redissolved in ethyl acetate (10 ml). After adding more hexane (100 ml), the 
precipitate was collected and dried in vacuo. The residue was further purified by
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column chromatography on silica eluting with 2:1 ethyl acetate: hexane yielding 
the product as yellow flakes (18 mg, 28.7%).
New data: Rf = 0.70 2:1 ethyl acetate:hexane; 5H (CDC13) 1.11 (12H, m, 4 x iPr),
2.46 (1H, t, J = 6.2 Hz, CH2CN), 2.51 (1H, dd, J = 6.8 and 13.6Hz, H-2'), 2.65 
(1H, dd, J = 5.9 and 13.6 Hz, H-2"), 3.49 (2H, m, H5' and H5M), 3.57 (2H, m, 
CHiPr), 3.57 -3.65 (8H, m, 2 x OCH3 and CH2OP ), 4.19 (1H, m, H-4’), 4.74 (1H, 
m, H-3'), 6.25 (1H, dd, J = 6.5 and 6.5, H-l'), 6.60-7.17 (13H,m, trityl group), 
7.32 (1H, s, H-6), 8.03 (1H, ddd, J = 11.4 and 2.4, H-9), 8.43 (1H, d, J = 10.8) 
and 8.93 (1H, d, J = 2.4, H -ll).
3',5'-0-Diacetyl-thymidine SH P18 (Michelson and Todd, 1955)
HN
AcO
OAc
Thymidine (3.2 g, 13.2 mmol) was evaporated three times with dry pyridine (3 x 
10 ml), then dissolved in dry pyridine (20 ml) and freshly distilled acetic 
anhydride (24 ml, 21.7 mmol) and imidazole (5.2 g, 38.1 mmol) were added. The 
reaction was stirred overnight at room temperature. The pyridine was removed in 
vacuo and the residue was azeotroped with toluene (3x15  ml). The resulting oil 
was recrystallised from isopropanol yielding the pure product as white needles 
(3.5 g, 80.8%); mp 126-128 °C (Michelson and Todd, 1955, mp = 125 °C).
New data: Rf = 0.7 (4:1 CHC13: MeOH); (Found C, 51.40; H, 5.56; N, 8.43. 
C]4H]gN20 7 requires C, 51.55; H, 5.52; N, 8.58%); vmax (KBr discVcm' 1 3414m 
(NH), 3042w (CH), 1750s and 1735s (CO) and 1671s (C=C); 5U (CDC1 ) 1.87
H 3
(3H, s, H-7), 2.05 and 2.06 (3H, 2 x s, OCH3-5' and OCH3-3'), 2.11 (1H, s, H-2’),
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2.41 (1H, ddd, J = 14.2, 5.6 and 1.9, H-2"), 4.17 (1H, ddd, J = 6.7, 5.9 and 3.9, H- 
4'), 4.29 (1H, dd, J = 12.1 and 4.2, H-5’), 4.31 (1H, dd, J = 12.1 and 4.2, H-5"), 
5.15 (1H, ddd, J = 6.5, 4.3 and 2.1, H-3’), 6.26 (1H, dd, J = 5.5 and 5.5, H-l'),
7.21 (1H, s, H-6) and 9.19 (1H, br. s, NH); Sc (CDC13) 11.1 (CH3-7), 19.8 
(OCH3-5' and OCH3-3'), 36.5 (CH2-2'), 62.8 (CH2-5’), 73.1 (CH-41), 81.1 (CH-3'),
83.8 (CH-1'), 110.5 (C-5), 133.4 (CH-5), 149.4 (CO), 162.6 (CO), 170.5 and
169.2 (OCH3-5’ and OCH3-3'); m/z (CI+) 327.1193 (M+) C]4 H]g N20 ? requires 
327.1192; m/z (%) 327.1 (100), 201.1 (27), 127.1 (30), 81.0 (36).
3',5'-ODiacetyl-5-bromomethyl-2,-deoxyuridine SH P19 (Sergiev et a l, 1997)
HN
AcO-
OAc
SH P18 (1.00 g, 3.06 mmol) was dissolved in freshly dried dichloroethane (5 ml, 
distilled from CaH2) in a three necked flask, equipped with a reflux condenser. 
The mixture was heated to reflux using two powerful tungsten lamps, and Br2 
(0.25 ml, 77.8 mmol) in dichloroethane (2 ml) was added dropwise over 3 h. The 
mixture was left to cool to room temperature, and concentrated in vacuo yielding 
a orange oil which was azeotroped with toluene (15 ml). The extract was 
dissolved in the minimum volume of CHC13 and purified using silica column 
chromatography, eluting with 4:1 hexane: ethyl acetate. The relevant fractions 
were collected and concentrated in vacuo yielding a yellow solid, recrystallised 
by dissolving in the minimum dichloroethane and dropping into hexane, yielding 
white flakes (550 mg, 44.4%).
New data: mp = 94-98 °C; Rf =0.19 (4:1 ethyl acetate:hexane); (Found C, 41.23; 
H, 4.62; N, 6.51. C14H]7N20 ?Br requires C, 41.51; H, 4.20; N, 6.91%); vmax (KBr
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L
disc)/cm 1 3388m (NH), 3080w (CH), 1745s and 1740s (CO), 1691s (C=C) and
742.2 (C-Br); 5H (CDC13) 2.05 and 2.09 (3H, 2 x s, OCH3-5' and OCH3-3'), 2.08 
(1H, m, H-2') and 2.52 (1H, ddd, J = 14.3, 5.5 and 1.7, H-2"), 4.18(1H, m, H-4’), 
4.23 (2H, d, CH2-7), 4.32 (1H, m, H-5'), 4.32 (1H, m, H-5"), 5.16 (1H, dd, J = 6.4 
and 6.4, H-3'), 6.19 (1H, dd, J= 5.5 and 5.6, H-l'), 7.61 (1H, s, H-6) and 9.38 (1H, 
br. s, NH); 8C (CDC13), 21.2 (OCH3-5' and OCH3 -3'), 25.2 (CH2-7), 38.5 (CH2- 
2'), 64.1 (CH2-5'), 74.5 (CH-4'), 83.1 (CH-3'), 86.1 (CH-11), 111.2 (C-5), 138.8
(CH-5), 150.1 (CO), 161.7 (CO) and 170.7 (OCH3-5' and OCH3-3'); m/z (CI+)
405.0299(M+) C]4H]7N20 ? Br requires 405.0301; m/z (%) 407.0 (50), 327.1 (30),
201.1 (30), 127.1 (15).
3',5'-0-Diacetyl-5-thioacetylmethyl-2'-deoxyuridine SH P20 (Langen and 
Barwolff, 1975)
HN
AcO-
OAc
A solution of SH P19 (2.0 g, 4.93 mmol) and potassium thioacetate (0.85 g, 7.50 
mmol) in dry dimethylformamide (15 ml) was heated to 70 °C under nitrogen and 
stirred overnight. The reaction mixture was diluted to with H20  (50 ml) and 
extracted with chloroform (2 x 50 ml). The dimethylformamide was removed by 
washing this organic layer with H20  (500 ml). The solution was then dried using 
anhydrous M gS04 and concentrated in vacuo, yielding a crude product which was 
subsequently purified using column chromatography on silica eluting with ethyl 
acetate. The relevant fractions were pooled and concentrated in vacuo yielding 
product which was recrystallised from isopropanol, yielding the title compound 
as deep orange flakes (882 mg, 53.7%).
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New data: mp = 140-141 °C; Rf = 0.68 (ethyl acetate); (Found C, 48.08; H, 4.92; 
N, 6.92. C 16H20N2O8S requires C, 48.02; H, 4.99; N, 6.99%); v „ x (KBr disc)/cm ‘ 
3435m (NH), 3077w (CH), 1744s (CO) and 1690s (C=C); 8„ (CDC1) 2.05, 2.14
H 3
and 2.24 (3H, 3 x s, OCH3-5\ OCH3-3' and S-OCH3; 2.17 (1H, m, H-2’), 2.38 
(1H, ddd, J = 14.2, 5.5 and 1.4, H-2"), 3.70 (2H, dd, J = 14 and 14, 2H-7), 4.27 
(3H, m, H-5', H-5" and H-4’), 5.18 (1H, dd, J = 6.4 and 1.8, H-3'), 6.25 (1H, dd, J 
= 5.5 and 5.5) and 7.65 (1H, s, H-6); 5C (CDC13), 19.9 (OCH3-5' and OCH3-3’),
24.8 (CH2-7), 29.5 (OCH3-9) 36.5 (CH2-2’), 63.0 (CH2-5’), 73.3 (CH-4’), 81.3 
(CH-3'), 83.9 (CH-1’), 110.7 (C-5), 136.6 (CH-6), 149.0 (CO), 161.3 (CO) and
169.4 (OCH3-5’ and OCH3-3’); m/z (CI+) 400.0937 (M+) C]6H2QN20 8S requires 
400.0946; m/z (%) 400.1 (5), 357.1(12), 201.1 (10), 157.0 (10), 81.0 (100).
3’,5’-(9-Diacetyl-5-thiocyanatomethyl-2'-deoxyuridine SH P21 (Langen and 
Barwolff, 1975)
7 SCNHN'
AcO'
OAc
To 3,,5'-0-diacetyl-5-bromomethyl-2'-deoxyuridine SH P19 (993 mg, 2.45 
mmol) in anhydrous dimethylformamide (10 ml) was added potassium 
thiocyanate (490 mg, 5.05 mmol). The reaction mixture was heated to 70 °C and 
stirred under N2 overnight. The crude reaction mixture was diluted with H20  (50 
ml) and extracted with chloroform (2 x 50 ml). This extract was then washed with 
H20  (1 litre) to remove excess dimethylformamide. The organic layer was dried 
with M gS04 and concentrated in vacuo yielding the crude product which was 
further purified using column chromatography on silica, eluting with ethyl 
acetate. The title compound was isolated as yellow foam (550 mg, 58.6%).
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New data: mp = 53-55 °C, Rf = 0.52 (ethyl acetate); (Found C, 46.60; H, 4.90; N,
10.46 C15H17N30 7S requires C, 47.01; H, 4.50; N, 10.86%); vmax (KBr d iscern ' 1 
3340m (NH), 3075w (CH), 1740s and 1735s (CO), 1691s (C=C); 5H(CDC13) 2.06 
and 2.07 (3H, 2 x s, OCH3-5' and OCH3-3'), 2.14 (1H, m, H-2’), 2.50 (1H, ddd, J 
= 14.2, 5.5 and 1.6, H-2"), 4.25 (2H, m, 2H-5), 4.40 (3H, m, H4’ and 2 H-5'), 5.18 
(1H, dd, J = 6.3 and 6.4, H-3'), 6.21 (1H, dd, J = 8.4 and 5.7, H-l'), 7.60 (1H, s, 
H-6) and 9.95 (1H, br. s, NH); 5c(CDC13) 38.3 (CH2-7), 42.1 (CH2-2'), 64.0 (CH2- 
5'), 74.5 (CH-4'), 83.2 (CH-31), 86.0 (CH-1'), 109.4 (C-5), 135.4 (qCN), 137.5 
(CH-6), 150.3 (CO), 162.2 (CO), 170.7 and 170.8 (OCH3-5' and OCH3-3'); m/z 
(CI+) 383.0785(M+) C15H17N30 7S requires 383.0792; m/z (%) 383.1 (90), 326.1 
(100), 324.1 (85) and 309.0 (60).
£f?-[3',5'-0-Diacetyl-2'-deoxyuridine-5 methyl]sulfide SH P22
HN
AcO
OAc
To the bromide SH P19 (1 g, 2.5 mmol) in dimethyl formamide (20 ml) was 
added sodium hydrosulfide (332 mg, 5.9 mmol). The solution was heated, with 
stirring, to 70 °C and left overnight. The reaction was diluted with H20  (50 ml) 
and extracted with chloroform (2 x 50 ml). The organic layer was washed with 
H20  (1 litre) to remove the dimethylformamide, dried with M gS04, filtered and 
concentrated in vacuo yielding crude sulfide (500 mg, 28.4%). The crude sulfide 
(263 mg, 0.38 mmol) was further purified by column chromatography on silica 
eluting with ethyl acetate, yielding the title compound as white flakes (180 mg, 
68.4%).
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New data: Rf = 0.26 (ethyl acetate); vmax (KBr disc)/cm' 3436m (NH), 2925w 
(CH), 2365s (SH), 1743s (CO) and 1685s (C=C); 6H (CDC13) 2.05 and 2.06 (12H, 
2 x s, 2 x OCH3-5' and 2 x OCH3-3’); 2.28 (2H, m, 2 x H-2'), 2.40 (1H, ddd, J =
14.2, 5.2 and 1.8 Hz, 2 x H-2"), 3.39 (4H, dd, J = 14 and 14, 2 x CH2-7), 4.30 
(6H, m, 2 x H-5', H-5" and H-4’), 5.18 (2H, m, 2 x H-3'), 6.26 (2H, dd, J = 5.6 
and 5.6, 2 x HI') and 7.19 (2H, s, 2 x H-6); 8C (CDC13), 21.3 (2 x OCH3-5’ and 2 
x OCH3-3'), 27.2 (2 x CH2-7), 37.7 (2 x CH2-2'), 64.2 (2 x CH2-5’), 74.6 (2 x CH- 
4'), 82.6 (2 x CH-3'), 85.6 (2 x CH-1'), 112.8 (2 x C-5), 137.9 (2 x CH-6), 150.3 
(CO), 163.3 (CO), 170.7 and 171.0 (2 x OCH3-5' and 2 x OCH3-3'); m/z (FAB) 
(M+H)+ 682.1864 C2gH35N40 ]4S requires 682.1873; m/z (%) 683.0 (35), 449.3 
(10), 325.0 (30) and 201.0 (100).
2',3',5'-Bis -0-(r-butyldimethylsilyl)-[N3-(2,4-dinitrophenyl)thio]uridine SH P23
0 2N-
— SiO
— SiO
To SH P6 (100 mg, 0.17 mmol) in dry THF (5 ml) N, N, N', N  '- 
tetramethylethylenediamine (TEMED; 150 jllI, 1.02 mmol) was added, and the 
mixture was cooled to -78 °C using a dry ice-acetone bath. After the addition of 
sec-BuLi (0.78 ml, 1.02 mmol) the mixture was stirred for a further 30 min. A 
solution of 2, 4-dinitrobenzene sulfenyl chloride (280 mg, 1.19 mmol) in dry THF 
(3 ml) was added. The reaction mixture was poured into H20  (50 ml), and 
extracted with ethyl acetate (3 x 50 ml). The organic layer was separated and
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washed with brine (10 ml), dried with MgS04 and concentrated in vacuo, yielding 
the crude product which was purified using column chromatography on silica, 
eluting with 2:1 ether: hexane, yielding the product as a yellow solid (120  mg, 
50.9%).
New data: Rf = 0.73 (2:1 ether: hexane); 8h (CDC13) -0.01, -0.02, 0.00 and 0.01 
(18H, 6 x s, 6 x SiMe), 0.80 and 0.85 (27H, 3 x s, 3 x f-butyl), 3.69 (1H, d, J =
11.5, H-5'), 3.87 (1H, d, J = 11.5, H-5"), 3.94-4.13 (3H, m, H-2’, H-3' and H-4’), 
5.90 (1H, d, J = 5.5, H-5), 6.04 (1H, d, J = 6.9, H -l’), 7.94 (1H, d, J = 5.3, H-6), 
7.92 (1H, d, J = 9.1, H-8 ), 7.94 (1H, d, J = 5.3, H-6), 8.17 (1H, dd, J = 9.9 and
2.4, H-9) and 8.95 (1H, d, J = 2.4, H -ll); 5C (CDC13) -5.2 to -3.8 (6 x SiMe),
18.3, 18.4 and 18.8 (3 x qC), 26.1, 26.2 and 26.3 (3 x t- butyl CH3), 62.1 (C-5),
71.0 (C-4), 76.5 (C-2), 84.8 (C-3), 89.3 (C-l), 102.2 (C-5), 120.6 (C-8), 126.2 (C- 
9),127.86 (C -ll), 136.0 (C-7), 138.1 (C-10), 138.5 (C-12), 140.7 (C-6), 150.6
(CO) and 163.7 (CO); m/z (FAB) 807.2927 (M+ Na)+ C33H56N4O10Si3Na requires 
807.2921 m/z (%) 807.2 (48), 610.6 (100), 366.4 (55).
3',5'-Bis -6>-(r-butyldimethylsilyl)-[N3-(2,4-dinitrophenyl)thio]-2'-deoxyuridine 
SH P24
To SH P5 (80 mg, 0.17 mmol) in dry THF (4 ml) was added N, N, N', N - 
tetramethylethylenediamine (TEMED; 157 pi, 1.05 mmol) was added, and the 
mixture was cooled to -78 °C using a dry ice-acetone bath. After the addition of
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sec-BuLi (0.80 ml, 1.05 mmol) the mixture was stirred for a further 30 min. A 
solution of 2, 4-dinitrobenzene sulfenyl chloride (286 mg, 1.22 mmol) in dry THF 
(3 ml) was added. The reaction mixture was poured into H20  (50 ml), extracted 
with ethyl acetate (3 x 50 ml). The organic layer was separated and washed with 
brine (10 ml), dried with MgS04 and concentrated in vacuo, yielding the crude 
product which was purified using column chromatography on silica, eluting with 
2:1 ether: hexane, yielding the product as a yellow solid (20 mg, 17.4%).
New data: Rf = 0.41 (2:1 ether: hexane); 5H (CDC13) -0.03, -0.02, 0.00 and 0.01 
(12H, 4 x s, 4 x SiMe), 0.78 and 0.81 (18H, 2 x s, 2 x f-butyl), 1.95 (1H, m, H-2'),
2.22 (1H, m, H-2”), 3.64 (1H, m, H-4'), 3.81 (3H, m, H-4' and H-5'), 4.31 (1H, m, 
H-3'), 5.57 (1H, d, J = 8.1Hz, H-5), 6.18 (1H, m, H -l’), 7.79 (1H, d, J = 8.1); m/z
(FAB) 674.8585 (M+ Na)+ C27H39N40 9Si2Na requires 674.8599.
3,,5'-(9-Diacetyl-5-[N3-(2,4-dinitrophenyl)thio]-2,-deoxyuridine SH P25
AcO-
OAc
3',5'-0-Diacetyl-2'-deoxyuridine SH P9 (156 mg, 0.50 mmol) and silver 
trifluoroacetate (166 mg, 0.75 mmol) in anhydrous MeCN (4 ml) were stirred at 
room temperature. To this was added 2, 4-dinitrobenzenesulfenyl chloride (175 
mg, 0.75 mmol) and then the reaction was stirred for a further 2 h. Tic analysis 
showed a new product had formed. The reaction mixture was filtered to removed 
the AgCl and the filtrate was concentrated in vacuo yielding the crude product. 
This was further purified by column chromatography on silica, eluting with 9:1 
dichloromethane: acetone, yielding (10 mg, 5%) of product; 8h (CDC13) 2.04 and
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2.07 (3H, 2 x s, OCH3-5' and OCH3-3'), 2.19 (1H, m, H-2') and 2.53 (1H, ddd, J =
14.3, 5.8 and 2.5, H-2”), 4.23-4.27 (3H, m, H-4' and 2 x H-5’), 5.17 (1H, dd, J =
6.3, H-3'), 5.93 (1H, d, J = 8.2, H-5), 6.19 (1H, dd, J = 6 .6 , H-l'), 7.05 (1H, d, J =
9.0, H-7), 7.27 (1H, d, J = 9.8, H-8), 7.61 (1H, d, J = 8.2, H-6), 8.31 (1H, dd, J =
9.0 and 2.4, H-9) and 9.09 (1H, d, J = 2.4, H-10); m/z (CI+) 509.4235 
C19H17N40„S  requires 509.4240; m/z (%) 509.4 (20), 326.1 (90), 201.1 (20) and 
81.0(100).
2.9 Attempted Synthesis of B^S'-O-Diacetyl-S-thiomethyl^'-deoxyuridine SH 
P26
HN SH
AcO
OAc
The brominated derivative SH P19 was reacted with a variety of reagents to 
convert it into the mercaptomethyl derivative SH P26. These included reactions 
with sodium hydrosulfide (Langen and Barwolff, 1975), sodium trithiocarbamate 
(Martin and Greco, 1968), thiourea (Urquhart et al., 1955) sodium iodide and 
thiourea (Melnick and Weinreb, 1988), N, A/-dimethyldithiocarbamate (Kulka, 
1956) and thioacetimide (Giner-Sorolla and Medrek, 1966). Several methods 
were attempted to hydrolyse 3',5'-(9-diacetyl-5-thioacetylmethyl-2,-deoxyuridine 
SH P20. Several methods of reducing 3',5'-(9-diacetyl-5-thiocyanatomethyl-2'- 
deoxyuridine SH 21 were attempted. These included reduction with sodium 
borohydride (Hideg et al., 1992; Marquet et al., 1993; Campanini et al., 1995) 
and DTT (Hanna and Meyer, 1996). The results of these reactions will be 
discussed in Section 2.11 and are illustrated in Figure 2.12.
6 0
0Ac 1. 2Na2CS3/H+
2. (NH2)2CS/NaOH 
SH P19 3. (NH2)2CS/NaI/EtOH/base SH P26
4. Na2S2CN(CH3)2/H+
5. CH3CSNH2/DMF/MeOH
6 . NaSH/EtOH
7. NaSH/DMF
. NaSH/TBAB/CH.CN
HNHN
AcOAcO
9. NaOH/MeOH
10. Ba(OH)2/MeOH
11. KOH/MeOH
OAcOAc
SHP20
12. NaOMe/MeOH
13. DTT/MeOH
HN HNSON
AcO AcO-
14. NaBH4/EtOHOAc OAc
15. NaBH4/Et0H/H20/THF 
SH P21 16. NaBH4/EtOH/NaB(>3.4H20
17. DTT/EDTA/MeOH
Figure 2.12 Attemped syntheses 3,,5,-0-Diacetyl-5-thiomethyl-2' 
deoxyuridine SH P26
Diagram summarising the attempted syntheses of the 5 
mercaptomethyl-2’- deoxyuridine SH P26.
2.10 Attempted Synthesis of S'jS'-O-Diacetyl-S-tS^^-dinitrophenyl]- 
thiomethyl-2*-deoxyuridine SH P27
HN N02
AcO'
AcO
Several methods were used to generate 3',5'-0-diacetyl-5-thiomethyl-2'- 
deoxyuridine SH P27. These included the methods to generate the free thiol 
(Section 2.9), and attempts to enact in situ protection of the thiol SH P26, with 
2,4-dintrobenzene sulfenyl chloride. These reactions are illustrated in Figure 2.13 
and will be discussed in Section 2.11.
2.11 Discussion
Prior to the synthesis of the diazirine-containing phosphoramidite nucleotide, a 
simple diazirine was synthesised to ascertain the feasibility of the reaction. The 
diazirine of laevulinic acid was prepared in three steps with an overall yield of 
14.6%. Another intermediate that was required for the synthesis of the diazirine 
target contained an aldehyde group at the 5-position of thymidine. This involved 
the synthesis of a hydroxymethyl precursor. The synthesis of this compound 
proved to be very poor, with yields of 8% or less. The diazirine target was 
therefore omitted from this study. Diazirines are often stabilised by having an 
adjacent trifluoroacetate group (Lui, 1986). For the above reasons, the synthesis 
of the diazirine target was omitted from this study.
The disulfide of 2, 4-dinitrobenzene was obtained in 84.3% yield. The reduction 
of the disulfide bond yielded the monomer thiol (Kharasch et al, 1955). The
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18. KOH/MeOH/FDNB
19. Ba(OH)2.8H20/MeOH/FDNB 
SH P19 20. NaSH/DMF/FDNB
SH P27
HN'HN'
AcO-AcO-
OAc A cO
21. NaOH/MeOH/FDNB
SH P20 22. Ba(OH)2/MeOH/FDNB
23. DTT/MeOH/FDNB
\ / N 02
o 2n
HN' SON HN'
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\ / n o 2
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SHP21
Figure 2.13 Attempted synthesis of S'jS'-O-Diacetyl-S-tS^^-dinitrophenyl] 
thiomethyl-2*-deoxyuridine SH P27
Illustration of the direct methods used to synthesise the 3',5'-0-Diacetyl-5- 
thiomethyl-2 '-deoxyuridine (section 2 .11).
reduction used glucose/NaOH (Bordwell and Andersen, 1953). However, this 
reaction proceeded in very low yield (less than 10%). The disulfide was not 
soluble in methanol or benzene, the two solvents in which the palladium cross 
coupling reaction is normally performed (Bergstrom et al., 1991). It was also 
insoluble in THF, the solvent required for the lithiation reaction (Armstrong et 
al., 1989).
The lithiation reaction was carried out on both uridine and 2’-deoxyuridine to 
allow for optimisation of reaction conditions. The starting nucleoside 2',3',5'-bis- 
0 -[ f-butyldimethylsilyl)dimethylsilyl]-uridine SH P5 and 3',5'-bis-0-[ t- 
butyldimethylsilyl)dimethylsilyl]-2'-deoxyuridine SH P6 were obtained in yields 
of 93.0% and 95%, respectively using TBDMSiCl, DMF, and imidazole as 
catalyst at 50 °C (Ogilvie et al. 1978). For the lithiation reactions the nucleoside 
was dissolved in dry THF and the required amount of sec-BuLi was added, in the 
presence of TEMED. The lithium salts were quenched with 2,4- 
dinitrobenzenesulfenyl chloride.
The methods for direct attachment to the pyrimidine ring with the 2, 4- 
dinitrobenzene-protected thiol gave mixture of both N-3 and C-5 lithiated 
products. Lithiation of SH P5 and SHP6, followed by quenching with 2,4- 
dinitrobenzenesulfenyl chloride, resulted in N-3 arylated products, indicating that 
the hydrogen at N-3 is more acidic in the pyrimidine ring than the C-5 position 
under the reaction conditions tried. SH P23 is contaminated with the 2',3',5'-Bis - 
(9-(r-butyldimethylsilyl)-[C-5,(2,4-dinitrophenyl)thio]uridine as indicated by the 
C-5 lithiated product at (m/z; (FAB) 808.2960 C33H57N4Oi0Si3Na requires 
808.3110) at 27.3% intensity compared to 47.6 % for the N-3 lithiated species. In 
addition there was another major species at (m/z; (FAB) 809.2964 
C33H58N4O10Si3Na requires 809.3107) at 16.6% intensity. Similarly SH P24 was 
contaminated with N-3 species that co-eluted with the C-5 lithiated species 
during column chromatography. Similarly, the reaction using silver reagents 
generated exclusively N-3 thioarylated product SH P25.
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The method used for incorporation of the thiol group required thiocyanation of 
the pyrimidine ring. Initial reported yields of this reaction on 2'-deoxyuridine 
were very low (10%), although there are literature reports (Bradley and Hanna,
1992) of up to 54% for the reaction on the unprotected form. The hydroxyls of 2'- 
deoxyuridine were protected as acetates in SH P9 yields ranging from 80-82%. 
Protection of the sugar hydroxyls by acetylation prior to thiocyanation resulted in 
higher yields (Nagamachi ei al, 1974) of up to 95%. The thiocyanation reaction 
involves generation of a nucleophilic 'Cl-SCN' species in situ by adding chlorine 
gas to a solution of dry glacial acetic acid. Prior to addition of the potassium 
thiocyanate, the amount of chlorine added was determined by iodometric 
techniques (Flaschka et al, 1969). The reaction proceeds by nucleophilic 
substitution of the pyrimidine ring on the 'Cl-SCN'. The thiocyanation went well 
yielding 5-thiocyanato-2'-deoxyuridine SH P10 in 73.5% yield.
Reduction of the thiocyanato group was achieved under mild reaction conditions 
using dithiothreitol, which displaced the cyano group yielding the mercaptan SH 
P l l  in 75.3% yield. Protection of the thiol was carried out using 2,4- 
dinitrofluorobenzene, in dry acetonitrile with triethylamine as a catalyst, yielding 
the protected thiol SH P12 in 62.8%. The deacetylation reaction via methanolysis 
of the diacetate with sodium methoxide in methanol gave the dihydroxyl SH P13 
in yields of 86.3%.
Protection of the 5'-hydroxyl as the dimethoxytrityl ether was carried out using 
two methods: the direct use of dimethoxytrityl chloride in pyridine; and using the 
tetrafluoroborate salt of dimethoxytrityl in pyridine. Hanna and Meyer (1996) 
suggested that the use of 4, 4'-dimethoxytrityl chloride in pyridine was an 
unsuitable method for protection of the 5'-hydroxyl group, and found increased 
yields using a method that used an activated trityl salt (Bleasdale et a l, 1989). In 
contrast to their results it was found that the reverse was true. The trityl choride 
method was superior, yielding the trityl-protected derivative SH P14 in yields of 
84.0%.
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It was desirable to make two different thiol-containing analogues, one with the 
thiol directly attached to the C-5 position and a second with a mercaptomethyl at 
C-5. The starting material for the 5-mercaptomethyl analogue was thymidine.
Protection of the hydroxyl groups using acetic anhydride in pyridine, as before, 
gave high yields of the diacetate SH P18 (80.8%). A precursor to the 
mercaptomethyl compound was the bromomethyl derivative SH P19. The 
method for photochemical bromination (Sergiev et al. 1997) using bromine in 
dichloroethane (DCE) was applied to the 3', 5'-diacetyl-thymidine SH P18, and 
gave the brominated derivative in 44.4% yield. Another method, involving 
bromination with A-bromosuccimide in carbon tetrachloride (Shealy et a l , 1986) 
did not yield any of the desired product, due to poor solubility of the starting 
material. The bromide was reacted with potassium thioacetate in 
dimethylformamide; the thioacetatomethyl derivative SH P20 was made in 
53.7% yield. In an analogous reaction, (Langen and Barwolff, 1975) the bromide 
reacted with potassium thiocyanate in dimethylformamide occurred with SN2 
displacement; the thiocyanatomethyl SH P21 (Langen and Barwolff, 1975) was 
obtained in 58.6% yield.
The methods used to attempt to synthesise 3',5'-0-diacetyl-5-thiomethyl-2'- 
deoxyuridine SH P26 are summarised in Figure 2.12. The reactions of the 
bromomethyl derivative illustrated in Figure 2.12.1-2.12.5 were carried out 
according to the literature methods (2.12.1; Martin and Greco, 1968); (2.12.2; 
Urquhart et al, 1955); (2.12.3; Melnick and Weinreb, 1988); (2.12.4; Kulka, 
1956); (2.12.5; Giner-Sorolla and Medrek, 1966). However, the only products 
from these reactions were unreacted starting material or decomposition products. 
However, reaction 2.12.6 and 2.12.7 (Baerwolff and Langen, 1975), resulted in 
sulfide SH P22. The reactions that involved the selective hydrolysis of the 
thioacetyl moiety of SH P20 (Figure 2.12.9-12) used aqueous methanolic 
hydrolysis using 0.5-1 equivalent of base. Under these conditions as well as 
hydrolysis of the thioacetyl group, hydrolysis of the hydroxyl acetyl protecting
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groups also occurred yielding a species that was highly charged and difficult to 
extract using organic solvents, making further purification difficult. Sodium 
borohydride reductions of the thiocyanatomethyl derivative SH P21 (Figure 
2.12.14-16) did produce the thiol moiety, but subsequent aqueous work up 
resulted in the sulfide SH P22 as the predominant product.
The failure to synthesise 3',5'-0-diacetyl-5-thiomethyl-2'-deoxyuridine SH P26 
was due to a number of factors. The extreme reactivity of the mercaptomethyl 
moiety generated during the reactions mentioned above was probably due to the 
proximity of the pyrimidine ring. The delocalisation of the electrons in the ring 
would push electrons towards the sulfur atom, thus increasing its nucleophilicity, 
resulting in the observed kinetic product, the sulfide SH P22. Any 
mercaptomethyl group that was formed immediately reacted with another 
molecule, forming the sulfide with the release of H2S.
The reaction of the bromomethyl compound with sodium hydrosulfide 
predominantly yielded the sulfide SH P22, usually contaminated with other thiol 
species. The high resolution mass spectra of the sulfide, that had been purified by 
column chromatography, showed in addition to the peak for the sulfide (m/z 
682.1), a peak at m/z 715.8 corresponding to the disulfide (C2gH35N4Ol4S2 requires 
715.1590; found 715.1592) was also present. The peak in the IR spectrum in the 
region where free thiols absorb indicates that some free thiol is present. Thus, the 
sulfide was contaminated with both the disulfide and the free thiol. Thin layer 
chromatography of the crude reaction mixture showed spots corresponding to the 
bromide compound SH P19, the diacetylated thymidine SH P9, and slower 
moving species below Rf = 0.3 (ethyl acetate). These slower moving products 
corresponded to the three different thiol species that co-eluted during column 
chromatography.
The reactions 18-21 in Figure 2.13 were carried out in order that any free thiol 
generated, either by hydrolysis or reduction of SH P19, SH P20 and SH P21
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could be protected in situ, by the addition of 2,4-dinitrobenzenesulfenyl chloride 
to the reaction mixture, yielding 3',5'-(9-diacetyl-5-[2,4-dinitrophenyl]thiomethyl- 
2'-deoxyuridine SH P27. Products were obtained with reactions 2.13.19, 2.13.21 
and 2.13.23. These had a mlz value of 524.6, corresponding to the desired product 
but in very low concentration. The 'H NMR spectra show product signals, but 
more than one set of aromatic signals are present, indicating that the product is 
contaminated with aromatic species that co-elute during chromatography.
In total three methods for making the phosphoramidites were used. The first used 
tetrazole and 2-cyanoethyl-A, N, N', A^-tetraisopropylphosphorodiamidite 
(Method A), the second used tetrazole diisopropylammonium salt and 2- 
cyanoethyl-A, N, N', N'- tetraisopropylphosphorodiamidite (Method B), and the 
third involved the use of the chlorophosphine reagent (Method C) as the 
phosphitylating reagent.
The diisopropyl ammonium salt of tetrazole (D. Picken, pers. commun.) was used 
to prevent any possibility of overactivation of the phosphoramidite, which could 
lead to polymerisation; i.e. the addition of an extra alcohol monomer to the 
activated trivalent phosphorus atom. Of the three methods used, the method that 
utilised the diisopropyl ammonium salt of tetrazole to activate the phosphitylating 
reagent was the favoured one (Method B). This method involving two 
precipitations of the crude phosphoramidite, followed by column chromatography 
with ethyl acetate as the eluant gave yields of over 50%. Method A involving a 
chromatography step with methanol and chloroform and the eluants, tended to 
cause oxidation of the phosphoramidite and lower yields of around 30%. Extra 
peaks in the 32P NMR spectra of the product made by method A showed that both 
oxidation products and dimerisation of the phosphoramidite had occurred.
Method C, although it gave pure products, was rather low-yielding; on average 
28% phosphoramidite was obtained. Due to the air sensitivity of the 
phosphoramidite it was impossible to obtain elemental analysis by combustion 
microanalysis.
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The 'H NMR spectrum of SH P17 is shown in Figure 2.14.
2.12 Conclusions
The direct methods for attaching the 2,4-dinitrophenyl protected thiol moiety to 
the C-5 position of the pyrimidine ring were unsuccessful. As discussed above the 
reactions gave the wrong products, or the yields were too low to be of synthetic 
use. This meant that the protected thiol had to be made by indirect methods.
5'-0-(Dimethoxytrityl)-5-[S-(2,4-dinitrophenyl)-thio]-2'-deoxyuridine-3'-O-(2- 
A,A"-cyanoethyl diisopropylphosphoramidite SH P17 was synthesised. 
Unfortunately, synthesis of the 5-mercaptomethyl phosphoramidite analogue 
proved too problematic, and only side products were isolated. The C-5 
mercaptomethyl derivative is more reactive than the C-5 thiol, which is 
deactivated by the pyrimidine ring.
The phosphoramidite SH P17 was incorporated into oligonucleotides and tested 
as a crosslinking agents for Tn 3 resol vase (Chapter 5).
Another approach that could have been tried to generate the mercaptomethyl 
derivative would have been to use methodology of Gupta et al., (1975). This 
involved the initial synthesis of the mercaptomethyl uracil, followed by coupling 
to the sugar group and isolation of the desired anomer. Although separation of the 
anomers can be difficult following this type of coupling reaction, it is still a 
feasible route to the mercaptomethyl derivative, and given the time over again 
this route could have been done in parallel alongside the other methods tried.
With more time an alternative thiol-containing pyrimidine nucleotide could have 
been synthesised. This analogue contains a thiol group at the end of a two carbon 
linker (Figure 2.8, compound 3). The synthesis of this analogue would have 
provided a means of comparing the reactivity of the thiol groups at the C-5 
position when they are directly attached to the pyrimidine ring system, or
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separated from the ring by one or two carbon chain linkers. The synthesis of this 
compound has been carried out using two different methods (Goodwin and Glick,
1993); in total, seven synthetic steps are required to produce the required 
protected phosphoramidite derivative. On reflection, this synthesis could have 
been carried out in parallel with the synthesis attempted in this work. It is 
possible to predict that the thiol that was separated from the pyrimidine ring by a 
two carbon chain would be less influenced by the ring, and should be stable to 
nucleophilic displacement leading to loss of sulfur.
Chapter 3: Materials and methods
3.1 Bacterial Strains
During the project the following bacterial strains were used, as illustrated in 
Table 3.1.
Table 3.1
Strain Genotype Source
AB1157 thr 1, leu6, hisG4, thi 1, ara\4, p roA l, argE3, 
galK2, sup31, xyl 15, rat/1, tsx33, str3l
DS941 AB1157, but rec¥\43, supE44, lacZAM\5, laclq D. J. Sherratt
DS902 AB1157, but recAY3 D. J. Sherratt
DH5a supE44, AlacUl69($>lacZAM15)hsdR\l, recAl, 
end A 1, gyr A96, thi~\ relAl
Gibco BRL
BL21 E.coli B, F', dcm, ompT, hsdS(rBmb)gal W. Studier, 
1990
BL21(DE
3)
hsd, gal, (kcl rs857, indl, Sami, ini5, lacUV5-Tl 
gene-1)
W.Studier,
1990
BL21(DE 
3) pLysS
As BL21(DE3), but has the T7 lysozyme expression 
plasmid pLysS
W. Studier, 
1990
3.2 Plasmids
The plasmids that were used and/or constructed for the work are listed in Table
3.2.
3.3 Chemical Reagents
The chemicals used in the molecular biology and the organic synthesis work are 
listed in Table 3.3.
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Table 3.3
Chemicals Source
General chemicals, biochemicals, organic solvents Aldrich/Sigma, BDH
Media Difco, Oxoid
Agarose BRL, FMC
Aery 1 amide National diagnostics, BioRad
Radiochemicals ICN Biochemicals
10 x Restriction enzyme buffers BRL, New England Biolabs
Reagents for oligonucleotide synthesis Cruachem
5 x Ligase buffer BRL
3.4 Oligonucleotides
The oligonucleotides used for cloning and for crosslinking are listed in Table 3.4.
3.5 Antibiotics
The antibiotics used as selectable markers are listed in Table 3.5.
Table 3.5
Antibiotic Stock Solution Working concentration
Ampicillin (Ap) 5 mg/ml in dHzO 50 (Lig/ml
Chloramphenicol (Cm) 2.5 mg/ml in ethanol 25 (ig/ml
Kanamycin (Km) 5 mg/ml in dH20 50 (ig/ml
Tetracycline (Tc) 12.5 mg/ml in 70% ethanol 12.5 (Ig/ml
3.6 Bacterial growth media
For the growth of E. coli for DNA preparation, transformations and protein 
purification.
L-broth: 10 g bacto-tryptone, 5 g bacto-yeast extract, 5 g NaCl, made up to 1 
litre with deionised water, adjusted to pH 7.5 with NaOH.
L-agar: L-broth with 15 g/l agar.
The above media are sterilised at 120 °C for 15 minutes before use.
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Table 3.4 Oligonucleotides
SHRV 
40 nt
5'CACTAGTCTGTTCGAAATATGATATCTTATCAGACATA
GG-3'
Section
6.2
SHTT 
40 nt
5 'C ACT AGTCTGTTCG A A AT ATT AT A A ATT ATC AG AC AT A 
GG-3'
Section
3.20
SHBT 
48 nt
5'AATTCCT ATGTCTG AT A ATTT AT AATATTTCGA AC AGAC 
TAGTGAGCT-3'
Section
3.20
SHR2 
48 nt
5'AATTCCTATGTCTGATAATTGATATCATTTCGAACAGA
CTAGTGAGCT-3'
Section
6.2
C155A 
56 nt
5'AACGCTTCATCAGAAGGGCACTGGTGCAACGGAAATT 
GCTCATCAATTGAGTATTG 3'
Section
4.5
C155B 
60 nt
5'CGCGCAATACTCAATTGATGAGCAATTTCCGTTGCACC 
AGTGCCCTTCTGATGAAGCGTT 3'
Section
4.5
C155C 
23 nt
5'-AATTGAGTATTTGTCGCTCCACGGTTTA-3' Section
4.5
C155D 
24 nt
5-TAAACCGTGGAGCGACAAATACTC-3' Section
4.5
C155E 
28 nt
5 A ATTG AGT ATTGCGTGTTCC ACGGTTT A-3' Section
4.5
C155F 
24 nt
5'-TAAACCGTGGAACACGCAATACTC-3' Section
4.5
C156A 
28 nt
5 '-A ATTG AGT ATTGC ACGCT GT ACGGTTT A-3' Section
4.5
C156B 
24 nt
5'-T A A ACCGTAC AGCGTGC A AT ACTC-3' Section
4.5
C156C 
28 nt
5-AATTGAGTATTGCACGCTCCACGGTTTG-3' Section
4.5
C156D 
24 nt
5'-CAAACCGTGGAGCGTGCAAT ACTC-3' Section
4.5
C156E 
32 nt
5'TTGTATTCTTGAAGACGAAAGGGCGAGCTGAGTCGAC-
3'
Section
4.5
C156F 
36 nt
5-TCGACTCAGCTCGCCCTTTCGTCTTCAAGAATACAA-3' Section
4.5
SHT1 
40 nt
5 'C ACT AGTCTGTTCG A A AT ATT AT A AATT ATC AG AC AT A 
GG-3'
Section
5.2
SHT3 
40 nt
5'CACTAGTCTGTTCGAAATATTATAAATT ATC AG AC AT A 
GG-3’
Section
5.2
SHT4 
40 nt
5 'C ACT AGTCTGTTCG A A AT ATT AT A A ATT ATC AG AC AT A 
GG-3'
Section
5.2
SHT12 
40 nt
5 'C ACT AGTCTGTTCG A A AT ATT AT A A ATT ATC AG AC AT A 
GG-3'
Section
5.2
SHB1 
48 nt
5'AATTCCT ATGTCTG AT A ATTT AT AAT ATTTCG AAC AG A 
CTAGTGAGCT-3'
Section
5.2
SHB3 
48 nt
5'AATTCCT ATGTCTG AT A ATTT AT AAT ATTTCG A AC AG A 
CTAGTGAGCT-3'
Section
5.2
SHB5 
48 nt
5'AATTCCTATGTCTGATAATTTATAATATTTCGAACAGA
CTAGTGAGCT-3'
Section
5.2
SHB13 5 'AATTCCT ATGTCTGAT A ATTT AT AAT ATTTCG AAC AG A Section
48 nt CTAGTGAGCT-3 5.2
2 x YT: 16 g bacto-tryptone, 10 g bacto-yeast extract, 5 g NaCl made up to 1 litre 
with deionised water and pH adjusted to 7.0 with NaOH.
Usually used for antibiotic expression after transformation of plasmid DNA. 
vj/ broth: 2% tryptone (w/v), 0.5% yeast extract (w/v), 20 mM MgS04, 10 mM 
NaCl, 5 mM KC1, adjusted to pH 7.5 with KOH.
MacConkey Galactose Agar: The MacConkey agar powder was supplied by 
Difco. A solution of 4 g in 95 ml deionised water was boiled and allowed to cool 
to 40 °C before adding 1% D-galactose (w/v).
3.7 Bacterial Cultures
Liquid cultures were grown at 37 °C with vigorous shaking, either to log phase of 
growth or overnight (as described in DNA preps).
Bacteria were grown on agar plates at 37 °C overnight, with the plates inverted. 
Plasmid cultures to be stored were made into glycerol stock solutions, mixing 1 
ml of the culture with 1 ml 2% peptone, 40% glycerol and kept at -70 °C.
Antibiotics were added to both liquid cultures and plates, as required for selection 
(see Table 3.5).
3.8 Preparation of competent E.coli cells
Competent cells for the transformation of plasmid DNA were prepared using the 
following methods:
3.8.1 Calcium chloride method (CaCl2)
10 ml of L-broth was inoculated with the strain of interest and shaken overnight 
at 37 °C. A 19 ml solution of prewarmed L-broth was inoculated with 1 ml of this 
starter culture and grown with vigorous shaking until OD600 of 0.4-0.6 was 
reached, then spun to 10,000 rpm in a pre-chilled Beckmann JA-20 rotor at 4 °C. 
Once the speed was reached the brake was applied immediately. The supernatant 
was removed and the pellet was gently suspended in 10 ml ice cold 50 mM 
CaCl2. The solution was respun as before and the supernatant removed. The cells 
were resuspended in 10 ml ice cold 50 mM CaCl2and stored at 4 °C, where they
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remained competent for 48 hours. Alternatively, aliquots were frozen in liquid 
nitrogen for long term storage at -70 °C.
3.8.2 Rubidium chloride method (RbCl)
TFB I: 30 mM KOAc, 100 mM RbCl, 10 mM CaCl2.2H20 , 50 mM MnCl2.4H20 , 
15% (v/v) glycerol, pH 5.8 with AcOH.
TFB II: 10 mM MOPS, 75 mM CaCl2.2H20 , 10 mM RbCl, 15% (v/v) glycerol, 
pH 6.8 with HC1 or KOH.
20 ml of \|/ broth was inoculated with the desired strain. Using 4 ml of this 
culture, a 200  ml pre-warmed solution of \|/ broth was inoculated and grown with 
shaking at 37 °C until an OD600 of 0.4-0.6 (approximately 1-2 hours). The cells 
were then chilled on ice before spinning in a J2-21 rotor at 5000 rpm for 10 
minutes at 4 °C. The supernatant was decanted and the pellet was resuspended in 
10 ml of ice cold TFB I and kept on ice for 30 minutes. Following another 5000 
rpm spin for 10 minutes at 4 °C the supernatant was discarded and the pellet was 
resuspended in 8 ml ice cold TFB II, and kept on ice for a 15 minute period. 200 
jil aliquots were removed, dispensed into Nunc tubes and frozen in liquid 
nitrogen for storage at -70 °C.
3.9 Transformation of E. coli with plasmid DNA
0.1 jig of plasmid DNA was added to 100 jllI of competent E. coli cells and gently 
mixed with a yellow pipette tip. The cell suspension was heat shocked at 37 °C 
for 5 minutes then placed in ice for 15 minutes. Five volumes of 2 x YT broth 
was added to the solution which was then incubated at 37 °C for 2 hours to allow 
for antibiotic expression. A 100 jil aliquot of the culture was spread on agar plates 
containing appropriate antibiotics for selection.
3.10 Phenol Extraction
The organic extraction of proteins from protein/DNA mixtures was carried out by 
adding 1 volume of phenol (containing 0 .1% 8-hydroxy quinoline and equilibrated
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with 0.5 M Tris-HCl pH 8). The sample was thoroughly mixed by vortexing, and 
spun at 14,000 rpm in a bench top centrifuge for 3 minutes. The DNA-containing 
aqueous layer (the upper layer) was recovered and re-extracted with more phenol 
if required. A further extraction of the aqueous layer with chloroform ensured 
removal of any residual phenol from the sample.
3.11 Ethanol Precipitation of DNA
1 x TE buffer: 10 mM Tris-HCl pH 8.2, 1 mM EDTA.
The sodium ion concentration of the DNA solution was adjusted to 0.30 M with 3 
M sodium acetate pH 5.2. To this solution was added 2 volumes of ethanol and 
after thorough mixing the solution was incubated at -20 °C for 30 minutes. The 
DNA was pelleted by spinning in a Eppendorf microfuge tube at 14,000 rpm for 
30 minutes at 4 °C in bench top centrifuge. The pellet was washed with 70% 
ethanol and re-spun for 5 minutes before drying at room temperature for 5 
minutes, then re-suspending in TE buffer.
3.12 Small scale preparation of plasmid DNA
The following procedure is adapted from Bimboim and Doly (1979) and utilises 
alkaline lysis to disrupt the cells.
Doly I: 50 mM glucose, 25 mM Tris-HCl (pH 8.0), 10 mM EDTA.
Doly II: 200 mM NaOH, 1% SDS (w/v) made fresh.
Doly III: 0.6 vol. 5 M KOAc, 0.115 vol. AcOH, 0.285 vol. H20.
3.12.1 Alkaline lysis method
1.5 ml cultures were grown for 12 hours at 37 °C until they reached stationary 
phase. The cells were pelleted by spinning at 14,000 rpm in a bench top 
centrifuge for 2 minutes, then re-suspended in 200 jil Doly I containing 4 mg/ml 
lysozyme and left at room temperature for 5 minutes. To this solution was added 
400 |il Doly II. After mixing with inversion the mixture was incubated on ice for 
5 minutes. Then 300 p,l of 7.5 M ammonium acetate was added to the solution 
which was mixed thoroughly before placing on ice for 10 minutes. The cell debris
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was pelleted by centrifugation at 14,000 rpm for 3 minutes. The supernatant was 
then removed and extracted with 3 x 0.5 volumes of phenol (the first extraction 
was gently mixed) then 0.5 volumes of 24:1 (v/v) chloroformiisoamyl alcohol. 
The aqueous layer was removed and the DNA was precipitated by addition of 
0.75 volumes of isopropanol, and leaving at room temperature for 10 minutes.
The solution was spun at 14,000 rpm for 30 minutes at 4 °C in a bench top 
centrifuge. The supernatant was decanted, and the pellet was washed with 70% 
ethanol, dried and resuspended in 50 pi of TE buffer.
3.12.2 'Boiling Prep'
STET buffer: 8% sucrose, 5% Triton X-100, 50 mM EDTA, 50 mM Tris-HCl 
(pH 8.2).
1.5 ml of overnight culture was spun at 12,000 rpm in a microfuge for 30 
seconds. The supernatant was discarded, and the pellet was re-dissolved in 350 pi 
STET buffer. To this solution was added 25 pi of freshly made 10 mg/ml 
lysozyme in STET. After briefly vortexing, the solution was incubated at room 
temperature for 5 minutes. The solution was vortexed briefly and immediately 
placed in boiling water for 40 seconds. Following a 15 minute spin at 4 °C the 
supernatant was retained. To this was added 40 pi of 3 M NaOAc and 400 pi of 
ice-cold isopropanol. After thorough mixing the solution was spun at 4 °C for 7 
minutes. The pellet was washed with 70% ethanol, dried and re-dissolved in 50 pi 
1 X TE buffer.
3.12.3 Qiagen Miniprep
This method was carried out according to the manufacturers' instructions.
3.13 Large scale preparation of plasmid DNA
200 ml overnight cultures were grown for 12 hours at 37 °C until reaching 
stationary phase. These were then spun in a JA-14 rotor at 8,000 rpm for 5 
minutes at 4 °C. The supernatant was removed, and the pellet was resuspended in
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4 ml Doly I and mixed with a cut-tipped pipette. The mixture was placed on ice 
for 5 minutes. To the mixture was added 8 ml of freshly made Doly II, and after 
mixing by inversion, placed on ice for 4 minutes. 6 ml of ice-cold Doly III was 
added, and after mixing by vortexing, the solution was kept over ice for 5 minutes 
before spinning in a large centrifuge using a JA-14 rotor at 18,000 rpm for 30 
minutes at 4 °C. The supernatant containing the DNA was then mixed with 12 ml 
isopropanol and allowed to stand at room temperature for 15 minutes before 
spinning at 18,000 rpm for 30 minutes at 20 °C. The pellet was washed with 70% 
ethanol and dried at 37 °C for 30 minutes. The pellet was resuspended in 2 ml TE 
buffer and placed on a horizontal shaker for 2 hours at 37 °C. A solution of 5 g of 
caesium chloride was added to 3 ml of water and placed in a Beckmann ultra­
centrifuge tube containing 270 pi of a 15 mg/ml solution of ethidium bromide and 
the dissolved DNA solution. The tubes were filled with liquid paraffin and heat- 
sealed before being weighed to balance within 0.1 g, and placed in a Beckman 
Ti70 fixed-angle rotor. The samples were spun in an ultracentrifuge at 49,000 
rpm for 16 hours at 15 °C. The DNA was visualised using a long wave (365 nm) 
UV transilluminator. Usually two bands were present, the upper band consisting 
of chromosomal and nicked plasmid DNA, the lower band being the supercoiled 
plasmid DNA.
Using a 1 ml syringe fitted with a 21 gauge needle, approximately 0.5 ml of 
supercoiled plasmid solution was removed and placed in a test tube. Excess 
ethidium bromide in the sample was removed using three extractions with 0.8 
volumes of n-butanol. The DNA solution was then placed in a Corex™ tube 
along with 3 volumes of deionised water and 8 volumes of ethanol, and after 
thorough mixing was incubated at 4 °C for 30 minutes. The solution was then 
spun in a JA-20 rotor at 7,000 rpm for 30 minutes at 4 °C. The pellet was then 
washed with 70% ethanol, dried and resuspended in 500 pi of TE buffer. The 
DNA was stored at -20 °C.
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3.14 UV spectroscopy
The concentration of plasmid DNA solutions and of oligonucleotides was 
determined by measuring A260 with a UV/visible spectrophotometer (Shimadzu). 
The following assumption was made when measuring the DNA concentration, 
that an absorbance of 1 at 260 nm corresponds to a DNA concentration of 50 
pg/ml for double-stranded DNA.
For oligonucleotides, the absorbance at 260 nm was used to estimate the DNA 
concentration using the Beer-Lambert Law
A = e. c. 1
Where A = absorbance at 260 nm
e = extinction co-efficient, estimated at 10,000 1 mol' 1 cm'1 per nucleotide 
c = molar concentration 
1 = path length of cell (usually 1 cm)
3.15 Restriction endonuclease digestion of DNA
Digestion was carried out in the supplier's recommended buffer, usually BRL 
React buffer or New England Biolabs buffer, with a 10 fold excess of enzyme to 
ensure complete digestion of the DNA (10 U/pg DNA). For cloning purposes, 
usually 1-5 pg plasmid DNA was digested, and for construction of artificial 
supercoiled substrates, 50 pg was cut and higher concentration enzymes were 
used.
In a typical digestion, the DNA was cut in 20 pi of the correct buffer for 1 hour at 
37 °C, and the reaction was stopped either by heat inactivation of the enzyme at 
70 °C for 10 minutes, by the addition of SDS loading buffer, or by extracting with 
1 volume of phenol.
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Double digests were carried out by cutting first with one enzyme, then heating to 
70 °C for 10 minutes. After adjusting the pH and/or concentration of sodium ions, 
if required, the second enzyme was used and the mixture was incubated for 60 
minutes at 37 °C as before.
3.16 5’-Phosphorylation of DNA
1 x T4 kinase buffer: 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.1 
mM spermidine, 0.1 mM EDTA.
This method allowed the introduction of either a labelled or unlabelled phosphate 
group at the 5' end of dephosphorylated linear DNA fragments or synthetic 
oligonucleotides. The phosphate group is derived from either unlabelled ATP or 
[y-32P]ATP.
Typically 2 pmol of DNA was added to 1 x T4 kinase buffer (20 fil) with either 
10 jnCi fy-32P]ATP (8000 jiCi/mmol) or 1 mM ATP, followed by 1 unit of T4 
kinase. After incubation at 37 °C for 45 minutes, the reaction was stopped by 
heating at 70 °C for 10 minutes. The phosphorylated DNA fragment was 
recovered by ethanol precipitation.
3.17 Filling in 3’ recessed ends of DNA fragments
Following restriction endonuclease digestion, it is sometimes desirable to fill in 
the 3’-recessed end, for a blunt-ended ligation or to remove a restriction enzyme 
site from plasmid DNA. This was achieved by adding the Klenow fragment from 
DNA polymerase 1(1 unit) and the appropriate dNTPs (100 |iM final) to the 
digested DNA, and incubating for 30 minutes at 37 °C.
3.18 3’-end labelling of DNA fragments
This was used to incorporate a radionuclide label into the DNA after a restriction 
digest, at the 3’ recessed end created by that digest.
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1-2 jug of DNA was cut with a restriction endonuclease generating a 3’ recessed 
end. 10 pCi of an [a-32P]dNTP (3000 jLiCi/mmol) and the other dNTPs at a final 
concentration of 10 pM were added to the digested DNA, along with 1 unit of the 
Klenow fragment of DNA polymerase I. The sample was incubated at room 
temperature for 20 minutes. Cold dNTPs were then added to a final concentration 
of 100 pM each and the solution was kept at room temperature for 20 minutes. 
The reaction was stopped by phenol and chloroform extraction and the 3’-labelled 
DNA was recovered by ethanol precipitation.
3.19 Ligation of DNA restriction fragments
1 x BRL ligation buffer: 50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 1 mM ATP,
1 mM DTT, 5% (w/v) polyethylene glycol-8000.
Ligations for cloning purposes used 1-2 pg (approx. 1 pmol) of DNA in a volume 
of 20 |L i l  with 1 x BRL ligation buffer and 1 unit of T4 DNA ligase. Samples were 
incubated at room temperature overnight, then used to transform competent E.coli 
cells.
If more efficient transformation was required, it was sometimes necessary to 
precipitate the ligation mixture with ethanol before transforming the competent 
cells.
3.20 Annealing oligonucleotides
Single-stranded oligonucleotides were annealed in 10 pi of 100 mM NaCl, 10 
mM Tris-glycine (pH 9.4). Unlabelled oligonucleotides were annealed in a 1:1 
ratio, whereas when annealing a [y-32P]ATP labelled strand to an unlabelled 
strand, a ratio of 2:1 labelled to unlabelled was used. This ensured complete 
annealing of the labelled strand. For the modified strands carrying the protected 
thiol group, a ratio of 1:1.5 wild-type strand to labelled modified strand was used. 
Typically, 2 pmol of oligonucleotide (labelled and/ or modified) was annealed to 
the corresponding strand in 10 pi of annealing buffer. The mixture was heated to 
70 °C for 10 minutes, then allowed to cool to room temperature.
3.21 Agarose gel electrophoresis
1 x TAE buffer: 40 mM Tris-acetate (pH 8.2), 20 mM sodium acetate, 1 mM 
Na2EDTA.
Agarose gel electrophoresis was used to separate and visualise DNA from single 
colonies, restriction digests, and recombination assays. Normally 0.7%, 1.2% and 
1.5% agarose gels were made by mixing BRL Ultrapure agarose in 250 ml of 1 x 
TAE buffer and heating for 3-4 minutes in a 950 W microwave oven until the 
agarose was completely dissolved. The hot solution was allowed to cool for 20 
minutes before pouring.
FMC low melting point ‘Seaplaque’ agarose was employed when it was 
necessary to recover DNA bands from the gel, i.e. for cloning or for making 
artificial supercoiled substrates. Seaplaque agarose was left to set at 4 °C.
A 150 x 200 mm horizontal slab gel was prepared by pouring the hot agarose 
solution (250 ml) into a gel formed with a 22 well comb close to one edge. 
Around 3 litres of 1 x TAE was required in the buffer reservoir tank. The gels 
were usually run for 3 hours at 100 V or at 40 V overnight.
Smaller gel kits were used to quickly check restriction digests. These ‘minigels” 
require 30 ml of agarose gel, 400 ml 1 x TAE and were run for 1 hour at 80-100 
V.
3.22 'Single Colony Gel' Analysis
Single colony lysis buffer: 2% ficoll (w/v), 1% SDS (w/v), 0.05% orange G 
(w/v), 0.01% bromophenol blue (w/v) in 1 x TAE buffer.
This technique was used to confirm that transformations with ligated DNA had 
been successful. Single bacterial colonies of interest were made into 1 cm2 
patches with a sterile toothpick on a fresh selective agar plate. The plates were 
grown overnight. A sample of the patch was picked up using a sterile toothpick,
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mixed in 1 x single colony lysis buffer, and incubated at room temperature for 20 
minutes. The samples were spun in a bench top centrifuge at 14,000 rpm for 20 
minutes. The supernatant was directly loaded onto a 1.5% agarose gel.
3.23 Purification of DNA from low melting point gels
Low melting point agarose ‘Seaplaque GTG’ was used to purify large linear 
DNA fragments, usually following restriction digestion. After visualising the 
bands of interest using the long wave (365 nm) transilluminator, they were 
excised from the gel using a clean scalpel and transferred to an eppendorf tube.
The gel chip was melted at 65-70 °C for 10 minutes, then allowed to cool briefly 
before extracting with 1 volume of phenol. At this point the solution was mixed 
gently by inversion to minimise emulsification. The solution was spun in a 
microfuge at 14,000 rpm for 5 minutes, then the aqueous layer was removed and 
placed in a fresh eppendorf tube. The solution was extracted further with another 
2 x 1 volume of phenol, mixing by vortexing before spinning, then with 1 volume 
of chloroform. The DNA was ethanol-precipitated. The pellet was washed with 
70% ethanol and dissolved in 1 x TE buffer.
3.24 Polyacrylamide Gel Electrophoresis
Different gel compositions and running conditions were used to analyse proteins, 
fragments of DNA, oligonucleotides and protein/DNA crosslinking.
1 x TBE: 89 mM Tris base, 89 mM boric acid, 0.2 mM EDTA.
1 x Tris-glycine: 50 mM Tris-glycine (pH 9.4), 0.1 mM EDTA. The buffer was 
made as a 10 x stock solution of 500 mM Tris, 100 mM glycine, 10 mM EDTA. 
The pH of this was approximately 9.4 and was not adjusted further.
3.24.1 SDS-polyacrylamide gels
1 x Laemmli running buffer: 25 mM Tris base, 20 mM glycine, and 0.1% SDS 
(w/v).
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These were used to check the induction of resolvase protein prior to purification, 
by looking at whole cell samples. They were also used to monitor the purification 
and yield of resolvase mutants. A Biorad Mini-Protean II dual slab gel kit was 
used, usually to run two gels simultaneously. A discontinuous buffer system was 
used which involved running the samples through gels of different percentage 
acrylamide and different ionic strength.
A resolving gel comprising 15% polyacrylamide, 0.375 M Tris-HCl (pH 8 .8), 
0.1% SDS was made by mixing 5 ml 30% acrylamide:0.8% bisacrylamide (w/v),
2.5 ml 1.5 M Tris-HCl (pH 8 .8), 100 pi 10% SDS, 2.35 ml dH20 , 50 pi 10% APS 
and 5 pi TEMED. The resolving gel was poured, overlain with isopropanol, and 
allowed to polymerise until set. The overlay solution was poured off, and the top 
of the gel was washed with de-ionised water and dried. The stacking gel, 
comprising 4% polyacrylamide, 0.125 M Tris-HCl (pH 6 .8), 0.1% SDS was made 
by mixing 1.3 ml 30: 0.8 acrylamide:bisacrylamide (w/v), 2.5 ml 0.5 M Tris-HCl 
(pH 6 .8), 100 pi 10% SDS, 6.1 ml dH20 , 50 pi 10% APS and 10 pi TEMED.
This solution was poured onto the resolving gel that had already set and a 10 well 
comb was inserted.
During the protein purification steps, aliquots of 1/200th of the total volume of 
the resolvase-containing fractions were taken for analysis. Before running the 
samples, 1-2 pi of (3-mercaptoethanol was added to the loading buffer (Section 
3.28) to ensure the protein would be fully reduced. Gels were run at 200 V for 45 
minutes.
3.24.2 Non-denaturing polyacrylamide gels
This technique was used to separate and isolate small fragments of DNA (< 300 
bp) and to analyse oligonucleotides.
Adjustable slab gel kits from CBS Scientific Co. were used. 160 mm x 180 mm 
glass plates were clamped with a rubber seal to prevent any leaks during pouring.
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The gel solution was poured between the plates, then a 15-well comb was 
inserted at the top of the gel and held in place with a clamp until set. After the gel 
had polymerised, it was clamped to the electrophoresis kit, and after the running 
buffer reservoirs were filled the gel comb was removed. Prior to loading the 
samples, the wells were washed thoroughly with running buffer. Typically gels 
were run at 200 V at room temperature for 3-4 hours. The DNA was visualised 
using ethidium staining, autoradiography or phosphor-imaging.
Gels of different percentages of acrylamide were made by changing the water to 
acrylamide ratio. Typically 40 ml 10% (w/v) gel was made from 14 ml 30%
30:0.8 acrylamide: bisacrylamide (w/v), 4 ml 10 x TBE (or Tris-glycine), 22 ml 
dH20 , 360 jlx.1 10% ammonium persulphate (APS) and 18 |il TEMED.
3.24.3 Denaturing polyacrylamide gel electrophoresis
For the analysis of crosslinking reactions the recipe for a 10% gel described in the 
previous Section was used. A 10% Tris-glycine gel was prepared, with SDS 
added to both the gel and the running buffer to a final concentration of 0 .1%.
For the purification of synthetic oligonucleotides, gels containing urea were 
prepared. A 75 ml, 15% gel was made by mixing 31.5 g urea, 7.5 ml 10 x TBE,
22.5 ml 40% 19:1 acrylamide: bisacrylamide (w/v), 21.5 ml dH20 . The mixture 
was warmed until the urea dissolved, then 480 pi 10% ammonium persulphate 
(APS) and 27 pi TEMED were added. The gel was poured between two plates 
(320 mm x 180 mm) and left to polymerise for 1 hour. The plates were loaded 
into the CB8 polyacrylamide gel kit. The wells were washed thoroughly and the 
gel was preheated at 400-500 V (15 W) prior to sample loading.
To the sample was added 1 volume of formamide loading buffer (Section 3.28), 
then the sample was heated to 70 °C for 5 minutes and loaded on to the gel and 
run at 500 V (constant voltage) for 2-3 hours. The gel was removed and stained 
with 70 ml dH20: 20 ml isopropanol: 10 ml 0.1% “Stains-all” (Section 3.29.4) in
formamide for 10 minutes or until the bands could be seen. After washing for 5 
minutes with deionised water, the bands were removed using a scalpel and placed 
in a Nunc tube. After adding 1 ml 1 x TE buffer and crushing with a glass rod, the 
samples were placed on a rotary mixer at 37 °C overnight. The mixture was 
passed through a Co-star microspin 0.45 jim filter and the eluate was dried 
directly in a gyrovap, or ethanol precipitated before re-dissolving in 1 x TE 
buffer.
3.24.4 DNA sequencing gels
These were used to analyse the dinitrophenyl-modified (DNP) oligonucleotides 
(Section 3.38). A 100 ml 10% acrylamide-7 M urea gel was made by mixing 40 g 
urea, 10 ml 10 x TBE, 25 ml 40% 19:1 acrylamide: bisacrylamide (w/v), 20 ml 
dH20  and 40 |il TEMED in a glass beaker. A Gibco BRL sequencing gel kit was 
used. The solution was warmed until the urea dissolved, then 800 (il 10% APS 
was added. The gel solution was poured between 410 mm x 330 mm plates and 
allowed to polymerise. The gel was pre-run at 80 W until the temperature reached 
48 °C, before sample loading. The samples were heated to 70 °C in 1 volume of 
formamide loading buffer (Section 3.28) before loading. The gel was run at 60 W 
for 1 hour.
3.25 DNA synthesis
The reagents used were supplied by Cruachem. Oligonucleotides were 
synthesised using an Applied Biosystems Model 392 DNA synthesiser. The 
synthesis of the oligonucleotides is based on standard cyanoethyl 
phosphoroamidite chemistry (reviewed in Goodchild, 1990). For the synthesis of 
the phosphorothioate-containing oligonucleotides, an additional step was used to 
replace the O with S. Prior to the oxidation step, the column was removed from 
the machine and washed with 1 ml of the sulfurization reagent 377-1,2- 
benzodithiol-3-one, 1,1-dioxide (10 mM) in acetonitrile for 2 minutes.
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3.26 DNA molecular weight standards
These were used on agarose and polyacrylamide gels, usually the Gibco BRL 1 
kb ladder.
3.27 Purification of DNA from polyacrylamide gels
The band of interest was excised from the gel using a clean scalpel. The gel chip 
was placed in a Nunc tube, crushed with a glass rod and placed in 1 ml of 1 x TE 
buffer. The sample was placed on a rotary mixer overnight at 37 °C. The excess 
acrylamide was removed by spinning the solution through a Co-star spinX 0.22 
pm column. The DNA solution was either precipitated with ethanol or 
concentrated in a gyrovap and re-dissolved in TE buffer.
3.28 Loading buffers
Formamide loading buffer: 80% deionised formamide (v/v), 10 mM EDTA (pH 
8.0), 1 mg/ml xylene cyanol FF, 1 mg/ml bromophenol blue.
One volume of the above was added to the oligonucleotide solutions prior to 
running on a denaturing polyacrylamide gel. To denature the oligonucleotides 
prior to loading on a gel, the samples were heated in the formamide buffer for 10 
minutes at 55 °C.
SDS loading buffer: 50% glycerol, 10 mM Tris-HCl (pH 8.2), 1% SDS, 0.01% 
bromophenol blue in 1 x TAE buffer.
0.25 volumes of the above was added to samples prior to running on agarose or 
polyacrylamide gels. To remove protein from crosslinked DNA, proteinase K at 
10 mg/ml was added to this buffer.
Laemmli loading buffer: 50 mM Tris-HCl (pH 6 .8), 1% SDS (w/v), 10% 
glycerol (v/v), 0 .1% bromophenol blue.
An aliquot from a protein purification step or 5-10 pi of a purified resolvase 
dilution was added to 20 pi of Laemmli loading buffer. 1-2 pi of 100% |3- 
mercaptoethanol was added to the samples, which after thorough vortexing were 
boiled for 10 minutes prior to loading on the gel.
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3.29 Gel staining and visualisation
3.29.1 Ethidium staining of agarose and polyacrylamide gels
Unlabelled DNA was visualised using ethidium bromide at a final concentration 
of 0.6 |Lig/ml in 1 litre of running buffer. The tray was shaken gently on a R100 
Luckham Shaker for 30 minutes, then the gel was rinsed in de-ionised water and 
allowed to de-stain for 30 minutes to remove excess ethidium bromide. For 
general DNA analysis and resolution reactions, the stained DNA was visualised 
using short-wave 254 nm UV light on a ultraviolet transilluminator (UVP). Bands 
that were required for further experiments were visualised on a long-wave 365 
nm transilluminator to reduce photochemical damage to the DNA.
3.29.2 Visualisation of radiolabelled DNA
Gels were placed on 3 layers of Whatman 3MM paper and were dried at 80 °C 
for 1-2 hours under vacuum in a Biorad slab gel drier. The dried gels were either 
exposed against a Fuji RX100 film then developed using an X-OMAT automated 
processor (Kodak), or against a Fuji phosphoimaging plate, then scanned on a 
Fuji BAS-1500 phosphor-imaging system.
3.29.3 Visualisation of proteins
Coomassie Stain: 1% Coomassie Blue R250 (w/v), 50% MeOH (v/v), 10% 
AcOH (v/v).
Coomassie Destain: 10% MeOH (v/v), 10% AcOH (v/v).
After electrophoresis, the gel was covered with stain solution and stained for 30 
minutes with gentle agitation, then destained for at least 1 hour. The protein 
bands were visualised on a light box.
3.29.4 Visualisation of oligonucleotides
“Stains-all”: 1 -ethyl-2-[3-( l-ethylnaptho[ 1,2-d]thiazolin-2-ylidene)-2- 
methylpropenyl]-naptho( 1,2-d)thiazolium bromide.
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The gel was placed in a shallow glass tray containing 70 ml of water and 20 ml of 
isopropanol. To this was added 10 ml of a 0.1% (w/v) solution of ‘Stains-all’ in 
formamide, and after gentle agitation for 5-10 minutes the bands appeared. After 
destaining by rinsing in water for 5 minutes, the bands were excised, crushed with 
a glass rod, then soaked in 1 ml of 1 x TE and placed on a rotary mixer overnight. 
Generally, the slowest moving strong band on the gel corresponded to the full 
length oligonucleotide.
3.30 Tn3 resolvase
Wild-type resolvase R17f33 was a gift from M. Boocock; its concentration was 
48 |liM (Blake, 1993; Watson, 1994). Wild-type Tn3 resolvase and the cysteine 
mutants (Section 3.30 and 4.10) were made into solutions of different 
concentrations by diluting in resolvase dilution buffer. These dilutions were 
annotated 2'\ 2‘2, 2'3, etc indicating a two-fold, four-fold and eight-fold dilution 
respectively.
Resolvase dilution buffer: 10 mM Tris-HCl (pH 7.5), 1 M NaCl, 50% glycerol 
(v/v), 0.1 mM EDTA, 0.1 mM DTT (1 mM DTT for cysteine mutants).
3.31 In vitro recombination
The reactions were carried out in the following buffers:
C8.2: 50 mM Tris-HCl (pH 8.2), 10 mM MgCl2, 0.1 mM EDTA.
C9.4: 50 mM Tris-HCl (pH 9.4), 10 mM MgCl2, 0.1 mM EDTA.
MD10: 50 mM glycine-NaOH (pH 10), 5 mM spermidine.3HC1, 5 mM EDTA.
For resolution reactions, 0.05 volumes of diluted resolvase was added to 0.8 jug of 
DNA in 40 \il of reaction buffer. For the cysteine-modified proteins 0.1 volumes 
of protein were used. Reactions were incubated at 37 °C for 60 minutes, then the 
protein was heat-inactivated at 70 °C for 10 minutes. The sample was divided 
into 2 x 20 jil aliquots, one of which was analysed by restriction digestion. 0.25 
volumes of SDS-loading buffer was added to the samples before loading on an
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agarose gel. 1 mM DTT was added to all the buffers used for reactions of cysteine 
mutants.
3.32 Band shift analysis
Binding buffer: 10 mM Tris-glycine (pH 9.4), 0.1 mM EDTA, 1 mM MgCl2, 
10% glycerol (v/v).
Non-specific carrier DNA, usually pUC71K (10-25 fxg/ml), was mixed with end- 
labelled res DNA or site I oligonucleotides (400-600 cps) in 200-300 (il binding 
buffer. The reactions were divided into 20 pi aliquots and 0.05 volume of wild- 
type protein and cysteine mutants was added. The samples were incubated at 37 
°C for 15 minutes, then loaded onto a 6% non-denaturing polyacrylamide gel 
(Section 3.24.2) and run at 200 V for 4 hours.
3.33 Preparation of competent BL21(DE3)pLysS cells
A glycerol stock solution of BL21(DE3)pLysS was available in the lab (Arnold, 
1999). A toothpick was used to remove a small sample of these cells which were 
streaked on agar containing 25 pg/ml chloramphenicol and grown overnight at 37 
°C. A single colony was removed using a sterile toothpick and placed in a tube 
containing 30 ml L-broth. This sample was grown, with shaking, overnight at 37 
°C.
This overnight culture was used to prepare competent cells of BL21(DE3)pLysS 
using the CaCl2 method (Section 3.8.1). These competent cells were left one ice 
overnight, then transformed with the pMS95-99 derivatives, which encode the 
resolvase C-terminal cysteine mutants. The transformations were plated on agar 
containing 50 Jig/ml ampicillin and 25 |ig/ml chloramphenicol and grown 
overnight at 37 °C. Colonies were streaked onto agar, with the same antibiotic 
selection as above, and grown overnight at 37 °C.
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3.34 Expression of the mutants in the expression strain BL21(DE3)pLysS 
Cell re-suspension buffer: 20mM Tris-HCl pH 7.5, lOmM MgCl2, O.lmM 
EDTA.
The transformant clones were streaked to single colonies, and these were used to 
inoculate an overnight starter culture. 1 ml of this starter culture was used to 
inoculate a 400 ml shake culture in L-broth with 50 |ig/ml kanamycin. The cells 
were grown at 37 °C until the A600 was between 0.45-0.60. The cells were then 
immediately induced with 0.5 mM IPTG and shaken vigorously at 37 °C for 3.5 
hours. The cells were harvested into pre-weighed 200 ml centrifuge tubes and 
centrifuged at 9 K for 10 minutes at 4 °C. The supernatant was removed and the 
spin step was repeated, to ensure that all the supernatant was discarded. The cells 
were washed in 100 ml of ice-cold re-suspension buffer on ice using a glass rod 
and gently pipetting up and down. The cells were spun at 9 K for 10 minutes as 
before and the supernatant was thoroughly removed. The dry pellets were 
weighed and stored at -70 °C.
3.35 Purification of cysteine mutants of Tn3 resolvase
The purification is based on a denaturing method (Boocock and Weinwieser, 
pers. comm.). All steps were performed at 4 °C unless otherwise stated, and after 
each wash the solutions were spun at 18 K for 15 minutes at 4 °C in a JA-20 
Beckmann rotor. At each step of the protocol, samples were taken to be run on 
Laemmli gels (Section 3.24.1).The quantities in the following correspond to 
starting with approximately 1-2 g dry cells.
TMDEP: 20 mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM DTT, 0.1 mM EDTA,
1.2 mM PMSF, 1% EtOH.
TDEP: 20 mM Tris-HCl pH 7.5, 5 mM DTT, 0.1 mM EDTA, 1.2 mM PMSF, 
1% EtOH.
Buffer A: 25 mM Tris-HCl pH 7.5, 25 mM NaCl, 0.1 mM EDTA, 5 mM DTT, 
6M urea.
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Buffer B: 25 mM Tris-HCl pH 7.5, 1.0 M NaCl, 0.1 mM EDTA, 5 mM DTT, 6 
M urea.
The cells were thawed over ice for 20 minutes, then placed at room temperature 
for 5 minutes before being re-dissolved in 15 ml TMDEP. Initially only 0.5 mM 
PMSF was added to the initial re-suspension buffer, with a further 0.5 mM added 
after the first sonication. The mixture was sonicated using a Vibra-cell VC100 for 
3 X1 5  seconds, then 2 X 30 seconds, at 40% amplitude using a button probe. 
Between sonication steps, 10 minutes cooling with a salt-ice mixture ensured that 
the temperature was maintained below 12 °C. The mixture was centrifuged at 18 
K for 15 minutes at 4 °C to precipitate the insoluble cell debris concomitantly 
with the resolvase.
The pellet was re-suspended in 10 ml TMDEP containing 100 mM NaCl, using a 
glass rod and vortexing. The solution was then transferred to a Dounce 
homogenizer, where it was thoroughly homogenized around 100 times. The 
solution was spun as before. At this stage the pellet should contain resolvase 
protein. The pellet was re-suspended in 10 ml TMDEP containing 2M NaCl using 
a glass rod, and vortexing. Homogenisation was as in the low salt wash step, 
although this time the homogenisation was more vigorous at 5-10 minute 
intervals over a period of 30 minutes. The solution was then spun as before. The 
supernatant was retained as it may contain some soluble resolvase at this stage.
The pellet was then re-suspended in 10 ml TDEP containing 6 M urea. As before, 
the pellet was initially broken up using a glass rod and vortexing, before being 
transferred to the Dounce homogeniser. This time, it was homogenised over a 
period of 90 minutes, allowing the solution to warm up to around 5-10 °C to 
encourage solubilisation. Following the spin, most of the resolvase was contained 
in the supernatant which was retained. As a final wash the pellet was re­
suspended in 10 ml TDEP containing 6 M urea and 1% SDS at room temperature 
for 10 minutes. Following the spin both the pellet and supernatant were retained.
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The fraction that contained the most resolvase, usually the 6 M urea fraction, was 
dialysed against 1 litre of TDEP/1 M NaCl for 6 hours, to allow for 
refolding/renaturation of the protein. This dialysate was then immediately 
dialysed against 1 litre of TMDEP to allow the protein to precipitate.
The precipitated protein was then centrifuged at 18 K for 15 minutes at 4 °C and 
the pellet was re-suspended in 10 ml buffer A. The protein was purified on a 
Millipore Waters 650E Advanced Protein Purification System using cation 
exchange resin SP sepharose in a 6 ml Pharmacia column. The column was 
washed thoroughly with 2 M NaCl, 25 mM Tris-HCl pH 7.5 before being re­
equilibrated using buffer A. The protein solution was freshly spun at 18 K for 15 
minutes at 4 °C before being loaded manually onto the column using a peristaltic 
pump (Pharmacia LKB Pump-Pl). The column was washed with several volumes 
of buffer A before the salt gradient was applied. The column was washed with a 
linear gradient of 25-250 mM NaCl for 25 minutes, then 250-1000 mM NaCl for 
a further 25 minute period.
The fractions collected were sampled on a Laemmli gel, and the protein- 
containing fractions were dialysed against 1 litre TMDEP containing 1 M NaCl 
for 6 hours followed by dialysis against low salt TMDEP as before.
The second purification step was using a Pharmacia MonoS™ cation exchange 
column. The protein from the low salt dialysis was re-suspended in 2 ml buffer A 
and applied to the column using the injector loop. This time, a linear gradient of 
25-1000 mM NaCl was run over 1 hour to achieve better separation of the 
proteins. The fractions were sampled on Laemmli gels as before, and the purest 
fractions were dialysed to refold and precipitate the resolvase.
The final dialysate was spun down for 5 minutes in the cold room, ensuring that 
all traces of supernatant were removed from the pellets. The pellets were re­
suspended in either 200 p,l or 400 pi of a solution containing 20 mM Tris-HCl pH
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7.5, 0.1 mM EDTA, 2 M NaCl and 5 mM DTT for 20 minutes over ice, pipetting 
up and down and vortexing to encourage solubilisation. The solutions were spun 
in a bench top microfuge at 4 °C and the supernatants were transferred to fresh 
Nunc tubes. After the addition of an equal volume of glycerol to the final protein 
solution, the samples were mixed thoroughly, spun briefly and stored at -20  °C.
3.36 Construction of artificial supercoiled substrates
Shore ligase buffer: 10 mM Tris-HCl (pH7.5), 50 mM NaCl, 10 mM MgCl2, 1
mM DTT and 1 mM ATP.
Artificial supercoiled substrates were made by ligating modified site I double­
stranded oligonucleotides into the EcoRl and Sstl sites of pMSH2 (Section 6.2). 
The substrate pMSH2 was digested with ZsctfRI and Sstl, and the large linear 
fragment was purified by gel electrophoresis using low melting point agarose 
(Section 3.21). This linear fragment was ligated to a double-stranded site I
32oligonucleotide labelled at one 5' end with y-[ P]ATP and T4 kinase. The 5' end 
of the other strand was phosphorylated with unlabelled ATP and T4 kinase 
(Section 3.16).
The procedure involves two ligation steps. The first ligation was in a volume of 
100 |il and contained ligation buffer (Shore et a l, 1981) and 150 U/ml T4 DNA 
ligase (BRL); the DNA concentration was about 300 (ig/ml. After incubating at 
room temperature for 15 hours, the ligase was inactivated by heating at 70 °C for 
10 minutes. The mixture, which was now concatameric linear DNA, was digested 
with 800 U/ml Sstl by incubating at 37 °C for 1 hour, and then the Sstl was 
inactivated by heating at 70 °C for 10 minutes. The mixture was diluted with 1 x 
ligation buffer to a final DNA concentration of 3 fig/ml, and then 5.1 |Lig/ml 
ethidium bromide, 1 mM ATP and 7.5 U/ml T4 DNA ligase was added. After 
ligating at room temperature for 15 hours, the solution was extracted with phenol, 
and DNA was ethanol-precipitated. The supercoiled, semi-synthetic plasmid was 
purified by electrophoresis using a 0.8% low melting point Seaplaque gel
(Section 3.21). Natural pMSH2 was run alongside the ligation products to 
indicate the position of the supercoiled form of the plasmid.
3.37 In vivo testing of mutant resolvase plasmids
A galK assay, developed previously (Blake, 1993), was used to test the ability of 
the cysteine mutants of resolvase to carry out recombination in vivo. 
Recombination in vivo is observed using MacConkey agar and a specifically 
designed test plasmid. Here pDB34 was used, which contains two full res sites in 
direct repeat, the sites flanking the galactose gene, galK.
The galK enzyme brings about phosphorylation of galactose prior to it being 
fermented to lactic and acetic acids. The formation of these acidic products turns 
the MacConkey agar plates (containing Neutral Red indicator) red. In the absence 
of galK the cells must utilise the amino acids present in the media, making 
ammonia as the chief by-product, raising the pH and thus turning the indicator 
white.
In the presence of a recombinationally-active resolvase, the test plasmid will be 
split into two smaller circles. The one containing the origin of replication will 
survive and the other, which contains the galK gene, will be lost. These cells will 
appear as white colonies on the selective media. Expression from plasmid 
containing a mutant resolvase that is inactive in recombination will give red 
colonies, due to the expression of galK.
CaCl2 competent cells of DS941 carrying the test plasmid pDB34 were prepared 
using kanamycin selection for cells containing the substrate. These cells were 
then transformed with the mutant resolvase expression plasmids, pMS95-pMS99, 
which carry ampicillin resistance. After transformation, the cells were plated on 
MacConkey agar plates containing ampicillin and kanamycin and incubated at 37 
°C overnight.
3.38 Synthesis of modified oligonucleotides
The site I oligonucleotides consisted of a 40-mer top strand and a 48-mer bottom 
strand (sequences shown in Table 3.4 SHT1-SHB5). The DNA was synthesised 
using an Applied Biosystems Model 392 DNA synthesiser (Section 3.25). The 
synthesis was altered to allow maximum incorporation of the chemically 
modified base. Once the modified base was added to the column, the coupling 
step was increased to 300 seconds.
3.39 Ammonia deprotection of the modified oligonucleotides
The oligonucleotides were cleaved from the glass support by treatment with 1 ml 
of 30% ammonium hydroxide for 1 hour, then stored at -70 °C to minimise 
degradation. Aliquots of oligonucleotides were removed and treated with an equal 
volume of ammonium hydroxide at room temperature for 72 hours, to ensure 
removal of exocyclic amides while maintaining the integrity of the DNP 
protecting group (Hanna and Meyer, 1996).
3.40 p-mercaptoethanol deprotection of 5-thiol DNP-containing 
oligonucleotides
2 pmol of the modified strand was first end-labelled with [y-32P]ATP then 
annealed to the complementary wild-type strand in 10 pi of annealing buffer. To 
this solution was added 26 pi of 20 mM Tris-HCl (pH 8.2) and 4 pi of fresh 
100% p-mercaptoethanol. The reaction mixture was heated at 45 °C for a 
minimum of 4 hours, although an overnight deprotection (12 hours) was also 
carried out. The solution was spun briefly, then ethanol-precipitated by adding 10 
pg of yeast tRNA, l/10th volume of 3 M NaOAc and 2 volumes of 100% ethanol. 
The mix was cooled to -20 °C for 30 minutes, then spun at 4 °C for 1 hour. The 
pellet was washed with 70% ethanol, centrifuged for 2 minutes at room 
temperature then dried in a gyrovap for 15 minutes. The pellet was redissolved in 
10 pi of annealing buffer (Section 3.20).
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3.41 Alkylation of thiol-containing oligonucleotides
The oligonucleotides were treated with P-mercaptoethanol and precipitated as in 
Section 3.40, then dissolved in 20 j l l I  of TE buffer. The samples were divided into 
2 X 10 pi aliquots, one of which was treated with 2 pi of iodoacetimido- 
fluorescein (IAF; 10 mM in dimethyl formamide) overnight at room temperature. 
The solution was ethanol-precipitated as with the p-mercaptoethanol deprotection 
step (Section 3.40) with a 1 hour spin at 4 °C, and redissolved in 10 pi TE 
containing 1 mM DTT. The treated and untreated samples were run on a 10% 
sequencing gel (Section 3.24.4).
3.42 Crosslinking reactions
The thiol-containing double-stranded (Section 3.20) oligonucleotides were 
reacted with the cysteine mutants in a binding reaction, followed by addition of 
crosslinking reagents:
Binding buffer: 10 mM Tris-glycine (pH 9.4), 0.1 mM EDTA, 1 mM MgCl2, 
10% glycerol (v/v).
Non-specific carrier DNA, usually pUC71K (10 pg/ml) was mixed with end- 
labelled (double-stranded) site I oligonucleotides (360-400 cps) containing the 
free thiol group. A total binding mix of 360 pi or 400 pi was prepared for 9 or 10 
40 pi crosslinking reactions. Then 0.05 volumes of the diluted resolvase cysteine 
mutant were added, and the reactions were incubated at 37 °C for 15 minutes.
The reactions were then treated with oxidising agents. To the 40 pi binding 
reaction, the oxidant was added, the solution vortexed, spun briefly and left at 
room temperature, for times ranging froml hour to 24 hours. A final 
concentration of 1 mM for glutathione and cfs-platinum diamine dichloride 
(cisplatin), and 0.5 mM for sodium selenite were used. For air oxidation, the tube 
was left open to the air overnight.
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After the oxidation step, the samples were divided into two 20 (il aliquots, one of 
which was treated with 0.2 volumes of SDS-loading buffer containing proteinase 
K, the other with SDS-loading buffer only. After 30 minutes, the reactions were 
loaded onto a 10% Tris-glycine-containing 0.1% SDS (v/v) polyacrylamide gel 
(Section 3.24.2), and run at 200 V for 4 hours.
3.43 2D gel analysis of crosslinked complexes
A binding reaction was carried out between the thiol-containing double-stranded 
oligonucleotides and the cysteine mutants, and the products were run out on Tris- 
glycine gels (Section 3.24.2). After running for 3 hours, the gel was soaked in 
running buffer containing 0.1 % SDS for 30 minutes, transferred to a horizontal 
gel kit, and run for 2 hours at 100 V at right angles to the original direction.
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Chapter 4: Synthesis and characterisation of novel 
cysteine mutants
4.1 Introduction
The overall aim of the project is to crosslink Tn3 resolvase to its binding site, to 
gain a greater understanding of the protein-DNA interactions involved. The 
method chosen for crosslinking is by forming disulfide bonds between a modified 
nucleotide in the substrate DNA and a cysteine residue in a mutant version of Tn5 
resolvase. The resolvase-DNA interactions occurring at site I, the site where the 
breakage and re-joining of the DNA occurs, will be studied using crosslinking.
In the y8 co-crystal structure (Figure 4.1; Yang and Steitz, 1995) the DNA- 
binding domain, residues 141-183, makes close contacts with the DNA. The 
domain binds to the DNA on the opposite side to the N-terminal domain. There is 
a 9 bp region of highly conserved sequence that constitutes the recognition motifs 
within res sites for binding resolvase. Each res site is flanked by a consensus 
TGT motif (Figure 4.2), and the recognition helix of the resolvase DNA-binding 
domain interacts with this sequence. Each binding domain of the dimer binds in a 
single major groove, and has its associated 'hinge' region (residues 140-147) in 
the adjacent minor groove. The sequence of the symmetrical oligonucleotide used 
to obtain crystallographic data for the site I resolvase interaction is shown in 
Figure 4.2.1 and the base at position 10 is a C. The oligonucleotides that were 
synthesised to contain the modifications have a T at position 10.
The thymines in the binding motif will be replaced by thiol-containing nucleotide 
analogues (Chapter 2). A cysteine residue must be placed in the recognition helix 
residues within a reasonable distance from the modified base, so that a disulfide 
can be made between the two. The requirement for a useful cysteine mutant is 
that the cysteine thiol must be close enough to the base modification to allow 
crosslinking. All the residues in the recognition helix that interact with the DNA 
in the major groove were mutated to cysteines (see Section 4.4). It is possible that 
mutating this region of the protein may have an adverse effect on the protein- 
DNA interactions.
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II-L
1 4 1 3 1 2 1 1  10 9 8 7 6 5 4 3 2 1
(2) IL and R TGTCCGATAATTTA
G
IL CGTTCGAAATATTA
(3) IR TGTCTGATAATTTA
TT A T CGA TT 
2L TGTCCATTAAATCGTCA
(4) 2R TGTCTATTATGCCAAAA
G AA
C T
(5) 3L t g t c t g a t a t t c g  
3R TGTACCTTAAATC 
T C
Figure 4.2 Sequences bound by Tn3 resolvase
(1) shows the res site. (2) shows the symmetrical site I used in the co­
crystal structure (top strand only) of the half site (3, 4 and 5) are the 
sequences of the natural resolvase binding sites of Tn3 (L = left, R = right). 
For the right half sites, the homologous (bottom strand) half site sequence 
is shown. The underlined bases above indicate different bases present in the 
res site of yb resolvase.
HN 5.6
Resolvase
DNA-
ResolvaseDNA base
DNA
Figure 4.3 Calculation of disulfide bond lengths
Illustration of how the distances were measured from the co-crystal 
structure (Yang and Steitz, 1995). (1) shows the bond lengths and angles 
between the atoms (2) shows the distance between the C-5 of thymidine 
and the p-carbon atom of the binding domain residue was used. R = 
A171, R172, S173, Y176 and K177. The true distance between the 
sulfur atoms, when taking into account the tetrahedral bond angles,
o
shown above will be less than 5.6 A. However, it can still be predicted 
that if the two interacting thiols are 5.6 A apart a disulfide will form 
between C-5 and the P-carbon atom.
The length of disulfides in the proteins trypsin and chymotrypsin were studied 
(M. Boocock, pers. comm.)* The distance from a-carbon to a-carbon in a cystine 
was 4.2-6.5 A. For the work here the distances between the interacting thiols was 
measured from the P-carbon of the amino acid to the C-5 position of the relevant 
thymine. The length of the sulfur-sulfur bond in disulfides is 2.0  A and the 
theoretical maximal distance between P-carbon atoms in a cystine disulfide is 5.6 
A, neglecting the bond angles, charges and interatomic effects (Figure 4.3). The 
mutants M106C and II10C made in y8 resolvase formed dimers via disulfide 
bonds (Hughes et al., 1993). In the co-crystal structure the p-carbon atoms of 
M106 and I I 10 were 6.5 A and 4.2 A away from the equivalent position in the 
other dimer. It can be predicted that disulfides in the protein and DNA will form 
if the distance between the interacting thiols is > 5.6 A.
The residues in the recognition helix A171, R172, S173, T174, V175, Y176 and 
K177 are all potentially suitable for cysteine mutagenesis and crosslinking as they 
are in the recognition helix of the DNA-binding domain. Of the residues listed 
above, T174 and V I75 were omitted as they point towards the centre of the 
DNA-binding domain and are quite far away from the DNA. A171, R172, S173, 
Y176 and K177 were chosen because they are potentially within a reasonable 
distance to make a disulfide with a modified base (see Figure 4.4-4.8).
4.2 The DNA-binding domain
The last 36 residues of Tn3 resolvase (148-183) constitute the DNA-binding 
domain. There is also involvement of the 'hinge' region of the protein (residues 
141-147), assisting the small domain to bind. The DNA-binding domain of y8 
resolvase comprises 3 a-helices, residues D149-Q157 (helix 1), S162-T167 (helix 
2) and R172-N183 (helix 3). These helices are stabilised by hydrophobic core 
residues V151,1164 and V I75 and by a salt bridge between R148 and E l81 in 
Helices 1 and 3 (Figure 4.9). Helices 2 and 3 form a backbone fold which is 
similar to the helix-tum-helix motif. Helices 1 and 3 cross with right-handed
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Figure 4.4 Interactions of A171 with the modified bases
A 171 is shown in CPK (CPK = Corey-Pauling-Koltun colours), the 
thymidines (green), cytosines (orange), adenines (purple) and guanines 
(pink). The DNA phosphate backbone is white. The oxygen atom of 
alanine is red. The bases are numbered as in Figure 4.2. The protein 
backbone of the C-terminal domain is cyan. The data are derived from 
Rasmol.
Figure 4.5 Interactions of R 172 with the modified bases
R172C is shown in CPK (CPK = Corey-Pauling-Koltun colours), the 
thymidines (green), cytosines (orange), adenines (purple) and guanines 
(pink). The phosphate backbone is white. The oxygen and nitrogen atoms 
of arginine are red and blue, respectively. The bases are numbered as in 
Figure 4.2. The protein backbone of the C-terminal domain is cyan. The 
data are derived from Rasmol.
Figure 4.6 Interactions of S I73 with the modified bases
S173C is shown in CPK (CPK = Corey-Pauling-Koltun colours), the 
thymidines (green), cytosines (orange), adenines (purple) and guanines 
(pink). The phosphate backbone is white. The oxygen atom of serine is 
red. The bases are numbered as in Figure 4.2. The protein backbone of the 
C-terminal domain is cyan. The data are derived from Rasmol.
Figure 4.7 Interactions of Y176 with the modified bases
Y176C is shown in CPK (CPK = Corey-Pauling-Koltun colours), the 
thymidines (green), cytosines (orange), adenines (purple) and guanines 
(pink). The phosphate backbone is white. The oxygen atom of tyrosine is 
red. The bases are numbered as in Figure 4.2. The protein backbone of the 
C-terminal domain is cyan. The data are derived from Rasmol.
Figure 4.8 Interactions of K 177 with the modified bases
K177C is shown in CPK (CPK = Corey-Pauling-Koltun colours), the 
thymidines (green), cytosines (orange), adenines (purple) and guanines 
(pink). The phosphate backbone is white. The oxygen and nitrogen atoms 
of lysine are red and blue, respectively. The bases are numbered as in 
Figure 4.2. The orientation of the co-crystal structure was changed 
(compared to Figures 4.4-4.7) in order that the interaction could be seen 
clearly. The protein backbone of the C-terminal domain is cyan. The data 
are derived from Rasmol.
R 1 4 8
Figure 4.9 The DNA-binding domain of y6 resolvase
The recognition helix is highlighted in green. The highly conserved 
residues that form the hydrophobic core are labelled in bold. The residues 
that form a salt bridge between the helices are also labelled in bold.
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folding topology (Liu et al., 1994). The helix-tum-helix motif is conserved 
through most members of the family of site-specific recombinases (Figure 4.10).
Binding of the DNA-binding domain of y8 resolvase has been studied using 
DNAse I footprinting (Abdel-Meguid et al., 1984) and ethylation interference 
experiments (Rimphanitchayakit et a l, 1989). yS resolvase was cleaved by 
chymotryptic digestion, isolating the N and C-terminal domains. The intact DNA- 
binding domain interacts at res subsites similarly to intact resolvase. A minimum 
12 bp binding sequence motif at both ends of site I was protected by the DNA- 
binding domain, indicating that this is the region of site I where the C-terminal 
domain binds. There was an additional area of protection at the centre of site I 
with the intact protein, on the opposite side to the regions protected by the DNA- 
binding domain, indicating that the catalytic and binding domains are on opposite 
sides of the DNA. The ethylation experiments confirmed the footprinting results. 
A strong inhibition of binding was seen at ethylated phosphates at positions IR- 
G13 and IR-T12 and an additional region of protection at positions IR-T8 and IR- 
A7 towards the centre of site I.
The sequence requirements for the binding of the C-terminal domain of y8 
resolvase to its recognition site were determined by saturation mutagenesis 
(Rimphanitchayakit and Grindley, 1990). Mutations were made at all positions in 
site I. The regions that were most affected by changing the bases could be divided 
into two regions; positions IR-T14-8 at the ends where the DNA-binding domain 
binds, and positions IR-C9 and IR-G10 towards the centre of the site, where the 
intact protein binds. The numbering of the bases in site I is explained in Figure
1.2. The substitution IR-C4 to IR-G4 in site I increased the binding affinity of y8 
resolvase for the site I compared to the wild-type site.
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4.3 Cysteine Mutants of Tn3 resolvase
Cysteine mutants in Tn3 and y8 resolvases have been created previously, for 
mechanistic studies (Hatfull and Grindley, 1986), crystallographic studies (Yang 
and Steitz, 1995), crosslinking between subunits (Hughes et al., 1993; Murley 
and Grindley, 1998; Weinwieser, 2001; MacDonald, 1999) and attachment of 
chemical modifications (MacDonald, 1999; Mazzarelli et al., 1993).
The cysteine mutant T162C was made for crosslinking analysis (MacDonald, 
1999) via the formation of a disulfide bond with a phosphorothioate-containing 
site I. Position 162 is in close contact with the phosphodiester at IR-T14. This 
phosphate was replaced with a phosphorothioate, which should form a disulfide 
with T162C under oxidising conditions. However no crosslinked complexes were 
obtained using this strategy, as the sulfur of the phosphorothioate was not reactive 
enough to form disulfides with the cysteine of T162C. The work here that has 
DNA bases containing thiols (as opposed to the DNA backbone) should be more 
effective at forming disulfide crosslinked complexes. There have been mutations 
made in y5 resolvase recognition helix 3. These are R172L, R172G, S173G, and 
Y176C.
4.4 Isolation of Novel DNA-binding domain mutants
All the positions chosen to be mutated, except A 171, form base-specific contacts 
with the DNA. Within the DNA substrates there is a region of sequence at 
positions 13-10 (Figure 4.2), GTCC, that forms an essential portion of the binding 
site where most of the chosen residues form interactions. During the co­
crystallisation studies (Yang and Steitz, 1995), it was observed that five out of the 
six of recognition sequences at the ends of the three subsites of res had at least 
one IR-G10 and IR-G11 (Figure 4.2) in the site I, indicating that a guanine at 
these positions is important for recognition by the DNA-binding domain.
A171 is positioned outside the consensus TGT motif, so is not essential for 
binding, but its close proximity to the DNA backbone makes it a good candidate
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for crosslinking. The (3 carbon of A 171 is 11-13 A away from the three 
thymidines in site I that will be modified with thiol groups, longer than the 
calculated value for a disulfide bond (Figure 4.4). However the interacting sulfur 
atoms in A171C and the thiols in the DNA may come closer during the reaction.
R172 has an electrostatic interaction with 06  and N7 of IR-G13, with a further 
hydrophobic interaction with the methyl group of IR-T14, the first T in the 
consensus TGT (Figure 4.5). From Table 4.1 the distance between the C-5 atom 
of T14 and the (3 carbon of R172 is 7.91 A, closer to the ideal value for a 
disulfide, making the formation of a disulfide between the two thiols plausible. 
The (3 carbon atom of R172 is further away from T12 and C(T)10 at 8.28 and
11.75 A respectively, perhaps still close enough for disulfide formation to occur.
In y8 resolvase, the arginine at position 172 has been mutated to leucine (R172L) 
and also to glycine (R172G). A screening experiment found that the R172L 
mutant binds selectively to complete res sites with the site I sequences mutated at 
IR-T14, IR-T13 and IR-T12 (Grindley, 1993; cf IR-T14, IR-G13 and IR-T12 in 
wild-type binding sites), and was selected for this property. The R172L mutant 
was isolated and purified, and was found to have activity similar to wild-type y8 
resolvase, although it had a weaker binding interaction with wild-type res sites. 
This preferential binding of R172L has been used extensively in targeting 
experiments (Murley et al., 1998, Wienwieser, 2001) designed to direct resolvase 
monomers to specific sites within res. Another mutant at this position, R172G, 
was found to have lost all recombinational activity.
The hydroxyl group of SI73 is involved in hydrogen bonding with the 0-6 atom 
of IL-G10 (Figure 4.6). This residue of y8 resolvase was mutated to glycine and 
purified. S173G displayed weaker binding activity than the wild-type protein 
(Grindley, 1994), but retained recombination activity. The (3 carbon atom of S173 
is closest to T 12 and C(T)10 from Table 4.1, being around 6 A from the C-5 of 
the thymidines. Disulfide formation should be possible between these positions as
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they are close enough. S173 interacts with the DNA towards the centre of the site, 
therefore it is 10.55 A away from the flanking T14.
The residue Y 176 interacts closely with the IR-T12 in the TGT motif and is 5.35 
A away from it (Figure 4.7). This interaction is the closest of all measured in 
Table 4.1 and is close to the ideal distance between the p-carbons in a disulfide. 
Therefore it can be predicted that a thiol at the C-5 of thymidine and the an 
equivalent thiol on the p carbon atom of Y176 should form a disulfide. The 
residue associates with the methyl group of thymine via its phenolic aromatic ring 
and also the P carbon of the amino acid side chain. y8 resolvase Y176C was 
found to be inactive in vivo.
K177 makes a hydrophobic interaction with the methyl group of IR-T8 and is 
approximately 9 A away from T12 and T14 in the DNA backbone (Figure 4.8), 
making the concept of disulfide bond formation as mentioned above, as 
possibility.
From the co-crystal structure (Yang and Steitz, 1995) using the Rasmol program, 
the distances for crosslinking were measured. The distances were from the p- 
carbon atom of the amino acid residue to the C-5 of thymidine (Figure 4.3) and 
are measured in angstroms (A).
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Table 4.1
proteins—>
T analogue^ A171 R172 S173 Y176 K177
TGTCT
(T14)
Cp—C-5 
12.87 
(13.07)
Cp—C-5 
7.71 
(7.91)
CP—C-5 
11.32 
(10.55)
Cp—C-5 
9.81 
(10.19)
CP—C-5 
14.67 
(14.99)
TGTCT
(T12)
Cp—C-5 
10.49 
(10.91)
Cp—C-5 
7.12 
(8.28)
CP—C-5 
6.31 
(6.24)
CP—C-5 
5.14 
(5.35)
Cp—C-5 
8.48 
(9.01)
TGTCT
(CIO)
Cp—C-5 
10.55 
(10.59)
CP—C-5 
11.29 
(11.75)
CP—C-5 
6.35 
(6.71)
Cp—C-5 
9.94 
(9.59)
Cp—C-5 
8.18 
(9.20)
The numbers refer to the distances from the P-carbon-C-5 methyl group in the 
target bases and amino acids in the co-crystal structure from the Rasmol 
programme. The numbers that are unbracketed represent the distances from one 
side of the structure, the bracketed numbers represent the corresponding 
measurements made from the other side of the symmetrical site I. The underlined 
numbers indicate that although the same distances were measured, one side of the 
site I-resolvase interaction in most cases is closer.
From Figure 4.3 a distance of < 5.6 A between the C-5 of the base and the 13- 
carbon should be acceptable for disulfide formation between the two thiols. 
Distances between the p-carbon of IL-T14 and C-5 range between 7.71-14.67 A. 
The IL-T12 distances range between 5.14-10.49 A and for the IL-C(T)10 position 
between 6.35-11.29 A. It can predicted that disulfide bond formation should 
occur with modification at IL-T12 as it is close enough in some cases. However, 
the measured distances are taken from the co-crystal structure, and the atoms may 
come physically closer during the recombination reaction. The modified 
oligonucleotides have a thymidine at position 10. In the symmetrical site I used in 
the crystallographic analysis, position 10 is a cytidine.
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4.5 The construction of plasmids encoding cysteine mutants
The DNA-binding domain open reading frame of Tn3 resolvase is shown in 
Figure 4.11. The three helices are indicated below the sequence; the recognition 
helix is the longest of the three. The plasmid pMA6211 contains the resolvase 
open reading frame between sites Ndel-Aspll%, carrying the T162C mutation 
(MacDonald, 1999). This plasmid was chosen because it contains restriction sites 
Hpal and BssHl in the last third of the resolvase reading frame. These sites were 
used to clone Hpal-BssHll oligonucleotides, which remove the T162C mutation, 
into the equivalently cut pMA6211.
The oligonucleotides, top strand 56 nucleotides (nt) and bottom strand 60 nt, 
(Figure 4.12.1) cloned between these sites carried an additional Mfel site. The 
new plasmid, pMS81, contains a unique Mfel site and two Psil sites and encodes 
wild-type resolvase. To facilitate cloning of the oligonucleotides containing the 
cysteine codons, it was necessary to remove the other Psil site. This was achieved 
by a full Sspl (three Sspl sites) digest and a partial Psil digest. The 4.9 kb 
fragment was re-circularised yielding pMS82, which contains a unique Psil site. 
The mutant oligonucleotides that carried the five mutant codons (Figure 4.12.2) at 
positions A171, R172, S173, Y176 and K177 in the resolvase reading frame 
(Figure 4.11.1), were cloned from the Mfel-Psil sites of pMS82 for A171C, 
R172C, S173C and Y176C, and from Psil to Sail for K177C, yielding the 
plasmids pMS89(A171C), pMS90(R172C), pMS91(S173C), pMS92(Y176C) and 
pMS93(K177C).
However, these constructs would only transform the strain DH5a. The reasons 
for this are unknown, but are probably due to the deletion of the Psil-Sspl 
fragment near the bla promoter. This meant that these plasmids could not be used 
in the in vivo assay (Section 4.7). The C-terminal sections of the reading frames 
were therefore excised by Eagl-AspllS digestion and replaced back into pAT6A 
(MacDonald, 1999), yielding plasmids pMS95(A171C), pMS96(R172C), 
pMS97(S173C), pMS98(Y176C), pMS99(K177C) and pMSlOO (wild-type).
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Hpal 
_ |__
CGGCCGCAGGCGTACCGTGGACAGGAACGTCGTGTTAACGCTTCATC
GCCGGCGTCCGCATGGCACCTGTCCTTGCAGCACAATTGCGAAGTAG
G R R R T V D R N V V L T L H Q
helix 1
_!
Mfel 
- E - 1
AGAAGGGCACTGGTGTAACGGAAATTGCTCATCAATTGAGTATT
TCTTCCCGTGACCACATTGCCTTTAACGAGTAGTTAACTCATAA
K G T G V T E I  A H Q L S I
BssHll
1
helix 2
Psil
l
Bbsl
1
i i
GCGCGCTCCACGGTTTATAAAATTCTTGAAGACGAAAGGGCGAGCT
CGCGCGAGGTGCCAAATATTTTAAGAACTTCTGCTTTCCCGCTCGA
A R S T V Y K I  L E D E R A S  s t o ]
helix 3
Sail
_L
Kpnl Xbal 
1 1
GAGTCGACGGTACCTCTAGA
CTCAGCTGCCATGGAGATCT
V D G T S R
Figure 4.11 The sequence of the C-terminal domain of Tn3 resolvase
The three helices are shown by the arrows. The restriction sites used 
for cloning and analysis are shown. The amino acid codons are 
written in bold beneath. The sequences of three a  helices of the DNA 
binding domain are shown beneath the codons as blue arrows.
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pMSlOO is illustrated in Figure 4.13. These plasmids could be tested in vivo 
(Section 4.7). Cloning was carried out by M. Burke.
4.6 Cloning of C-terminal sequences into the expression plasmid
pALY15 (6693 bp) is a pSAl 101-based (S. Rowland) overexpression plasmid 
that carries the T162C mutant resolvase open reading frame (MacDonald, 1999). 
pALY15 was digested with A spllS  and Eagl to remove the DNA that encodes 
the C-terminal domain of the T162C mutant. The plasmids carrying the DNA- 
binding domain mutants pMS95-pMS99, were also digested with A spllS  and 
Eagl, thus releasing DNA-binding domain fragments of the mutants A171C to 
K177C. The large fragments from the pALY15 digest (6548 bp) and the small 
fragments (145 bp) from the pMSlOO-derived plasmids were isolated using 
agarose (Section 3.21) and acrylamide gel electrophoresis (Section 3.24.2), 
respectively.
The fragments were ligated, and the ligation products were used to transform 
DS941. The clones were checked by single colony analysis and restriction 
enzyme digests to ensure that the reading frames were correctly constructed. The 
absence of certain restriction sites in the clones that arose from the initial cloning 
of the mutant oligonucleotides, was also confirmed; i.e., the oligonucleotides for 
A171C, R172C, S173C and Y176C were designed to remove the RwHII site in 
the plasmids, and the K177C oligonucleotide should delete the Bbsl site. The 
Y176C and K177C mutations also destroy the Psil site in this region, because the 
codons overlap with the site. The new C-terminal sequences are illustrated in bold 
letters in the oligonucleotides used for the cloning (Figure 4.12.2).
4.7 In vivo recombination assay
The plasmids containing the mutant resolvase were transformed into DS941 
containing one of three different plasmids. pDB34 contains two full res sites in 
direct repeat (Figure 4.14). Competent cells of DS941 carrying the test plasmid 
pDB34 were prepared using kanamycin selection for cells containing the
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Figure 4.13 Illustration of pMSlOO
The diagram shows the plasmid used for the in vivo screen. This is the 
wild-type version of the plasmids pMS95-99 that encode the cysteine 
mutants.
Pc/rgR
res gcilK
Kmr pDB34
res
ori
repA
Figure 4.14 Diagram of resolvase in vivo screening plasmid pDB34
The plasmid used for the in vivo screening of resolvase cysteine mutants 
(Arnold et al., 1999). The origin of replication and repA gene for the 
replication initiator protein are from pSClOl. The galK gene is 
transcribed from PcmgR, the promoter of the E.coli argR gene.
substrate. These cells were then transformed with pMS95-99 encoding the 
cysteine mutants and plated onto media containing galactose (See Section 3.37). 
Any resolution of pDB34 by the mutants results in loss of the galK gene from 
pDB34, and so white colonies grow on the plates.
The results of the in vivo testing for recombination are shown in Figure 4.15. 
Three out of the five cysteine mutants show in vivo recombination activity. The 
recombinationally active proteins are A171C, S173C and K177C, indicated by 
the presence of white colonies on the MacConkey agar. The mutants that are 
unable to carry out recombination in this assay, i.e. R172C and Y176C, are likely 
to be deficient in binding activity.
4.8 Expression of the mutants in the strain BL21(DE3)pLysS
For details see Section 3.34.
Derivatives of the E.coli strain BL21 were used to express the Tn3 resolvase 
cysteine mutants. The BL21(DE3) strain carries a stable bacteriophage X lysogen 
derivative (X DE3), in the chromosome of BL21, which contains the gene for T7 
polymerase under the control of a lacUY promoter. The lacUV promoter is bound 
by lac repressor, and is inducible by isopropyl-P-D-thiogalactopyranose (IPTG).
T7 lysozyme is an inhibitor of T7 polymerase, so it reduces the potentially 
damaging effects of transcription before induction (Studier et al., 1990). The 
strain BL21(DE3)pLysS contains the gene encoding T7 lysozyme on a plasmid 
conferring chloramphenicol resistance. The low level of lysozyme production by 
this strain has little effect on the induction of target genes, so it is very efficient at 
producing high levels of target protein in the presence of IPTG.
4.9 Purification of cysteine resolvases
For experimental details see Section 3.35.
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Figure 4.15 In vivo recombination of pDB34 by A171C, R172C, S173C, 
Y176C and K177C
The left panels show A171C, R172C and S173C, and the right panel 
shows shows Y176C and K177C in vivo recombination.
Red colonies = no resolution and white colonies = resolution.
The method of purification used is a denaturing preparation that exploits the 
solubility of resolvase in buffers containing varying concentrations of salt. At 
high salt concentrations resolvase is solubilised, whereas in buffers containing 
low salt concentrations resolvase is insoluble and so can be precipitated. Initially 
the cells are disrupted using sonication, ensuring that the temperature is kept low 
to reduce protein degradation. After disruption the cells are spun, which pellets 
the cell debris and the resolvase. After a series of washings at low salt, the cell 
debris and other contaminant proteins are removed by centrifugation. The final 
wash at 2 M NaCl solubilises the resolvase, and following centrifugation, the 
remaining proteins are pelleted, while the resolvase remains in solution. To 
ensure that all the resolvase is recovered, an additional 2 M salt/6  M urea step 
ensured solubilisation of the resolvase in the pellet. After checking the 
purification using Laemmli gels (Section 3.24.1), the denatured resolvase- 
containing fractions were dialysed against 2M salt buffer to allow the protein to 
refold. The resolvase was precipitated by dialysis against a low salt buffer. The 
precipitate was collected and dissolved in buffer containing 6 M urea.
The resolvase fractions were purified further using ion exchange chromatography. 
Two cation exchange columns were run, the first with a linear gradient of 25-250 
mM NaCl for 25 minutes then 250-1000 mM NaCl for a further 25 minutes. The 
second column used a linear gradient of 25-1000 mM NaCl, run over 1 hour to 
achieve better separation of the proteins. The cysteine mutants eluted between 
280-300 mM NaCl.
4.10 Concentration of cysteine mutants
The standard A l 13C was used to determine the concentration of the cysteine 
mutants as it had been calibrated with R17f33 (48 |nM; M. Boocock). The 
concentration of A l 13C is 40 jiM. R17f33 is an HPLC fraction of wild-type 
resolvase that has been determined by amino acid analysis to have a concentration 
of 48 pM, and is used as the lab benchmark standard for determining the 
concentration of resolvase solutions.
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Figure 4.16 Concentration of cysteine mutants
Lane Volume 
loaded (pi)
Cysteine resolvase Concentration
(MM)
Concentration
(mg/ml)
1 0.5 A113C 20 0.4
2 5 A171C - -
3 5 R172C - -
4 5 S173C - -
5 5 Y176C - -
6 5 K177C - -
7 1 A113C 40 0.8
8 5 A 171C + 5 mM DTT 3 0.06
9 5 R172C + 5 mM DTT 8 0.16
10 5 S173C + 5 mM DTT 8 0.16
11 5 Y176C + 5 mM DTT 40 0.8
12 5 K177C + 5 mM DTT 2 0.04
13 0.25 A113C 10 0.2
The left half of the gel (Figure 4.16) shows samples of the protein stock solutions 
stored at 1 mM DTT. The higher band shows that some oxidation has occurred. 
The geometry of the protein is such that these interactions are unlikely, although 
prolonged storage must have resulted in disulfides being formed between cysteine 
residues in the binding domain. The right half represents stock solutions that have 
had 5 mM DTT added to them. To calculate the concentration, the right hand 
samples were used. The extra band in some of the samples is an unknown 
contaminant that elutes at the same salt concentration as resolvase (S.Weinwieser, 
pers. comm.).
4.11 In vitro resolution of pMM5 using novel cysteine mutants
The five cysteine mutants were tested for their ability to carry out the resolution 
of pMM5. This assay was used to determine whether or not these novel binding 
domain mutants were active in recombination under standard in vitro conditions. 
The substrate plasmid is a supercoiled molecule with two res sites. The main 
product from the reaction with resolvase is a supercoiled catenane. After the 
resolvase was inactivated by heat treatment the products were digested with 
specific restriction endonucleases, here Bglll was used. The possible products 
from the Bgtll digest are linearised starting plasmid (unresolved product), 
supercoiled circle (one in catenane that lacks Bglll site) and linear DNA (from 
circle in catenane that contained the Bglll site).
Figure 4.17 shows the resolution of pMM5 by A171C and R172C. The results of 
the resolution of pMM5 with S173C, Y176C and K177C are shown in Figure 
4.17.
A171C, S173C and K177C all show recombination activity. The concentration of 
wild-type resolvase was 12 |iM. A171C was active at 3 jiM and 1.5 (XM (Figure
4.17 lanes 11 and 12). S173C was active at 8 |xM and 4 |iM (Figure 4.18 lanes 7 
and 8 ) and K177C was active at 2 jxM (Figure 4.18 lane 22). The mutants A171C 
and S173C are as active as wild-type resolvase. K177C was active, although the
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resolvase
Figure 4.17 Resolution of pMM5 with A171C and R172C
R = recombinant, 1 = linear, sc = supercoiled, nr = non-recombinant
The reactions were carried out using C8.2 buffer and 0.4 pg/lane of DNA and 
were incubated with 1/10th volume of diluted protein solution at room 
temperature. The reaction mixture was adjusted to 1 mM DTT prior to addition of 
the cysteine mutants. The reaction was stopped by heating to 70 °C for 5 minutes, 
then analysed by restriction enzyme digestion.
Lanes 1 - No resolvase (dilution buffer), 1 hour
2 - as lane 1 + BglW
3 - 16-fold dilution of wild-type resolvase, 1 hour
4 - as lane 3 + Bglll
5 - Undiluted A 171C resolvase
6 - 2-fold dilution of A 171C resolvase, 1 hour
7 - 4-fold dilution of A 171C resolvase, 1 hour
8 - 8-fold dilution of A 171C resolvase, 1 hour
9 - 16-fold dilution of A 171C resolvase, 1 hour 
10 - 32-fold dilution of A 171C resolvase, 1 hour 
11-16 as lanes 5-10 + BglW
17 - Undiluted R172C resolvase, 24 hours
18 - 2-fold dilution of R172C resolvase, 24 hours
19 - 4-fold dilution of R172C resolvase, 24 hours
20 - 8-fold dilution of R172C resolvase, 24 hours
21-24 as lanes 17-20 + BglW
pMM5 
4.9 kb resolvase 2.3 2.6
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Figure 4.18 Resolution of pMM5 with S173C, Y176C and K177C
R= recombinant, 1 = linear, sc = supercoiled, nr = non-recombinant, n = nicked.
The reactions were carried out using C8.2 buffer and 0.4 pg/lane of DNA and 
were incubated with 1/10th volume of diluted protein solution at room 
temperature. The reaction mixture was adjusted to 1 mM DTI" prior to addition of
the cysteine mutants. The reaction was stopped by heating to 70 °C for 5 minutes,
then analysed by restriction enzyme digestion.
Lanes 1- Undiluted S173C resolvase, 1 hour
2 - 2-fold dilution of S173C resolvase, 1 hour
3 - 4-fold dilution of S173C resolvase, 1 hour
4 - 8-fold dilution of S173C resolvase, 1 hour
5 - 16-fold dilution of S173C resolvase, 1 hour
6 - 32-fold dilution of S173C resolvase, 1 hour 
7-12 as lanes 1-6 + Bglll
13 - Undiluted Y176C resolvase, 24 hours
14 - 2-fold dilution of Y176C resolvase, 24 hours 
15-16 as lanes 13-14 + Bglll
17 - Undiluted K177C resolvase, 1 hour
18 - 2-fold dilution of K177C resolvase, 1 hour
19 - 4-fold dilution of K177C resolvase, 1 hour
20 - 8-fold dilution of K177C resolvase, 1 hour
21 - 16-fold dilution of K177C resolvase, 1 hour
22 - 32-fold dilution of K177C resolvase, 1 hour 
23-28 as lanes 12-18 + Bglll
resolvase concentration was low. The A171C, S173C and K177C proteins were 
able to bind, form a productive synapse and recombine the substrate DNA with 
similar efficiency to the wild-type protein. The engineered cysteine mutants at 
positions 171, 173 and 177 therefore do not affect the ability of the proteins to 
catalyse the recombination, although they may not bind as efficiently as wild-type 
resolvase.
The mutants R172C and Y176C show no resolution activity but display 
topoisomerase activity as observed in Figure 4.17 (see lanes 17-20) for R172C 
and Figure 4.18 (lanes 8 and 9) for Y176C. The ladder of bands, or topoisomers 
arose as a result of relaxation of negative supercoils in pMM5. This occurs when 
only one phosphodiester bond is broken, whereas recombination requires four 
strand breaks. Even though they were deficient at promoting recombination, 
Y176C and R172C retained the ability to promote cleavage and re-ligation, 
displayed by the observed topoisomerase activity.
A more important consideration is whether or not the introduction of the cysteine 
residues in the DNA-binding domain will affect binding. The above positive 
recombination results show that the presence of cysteine thiols at positions 171, 
173 and 177, do not completely prevent binding. A171C, S173C and K177C still 
have the ability to bind to the DNA in the correct geometric arrangement and with 
enough efficiency to allow a productive synaptic complex to be formed. Once this 
synaptic structure is formed, the catalysis and the strand exchange reaction can 
occur resulting in a -2 catenane. The cysteines at 172 and 176 show 
topoisomerase activity, that similarly requires binding to all or part of res.
4.12 Band shift analysis of mutants
To determine the binding activities of the novel cysteine mutants of Tn3 
resolvase, binding assays were carried out. It was important to know the extent to 
which the modified proteins bind to the DNA, in order to determine the effect the 
binding efficiency might have for crosslinking.
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The binding assay (or gel retardation assay) displays the different mobilities of 
complexes that are formed between res and resolvase, as they move through 
polyacrylamide gels. Complexes having one or two protein monomers attached 
(i.e. one subsite of res fully occupied) run much faster than higher complexes, 
having the three subsites of res occupied by up to six protein monomers.
In-depth binding analysis of res subsite II (Blake et al., 1995) indicated that Tn3 
resolvase is monomeric in solution and binds to the subsites in a co-operative 
manner. A protein monomer is thought to bind to the left end of site II, and when 
a second monomer associates with this monomer-binding site complex, 
dimerisation is completed. Six complexes can been seen in binding assays of Tn3 
resolvase with res (Blake et al., 1995).
It is known from the co-crystal structure of yS resolvase that a dimer is present at 
site I, and all binding of y8 resolvase to the other res subsites is by pre-formed 
dimers. Only three complexes, corresponding to each subsite of res occupied by 
dimers, were observed (Abdel-Meguid, 1984; Blake, 1993). The y8 resolvase 
exists in a dimeric conformation in solution, indicated by the binding profiles and 
by the results of crystallographic analysis of the N-terminal domains (Sanderson 
et al, 1990) and by dimerisation studies (Liu et al., 1993).
4.13 Binding of resolvase cysteine mutants to res DNA
The labelled res site was derived from the plasmid pOG5, which contains a single 
res site, illustrated in Figure 4.19. pOG5 was cut with Xbal then end-labelled 
(Section 3.18). The linear fragment was then cut with A spllS , releasing the 
labelled res site.
Figure 4.20 shows binding of the wild-type and all the mutant resolvases to res. 
Lane 1 contains labelled fragment only. Lane 2 contains the wild-type protein as a 
positive control. The wild-type control shows full occupancy of all six binding 
sites in res.
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Figure 4.19 Diagram of pOG5
The plasmid shown provided the res fragment that was used in the 
binding assays. The fragment was cut from pOG5 by an Xbol-Aspl 18 
restriction digest. Three base pairs between sites I and II have been 
mutated in pOG5 to create an ZscoRI site (Blake et cil, 1995).
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Figure 4.20 Binding of A171C, R172C, S173C, Y176C and K177C resolvases 
to res
The numbers denote the following binding s ite  occupancy by resolvase •
2 • •
3
4
5
6 • • • •  • •
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - Undiluted R172C resolvase
6 - 2-fold dilution of R172C resolvase
7 - Undiluted S173C resolvase
8 - 2-fold dilution of S173C resolvase
9 - Undiluted Y176C resolvase
10 - 2-fold dilution, of Y 176C tesolvase.
11 - Undiluted K177C resolvase
12 - 2-fold dilution of K177C resolvase
In lanes 3 and 4 (A171C) there is a very intense band representing complex 2, 
indicating that the resolvase monomers bind co-operatively. There are also some 
higher complexes formed by the protein binding to more subsites of res, although 
weaker than complex 2. Approximately half of the labelled res DNA is bound in 
total. The strong band of complex 2 indicates that mutation at position 171 does 
not disrupt co-operative binding to res.
Lanes 5 and 6 show the binding of the R172C. Binding is very poor, with no 
complexes detected. This indicates that an interaction that is essential for binding 
under normal conditions has been disrupted by the introduction of a cysteine 
residue at this position. Some of the R172C-bound DNA is stuck in the wells. 
This may be due to aggregation following aberrant binding. The faint band could 
indicate binding of a monomer (as seen in lanes with 7 and 8 , and 11 and 12 with 
different mobility to A 171C and wild-type complexes).
Lanes 7 and 8 represent the complexes formed between S173C and res. The 
bands representing complex 1 and 2 appear to be almost equal in intensity. This 
may indicate loss of co-operative binding between the protein monomers. There 
were overall fewer complexes present than with A171C, indicating that this 
mutation is having a more inhibitory effect.
The Y176C binding profile is shown in lanes 9 and 10. At both concentrations 
there were very low levels of binding complexes on the gel. A weak band 
representing complex 2 indicated that a small amount of binding may be 
occurring.
Lane 11 and 12 represents the K177C mutant binding to res. At the highest 
concentration (lane 11) there are two main bands representing complex 2 , and a 
slightly weaker higher band representing complex 4. The apparent widening of 
the bands and smearing of the complexes could be due to the dissociation of the 
non-covalent protein-DNA complexes during the electrophoresis, perhaps
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because the mutation causes a weaker binding interaction than with wild-type 
protein.
4.14 Binding of resolvase cysteine mutants to site 1 DNA
It was important to measure the binding of the cysteine mutants to site I DNA, as 
it was this site that was to be modified with the crosslinking group. An important 
pre-requisite to crosslinking was that there was sufficient binding of the proteins 
to res subsite I. Oligonucleotides (40 nt top strand and 48 nt bottom strand) 
forming wild-type subsite I were radiolabelled with 32P (Section 3.16).
Figure 4.21 shows binding of A171C, S173C and K177C to labelled site I. The 
wild-type control is shown in lane 2. The expected binding complex 1 was 
observed, corresponding to the two resolvase monomers bound at site 1. One of 
the bands represents the expected complex 2 , while the other may be some 
oxidised form as illustrated in Figure 4.22 which may (or not) be more retarded 
than wild-type complex 2. It could be that the ‘normal’ complex 2 would run 
closer to the wild-type complex 2 and that the ‘oxidised’ complex 2 would be 
more retarded.
The R172C and Y176C resolvases form no detectable complexes with site I DNA 
(results not shown). This was expected, as no complexes were observed with 
binding reactions using res DNA.
There is overall less binding to site I DNA compared to res DNA with the 
cysteine mutants. This could be due to the site I complexes being more unstable 
than complexes of the full res site, causing them to dissociate under the gel 
electrophoresis conditions.
The mutants A171C, S173C and K177C are able to bind to both res and site I 
DNA, whereas R172C and Y176C have greatly reduced binding to res DNA and 
are unable to bind to site I DNA sufficiently to see complexes under the assay
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Figure 4.21 Binding of A171C, S173C and K177C resolvases to site I
2ox = oxidised 
complex 2
2 = complex 2
SH
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - 8-fold dilution of A 171C resolvase
7 - Undiluted S173C resolvase
8 - 2-fold dilution of S173C resolvase
9 - 4-fold dilution of S173C resolvase
10 - 8-fold dilution of S173C resolvase
11 - Undiluted K177C resolvase
12 - 2-fold dilution of K177C resolvase
13 - 4-fold dilution of K177C resolvase
14 - 8-fold dilution of K177C resolvase
Complex 2 
wild-type site I
Complex 2- oxidised
Figure 4.22 Doublet band in binding gels
Representation of the possible structure of the slower moving band present 
in site I binding gels. The oxidised species would be more retarded 
because of an altered shape of the DNA binding domains. N denotes the 
N-terminal domain of resolvase and C indicates the C-terminal DNA 
binding domain.
conditions used. However R172C and Y176C may still in close enough proximity 
to the DNA, but the interaction is not strong enough to remain intact during the 
conditions used here. The fact that there are binding complexes detected with site 
I for A171C, S173C and K177C make them good candidates for crosslinking. 
Although R172C and Y176C show almost no binding under these assay 
conditions, they may still bind weakly to the DNA, whereby they could form 
covalent crosslinks between the proteins and the DNA if the two thiols in close 
proximity form disulfides.
4.15 Discussion
A171C, S173C and K177C show both binding and recombination activity, 
whereas R172C and Y176C show little binding activity, and no recombination, 
with topoisomerase activity after extended reaction times. The topoisomerase 
activity of resolvase is proposed to occur by rotation of the left half of the cleaved 
site I, after all four half sites have been cleaved (Boocock et al., 1995). It is more 
likely that the left half rotates, as the right half of site I is directly influenced by, 
and is thought to be structurally maintained by interaction of dimers bound to 
sites II and III.
The results of the in vitro assay (Section 4.11) correlate well with the in vivo 
studies (Section 4.7). The proteins that were able to carry out recombination in 
vivo, could do so in vitro, and also formed detectable protein-DNA-binding 
complexes. Similarly, the proteins that failed to recombine in vivo formed no 
detectable protein-DNA complexes and showed no full recombination activity in 
vitro. Even when there is no observed recombination and/or binding activity, the 
R172C and Y176C mutants may still interact with the DNA sufficiently to be 
crosslinked.
Although A171 does not interact with the DNA in the crystal structure of the 
protein-DNA complex (Yang and Steitz, 1995), it is still theoretically close 
enough to the DNA for crosslinking to be carried out. It was predicted that
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mutation of this residue should not have any great impact on binding and 
recombination in the A171C resolvase mutant. The in vivo galK assay for binding 
(Section 4.7) showed a positive result with the production of white colonies on 
MacConkey agar plates, showing that the A171C protein can catalyse 
recombination in cells. The results of the binding and recombination assays 
showed that the presence of the cysteine residue at the 171 position does not 
cause major unfavourable obstructions to the binding or recombination reaction. 
In vitro recombination by A 171C is as efficient as wild-type resolvase in vitro. 
The binding gel of A171C to res (see Figure 4.20) shows strong bands 
corresponding to complexes 2 and 3, with a smeary band representing where the 
higher complexes would run. The binding profile is different to that of the wild- 
type protein, indicating that the mutation of this position caused changes that do 
not allow binding to occur naturally. This suggests that A171 in the protein is 
essential for a normal binding interaction to occur, so it may in fact interact with 
the DNA, perhaps by indirect methods. The distance between the (3-carbon of 
A 171 and the C-5 of thymidine is 12.87 A for IL-T14, 10.49 A for IL-T12 and 
10.55 A for EL-C(T)10 (Figure 4.23).
Mutation of R 172 to cysteine resulted in a dramatic decrease in binding to the 
DNA, although a very low level of complex 2 was observed with a labelled res 
site. Although it is inactive in vivo and shows little binding activity in the gel 
assay, the topoisomerase activity of R172C indicates that the mutant may still be 
a candidate for crosslinking. The fact that some binding and single-stranded 
cleavage of the DNA is occurring as observed in Figure 4.18, means that the 
formation of a disulfide between the protein thiol and the modified DNA is 
feasible. The modification R—>C replaces a charged long chain residue with the 
cysteine methyl thiol. In the co-crystal structure, the arginine at position 172 
interacts with IR-T14 and IR-G13 in the consensus TGT binding motif. The 
arginine guanidinium nitrogen atoms interact with the 06  and N7 of IL-G13, and 
the aliphatic (CH2)3 portion of the arginine makes hydrophobic interactions with 
the methyl group of IL-T14. One would expect a reduction in activity as all of the
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IL -(C )T 1 0
Figure 4.23 Interaction of A171 with modified bases
The three positions of the DNA that are modified relative to the A 171 
residue. The black dots indicate the positions that will have thiol groups. 
The distances between the thiols are numbered. Atoms in CPK (Corey- 
Pauling-Koltun) colours. The data are derived from Rasmol.
wild-type interactions are abolished by the cysteine mutation. The calculated 
distance for crosslinking is 7.71 A for IL-T14, 7.12 A for T 12 and 11.29 A for 
C(T)10 (Figure 4.24).
Like A 171C, the S173C mutant displayed in vivo activity. The change S—>C is 
quite conservative, the electronegative oxygen atom of the natural serine replaced 
with a sulfur atom. The electronegativity of the atom at this position is 
maintained. However, replacement of oxygen with sulfur will cause a size change 
due to the larger atomic radius of sulfur. From analysis of the co-crystal structure 
it was observed that the serine at position 173 differs in its interaction with each 
of the two DNA-binding domains in the complex. The hydrogen of the serine 
hydroxyl group is involved in hydrogen bonding to the 06  of IR-G10 and IR-G11 
and IR-G10' in one subunit only (Figure 4.25).
Replacing the hydroxyl group with a cysteine thiol should not necessarily disrupt 
binding interactions, as the cysteine thiol hydrogen could still participate in 
hydrogen bonding to the IL-G10 or IL-G11. The crosslinking potential at this 
position is high, since binding is not prevented by the presence of the sulfur atom. 
The (3-carbon atom of S173 is 11.32 A away from IL-T14, 6.31 A away from IL- 
T12 and 6.35 A away from IL-C(T)10 (Figure 4.25).
The tyrosine at position 176 is the closest to the DNA of the five residues chosen 
to be mutated. This tyrosine forms hydrophobic interactions between the 13- 
carbon atom and the methyl group of IL-T12. The mutation Y—>C introduces a 
sulfur atom and a dramatic size change; the steric bulk induced by the phenol ring 
in the natural base is lost. The change in polarity and differences in conformation 
of the Y176C mutant lead to disruption of all the wild-type interactions. The p- 
carbon of Y176 is 9.81 A away from IL-T14, 5.14 A away from IL-T12 and 9.94 
A away from IL-C(T)10 (Figure 4.26).
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IL-(C)T10
Figure 4.24 Interaction of R 172 with modified bases
The three positions of the DNA that are modified relative to the R172 
residue. The black dots indicate the positions that will have thiol groups. 
The distances between the thiols are numbered. Atoms in CPK (Corey- 
Pauling-Koltun) colours.
Figure 4.25 Interaction of SI73 with modified bases
The three positions of the DNA that are modified relative to the S I73 
residue. The black dots indicate the positions that will have thiol groups. 
The distances between the thiols are numbered. Atoms in CPK (Corey- 
Pauling-Koltun) colours.
Figure 4.26 Interaction of Y176 with modified bases
The three positions of the DNA that are modified relative to the Y 176 
residue. The black dots indicate the positions that will have thiol groups. 
The distances between the thiols are numbered. Atoms in CPK (Corey- 
Pauling-Koltun) colours.
K177
IL -(C )T10
Figure 4.27 Interaction of K 177 with modified bases
The three positions of the DNA that are modified relative to the K177 
residue. The black dots indicate the positions that will have thiol groups. 
The distances between the thiols are numbered. Atoms in CPK (Corey- 
Pauling-Koltun) colours.
The lysine residue at position 111 forms hydrophobic interactions with the methyl 
group of IR-T8 , and a salt-bridge between the phosphate backbone of the DNA 
and its amine group. Like A171C and S173C, the K177C mutant showed 
recombinational activity in vivo and in vitro, and formed protein-DNA complexes 
with both res and site I DNA. The mutation K—>C replaces a four carbon chain, 
carrying a charged amino group, with an electronegative mercaptomethyl group. 
Therefore in the K177C mutant the hydrophobic interaction is lost, as is the 
formation of the salt bridge. The binding gel of K177C showed very smeary 
complexes indicating that the interaction is somewhat unstable. The changes in 
polarity could mean that the binding interaction in the mutant protein is much 
weaker than the wild-type protein, resulting in aberrant binding complexes. The 
p-carbon of K177 is 14.67 A away from IL-T14, 8.48 A away from IL-T12 and
8.18 A away from EL-C(T)10 (Figure 4.27).
4.16 Conclusions
The novel Tn3 cysteine mutants purified and characterised in this chapter are all 
good candidates for crosslinking. Three out of the five, A171C, S173C and 
K177C are still able to bind well to res DNA, which is essential for crosslinking. 
R172C and Y176C do not bind strongly, but may be come close physically close 
enough during the reaction to be crosslinked.
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Chapter 5: Crosslinking using modified oligonucleotides 
and cysteine mutants
5.1 Uses of modified oligonucleotides
Oligonucleotides can be modified at a number of different sites. These 
modifications can be introduced at the 5' and 3' termini, the intemucleotide 
linkage, the sugar group or the bases (reviewed in Goodchild, 1990; Verma and 
Eckstein, 1998). The oligonucleotides used here were modified with a thiol- 
containing base analogue protected as the phosphoramidite (reviewed in 
Beaucage and Iyer, 1993).
5.2 Oligonucleotides containing the DNP group, T1-T4 and B1-B5
5'-0-(Dimethoxytrityl)-5-[S-(2,4-dinitrophenyl)-thio]-2'-deoxyuridine, 3'-0-(2- 
V,V"-cyano-ethyl diisopropylphosphoramidite SH 17 was incorporated into 
oligonucleotides with sequences corresponding to res subsite I (illustrated in 
Figure 5.1). The phosphoramidite obtained from phosphoramidite method B 
(Chapter 2) was used in all the oligonucleotide syntheses, as it was the best 
quality product. The top strand 40-mer and the bottom strand 48-mer were 
synthesised on an Applied Biosystems 392 DNA synthesiser (Section 3.38). 
Following the removal of the crude oligonucleotides from the CPG support, the 
nucleotides were deprotected, purified and analysed for the presence of the 5- 
dinitrophenyl (DNP) group. The positions T l, T3, T4, B l, B3 and B5 were 
chosen for modification because they are within reasonable distances of residues 
in the resolvase recognition helix, that were mutated to cysteine (Chapter 4). The 
oligonucleotides T12 and B 13 were synthesised as controls.
5.3 UV Spectrometry of the DNP modified oligonucleotides
Oligonucleotides that have no modifications show two main UV absorptions at 
215 and 260 nm. Initial measurements of the absorbance of the oligonucleotides 
containing SH 17 showed little absorbance above 300 nm, in the region where the 
DNP group would absorb SH P12 (^max= 315 nm, e = 24,5001 m ol1 cm'1).
Taking into account that only one base in 40 (for top strand modifications) carries 
the DNP group, the predicted UV spectrum of a 40-mer oligonucleotide
116
(1)
S s t l \ CACTAGTC
TCGAGTGATCAG
TGTTCGAAATATTATAAATTATCAGACA
a c a a g c tt ta ta a ta ttta a ta g tc tg t
T A q q [ E c o _ R 1
ATCCTTAA 1
(2)
Top Strands
CACTAGTCTGTTCGAAATATTATAAATTATCAGACATAGG = T1 
CACTAGTCTGTTCGAAATATTATAAATTATCAGACATAGG = T3 
CACTAGTCTGTTCGAAATATTATAAATTATCAGACATAGG = T4 
CACTAGTCTGTTCGAAATATTATAAATTATCAGACATAGG = T12
Bottom Strands
AATTCCTATGTCTGATAATTTATAATATTTCGAACAGACTAGTGAGCT = B1 
AATTCCTATGTCTGATAATTTATAATATTTCGAACAGACTAGTGAGCT = B3 
AATTCCTATGTCTGATAATTTATAATATTTCGAACAGACTAGTGAGCT = B5 
AATTCCTATGTCTGATAATTTATAATATTTCGAACAGACTAGTGAGCT = B13
(3)
TTTTTTTTTT = T10 
Figure 5.1 Site I oligonucleotides
(1) Illustration of the synthetic site I, flanked by Sstl and EcoRl sites. The 
thymidines in bold were substituted individually by SH 17 (see (1).
(2) The individual top and bottom strands, the position of the SH 17 
analogue is highlighted in bold. (3) Shows the control thymidine only 
T10.
BWT T1
(1)
- 0 . 0 0 3  —
2 5 0 . 0 5 0 0 . 0
W a v e le n g th  (r
(2 )
0
0 ,
0 .
0 .
30 0.0 350 .0250.0
W a v e l e n g t h  ( r u n . )
2 5 0 .0  3 0 0 .0  3 5 0 .0  4 0 0 .0
. W avelength (run.)
Figure 5.2 UV spectra of DNP modified oligonucleotides
(1) UV absorbance of a wild-type £'cc>RI-Vs,d  bottom strand wild-type 
oligonucleotide. (2) The absorbance of a top strand 40-mer T l, with the 
first T in TGT containing SH 17 (3) spectrum of the T10 modified 
oligonucleotide.
containing one DNP-modified thymidine should show a large absorbance at 260 
nm, and a peak corresponding to approximately 5% of the intensity of the 260 nm 
peak at 330 nm. It was found, however, that there was no detectable difference 
between the UV spectra of purified wild-type oligonucleotides and 
oligonucleotides containing the DNP modification (Figure 5.2, compare spectra 
1. and 2.). Indeed, even UV measurements using the ammonia stock solutions of 
the modified oligonucleotides, that had been cleaved from the columns and taken 
directly from storage at -70 °C, showed no obvious peaks above 300 nm. The 
absorbance of the DNP group was probably not detected because of the high 
levels of background absorbance from other chromophores.
In order to establish the presence of the DNP group in the modified 
oligonucleotides using UV spectrometry, a smaller oligonucleotide was 
synthesised. A 10-mer oligonucleotide containing 9 thymines, SHT10, one of 
which was modified with the phosphoramidite SH 17 was synthesised. 
Thymidines have no exocyclic amide protecting groups, therefore the long 
ammonia deprotection step is not required. Therefore, the chances that the DNP 
group will be lost (by hydrolysis or ammoniolysis) during the ammonia 
deprotection step are reduced. By using a shorter modified oligonucleotide in the 
UV measurements, the ratio of absorbances at 330 nm and 260 nm should be 
increased. The oligonucleotide SHT10 should show an absorbance above 300 
nm.
The UV spectra of wild-type and two DNP modified oligonucleotides are shown 
in Figure 5.2. An absorbance at 330 nm of SHT10 was observed, corresponding 
to the DNP moiety. The extinction co-efficient (e) of the DNP group is 
approximately 20,000, whereas for the natural bases a Figure of 10,000 is taken 
as the average value for the natural nucleotides. The signal for the DNP group 
should mirror that ratio and be approximately 20% of the large 260 nm peak. The 
absorbance of the 330 nm peak was actually 10% that of the 260 nm absorbance. 
This apparent reduction in absorbance at 330 nm could be due to the presence of
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some oligonucleotides that do not contain the DNP group, i.e. some 
ammoniolysis or hydrolysis could have occurred during purification. Another 
explanation is that the value of e is reduced when the DNP group is in the 
oligonucleotide.
5.4 Deprotection using P-mercaptoethanol and alkylation using IAF
The DNP group is removable by treatment with the reducing agent p- 
mercaptoethanol (Hanna and Meyer, 1996). Following the deprotection step, an 
alkylation reaction was carried out in order to confirm the presence of the free 
thiol group in the oligonucleotides. The oligonucleotides were deprotected in the 
first instance using 1.4 M P-mercaptoethanol (Section 3.40), then alkylated using 
4(5)-(iodoacetamido)-fluorescein (Section 3.41). The products were separated on 
a sequencing gel (Section 3.24.4).
An autoradiograph of the gel is shown in Figure 5.3. Four different modified 
oligonucleotides were used, modified with phosphoramidite SH 17 at different 
positions within the oligonucleotides. T1 and T3 are top strand oligonucleotides 
with the first and third thymidine of the TGT motif having a thiol-containing 
modification. B 1 and B3 have the ninth and eleventh base of the bottom strand 
oligonucleotide bearing the DNP modification as illustrated in Figure 5.1.
For each oligonucleotide, samples before deprotection, after deprotection and 
after alkylation were run on the gel. The lanes containing oligonucleotides treated 
with p-mercaptoethanol will have lost the DNP group, and should have a mass 
that is 250 units less (the size of DNP). The lanes that have been treated with P~ 
mercaptoethanol and subsequently alkylated using IAF should have gained a 
mass of 300 (molecular weight of IAF group).
Figure 5.3 (lanes 1-3) represent the deprotection/alkylation of oligonucleotide Tl. 
In lane I the oligonucloetide has ran quite unevenly, but a change in gel mobility 
is apparent between lanes 2 and 3. The band in lane 3 is more retarded than that
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37
Figure 5.3 Autoradiograph of deprotection and alkylation of T l, T3, B1 and
The third track in each set is taken up in a smaller volume (10 pi) than the initial 
starting volume of the DNP-protected oligonucleotides (20 pi). The sequences of 
T l, T3, B1 and B3 are shown in Figure 5.1. The arrows indicate the positions 
where one would expect the differently sized oligonucleotides to run. A reference 
wild type 40 mer was labelled and run at the edge of the gel (not shown) as a 
reference point for the size determination of the truncated oligonucleotides.
Lane 1 - Untreated Tl
2 - T l treated with (3-mercaptoethanol
3 - as lane 2, treated with IAF
4 - Untreated T3
5 - T3 treated with (3-mercaptoethanol
6 - as lane 5, treated with IAF
7 - Untreated B 1
8 - B 1 treated with (3-mercaptoethanol
9 - as lane 8, treated with IAF
10 - Untreated B3
11 - B3 treated with (3-mercaptoethanol
12 - as lane 11, treated with IAF
B3
of lane 2, indicating that the oligonucleotide has been alkylated. There is also a 
faster moving band in lane 3 with the same mobility as the thiol-containing 
oligonucleotide in lane 2, indicating that not all the free thiol was alkylated.
From Figure 5.3 (lanes 4-6) the observed changes in mobility are similar to the 
results obtained for T l. There is a band in lane 5 faster moving than that in lane 4, 
indicating that the oligonucleotide has lost the DNP group. Again the band in lane 
6 is more retarded than lane 4, indicating that alkylation has occurred, and there is 
also a faster moving band, indicating that the thiol in T3 has not been completely 
alkylated.
The experiment with oligonucleotide B 1 (Figure 5.3; lanes 7-9) showed that there 
are two species of oligonucleotide present. The top band is a 48-mer and 
corresponds to the full length oligonucleotide, where a change in size is observed 
on deprotection and subsequent alkylation, more noticeable between lanes 8 and 9 
than in lanes 7 and 8. The lower set of bands are a 39-mer, having nine bases less 
than the full length oligonucleotide. This oligonucleotide is a result of failure of 
addition of the modified nucleotide during the DNA synthesis cycle. The 
modification in B 1 is at the ninth position from the end of the oligonucleotide 
(Figure 5.1). Therefore, oligonucleotides in the lower bands in lanes 7-9 show no 
differences in size, because they have no DNP group present.
Similarly B3 has no full length 48-mer oligonucleotide; only a 37-mer is present. 
This result indicates that the DNA polymerisation reaction failed completely at 
the modified base. Oligonucleotides B 1 and B3 were resynthesised for use in 
crosslinking studies.
In all lanes there is more labelled DNA in the third track, compared to the first 
two tracks. This is because after the alkylation step the DNA was taken up in a 
smaller volume of buffer than it was originally dissolved in, i.e. a 20 \x\ initial
119
solution of DNP-protected oligonucleotide was taken up in a final volume of 10 
\L\.
The chemical steps in the (3-mercaptoethanol deprotection and the subsequent 
thiol alkylation are shown in Figure 5.4. A simple SN2 displacement of the iodine 
of IAF by the thiol results in the alkylation of the pyrimidine thiol. The 
mechanism for the (3-mercaptoethanol deprotection is shown in Figure 5.4.
The results of the deprotection/alkylation experiment confirm the presence of the 
thiol in the oligonucleotides, indicated by the observed changes in mobility. The 
partial and complete failure of the DNA synthesis of the DNP-containing 
oligonucleotides could be due to chemical changes in SH 17. Extensive 
characterisation of the phosphoramidite SH 17 made by method B (Chapter 2) 
indicated that all the protecting groups were present; this was confirmed by ]H, 
13C, 32P NMR, and accurate mass. The 4,4'-dimethoxytrityl (DMT) group on the 
5'-hydroxyl is very acid labile and removed by treatment with trichloroacetic acid 
prior to the coupling step with the incoming phosphoramidite monomer. 
However, there was no evidence that this group was not present in SH 17 
(Chapter 2). However if the DMT group had been lost this would result in failure 
of the synthesis at the coupling step.
A possible problem with the 3’-hydroxyl phosphoramidite protecting group, is 
that some oxidation of the phosphorus may have occurred, as it is very sensitive 
to air oxidation causing Pin-Pv. However, great care was taken to ensure that SH 
17 was protected from atmospheric oxygen. Even if some of SH 17 contained Pv, 
this would not prevent the coupling step as Pv is unreactive, but would probably 
cause a lower yield of the DNP-protected oligonucleotides.
A more important consideration is whether the integrity of the DNP protecting 
group in the oligonucleotides was compromised. In DNP-modified 
oligonucleotides that had been deprotected in ammonia for longer times, there 
was an observed colour change from yellow to clear, indicating that the DNP
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P-mercaptoethanol 
O-DNA  O-DNA
0 2N
(2) IAF
HN‘ NH
DNA-O
HOOC'
O-DNA
OH
Figure 5.4 Chemistry of deprotection and alkylation of 5-mercaptouridine
(l)The mechanism of removal of DNP, generating the free thiol. Step (2) 
is alkylation using 4(5)- (iodoacetamido)-fluorescein (IAF).
group was no longer present. The presence of thiol in the oligonucleotides was 
tested using Ellmans reagent [5, 5'-dithiobis(2-nitrobenzoic acid)]. This reagent 
should form a mixed disulfide with any thiol present and cause an intense yellow 
colour due to the liberation of 1 mole of nitrothiobenzoate per mole of thiol group 
present. The results of this test were negative (results not shown). It was also 
possible the DNP group may have formed fo's(2,4-dinitrophenyl)disulfide, which 
is colourless. Addition of DTT should reduce this and form 2,4-dinitrobenzene 
thiolate ion that would be yellow. Again the test failed. It is more likely that 
hydrolysis or ammoniolysis of the DNP group in the modified oligonucleotides 
occurred, yielding by-products (Figure 5.5).
5.5 Binding of the modified oligonucleotides to the cysteine mutant proteins
The oligonucleotides containing the DNP modification were end-labelled 
(Section 3.16), then annealed to the complementary wild-type strand (Section 
3.20). It was important to show that the modified oligonucleotides could bind to 
the cysteine mutants, as it is essential for crosslinking. Binding analysis was 
performed with different concentrations of DTT in the binding mix, ranging from 
1 mM to 5 mM. The results of binding at 5 mM are shown in Figures 5.6 and 5.7. 
The binding assay carried out in 2 mM DTT showed very weak binding with 
S173C; no complexes were observed for the other cysteine mutants (data not 
shown).
In all lanes in Figure 5.6, there is a band representing the unbound 
oligonucleotides. One of these bands (band 1) is double stranded oligonucleotides 
containing one thiol group. The other band, present in Figure 5.7 (band 2) is 
single-stranded oligonucleotide, due to not enough cold oligonucleotide being 
added to the annealing reaction, or the double-stranded oligonucleotides may 
have denatured prior to the gel being run. An oxidised dimer of oligonucleotides, 
less retarded than the oxidised oligonucleotides, was observed in all the 
crosslinking gels (Figure 5.10-5.16).
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Figure 5.5 Hydrolysis /ammoniolysis by-products of DNP-containing 
oligonucleotides
Illustration of the possible by-products generated from hydrolysis of the 
DNP protected oligonucleotides. (1) shows hydroysis resulting in the 
diketone, whereas (2) shows the 5-aminouracil by-products.
Figure 5.6 Binding of double stranded oligonucleotide with
modification at position B1 to A171C, R172C, S173C, Y176C and 
K177C (5 mM DTT)
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - Undiluted R172C resolvase
7 - 2-fold dilution of R172C resolvase
8 - 4-fold dilution of R172C resolvase
9 - Undiluted S173C resolvase
10 - 2-fold dilution of S173C resolvase
11 - 4-fold dilution of S173C resolvase
12 - Undiluted Y176C resolvase
13 - 2-fold dilution of Y176C resolvase
14 - 4-fold dilution of Y176C resolvase
15 - Undiluted K177C resolvase
16 - 2-fold dilution of K177C resolvase
17 - 4-fold dilution of K177C resolvase
I i  3 4  5 b 7 S *3 1C II
Figure 5.7 Binding of double stranded oligonucleotide with
modification at position B3 to A171C, S173C and K177C to B3 (5 
mM DTT)
Lane 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - Undiluted S173C resolvase
7 - 2-fold dilution of S173C resolvase
8 - 4-fold dilution of S173C resolvase
9 - Undiluted K177C resolvase
10 - 2-fold dilution of K177C resolvase
11 - 4-fold dilution of K177C resolvase
Increasing the DTT concentration to 5 mM increased reduction of any oxidised 
forms of the cysteine mutants that may have been present in the samples, that 
may have impeded binding. Thus the cysteine monomers containing free thiol 
groups should give more binding complexes.
The binding assays resulted in complexes for A171C, S173C and K177C (Figure 
5.6; lanes 3-5, 9-11 and 15-17). In general there were less binding complexes 
observed for the proteins, compared to wild-type resolvase (Figure 5.6; lane 2). A 
band corresponding to complex 2 was observed, although an additional retarded 
band was observed with all the mutants, but not with wild-type resolvase. This 
band was also observed in binding assays with wild-type site I oligonucleotides 
(Section 4.14; Figure 4.21).
These results indicate that the mutants A171C, S173C and K177C are able to 
bind to binding site I with the bottom strands B1 and B3.
An apparent correlation between the amount of DTT and the extent of binding 
was found. At higher concentrations of DTT the binding was generally at higher 
levels. For the purposes of crosslinking this could be problematic, as increasing 
the amount of reducing agent in the binding reactions will discourage disulfide 
formation.
5.6 Crosslinking to mutant proteins
It was predicted that placing two thiol groups, one in the resolvase binding 
domain, and one in an oligonucleotide of the binding site, in close enough 
proximity should result in a disulfide bond being formed, thus forming a 
covalently linked protein-DNA complex (Figure 5.8).
For all crosslinking reactions (Section 3.42), a binding reaction was first carried 
out to enable the protein and DNA to come into close contact. The second part of 
the reaction involved the addition of oxidising agent to encourage the thiols to
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Figure 5.8 Crosslinking of the DNA binding domain
Illustration of disulfide formation between a cysteine thiol in the DNA 
binding domain and a thiol-containing base in a site I oligonucleotide.
r
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glutathione (oxidised)
sodium selenite cis platinum diamine dichloride
(cisplatin)
Figure 5.9 Agents used in crosslinking
Diagram illustrating the oxidising and crosslinking agents used to link 
C-5 thiols in DNA and cysteines in the recognition helix of TnJ 
resolvase. Air oxidation was also used.
form disulfides. The oxidising and crosslinking reagents tested are illustrated in 
Figure 5.9. The products of the crosslinking reactions were run on 10% Tris- 
glycine gels containing 0.1% SDS. The gels were dried, and the products 
visualised using autoradiography.
In most of the crosslinking assays (Figure 5.10-5.16) there is a weak band 
approximately half way between the top of the gels and the unbound 
oligonucleotides. This band is due to products of oligonucleotide oxidation only, 
as it is not sensitive to proteinase K (see right half of gels). This band is probably 
due to the thiol-containing oligonucleotides being oxidised. A small proportion of 
the oligonucleotides may form disulfides with each other, yielding dimeric 
species.
In lane 1 of all the crosslinking gels, which contains binding buffer and 
oligonucleotide only, there are varying amounts of this oxidised oligonucleotide 
species. The amount depended on how long the oligonucleotide solutions had 
been stored prior to use in the crosslinking assays. If the DTT in the buffer was 
depleted (initial thiol-containing oligonucleotides were in 1 mM DTT) then 
oxidation may occur over time. The oligonucleotides that had no dimer present 
were used immediately in the crosslinking reactions.
In some of the gels there are proteinase-K sensitive bands in the wild-type 
resolvase controls. In all cases, the presence of the cysteine in the mutants 
increased the amount of crosslinking, indicating that the thiol modification is 
causing more crosslinking than with wild-type protein.
5.7 Crosslinking of double stranded oligonucleotide with modification at 
position B1
The oligonucleotide B 1 has the first thymidine in the consensus TGT modified 
with a thiol group, in the 48 nt bottom strand.
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Figure 5.10 Crosslinking of double stranded oligonucleotide with
modification at position B1 to A171C, R172C and S173C with 
glutathione oxidation
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - 4-fold dilution of A171C resolvase
6 - Undiluted R172C resolvase
7 - 2-fold dilution of R172C resolvase
8 - 4-fold dilution of R172C resolvase
9 - Undiluted S173C resolvase
10 - 2-fold dilution of S173C resolvase 
11-19 - as lane 2-10 + proteinase K
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Figure 5.11 Crosslinking of double stranded oligonucleotide with
modification at position B1 to A171C, R172C and S173C with 
selenite oxidation
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - Undiluted R172C resolvase
7 - 2-fold dilution of R172C resolvase
8 - 4-fold dilution of R172C resolvase
9 - Undiluted S173C resolvase
10 - 2-fold dilution of S173C resolvase
11-19 - as lane 2-10 + proteinase K
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Figure 5.12 Crosslinking of double stranded oligonucleotide with
modification at position B1 to A171C, R172C and S173C with 
air oxidation
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - Undiluted R172C resolvase
7 - 2-fold dilution of R172C resolvase
8 - 4-fold dilution of R172C resolvase
9 - Undiluted S173C resolvase
10 - 2-fold dilution of S173C resolvase
11- 4-fold dilution of S173C resolvase
12-21 - as lane 2-11+ proteinase K
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Figure 5.13 Crosslinking of double stranded oligonucleotide with
modification at position B1 to A171C, R172C and S173C with 
cisplatin oxidation
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - Undiluted R172C resolvase
7 - 2-fold dilution of R172C resolvase
8 - 4-fold dilution of R172C resolvase
9 - Undiluted S173C resolvase
10 - 2-fold dilution of S173C resolvase
1 1 -4 -  fold dilution of S173C resolvase
12-19 as lane 2-10 + proteinase K
Figure 5.10 shows crosslinking between B1 and A171C, R172C and S173C using 
oxidised glutathione as the oxidant. There are two faint proteinase K-sensitive 
bands in lane 6 (x-link 1 and x-link 2), corresponding to crosslinked complexes 
between R172C and B l. Although R172C showed very little binding to res and 
site I DNA in the binding assays (Section 4.14) it seems to have crosslinked in 
this assay. There is a lot of material stuck in the wells in lanes with the R172C 
crosslinking reaction. This material could be a result of aggregation of the R172C 
crosslinked complexes. The distance between the [3-carbon of R172 and the C-5 
of thymidine Bl (Table 4.1) was 7.71 A, longer than the predicted distance (<5.8 
A) for a disulfide crosslink to be formed.
Figure 5.11 shows crosslinking between Bl and A 171C, R172C and S173C using 
sodium selenite as the oxidising agent. Similarly to crosslinking with glutathione, 
there are crosslinked species with the mutant R172C as observed in lanes 6-8 (x- 
link 1). For all concentrations of R172C used, proteinase K-sensitive bands were 
observed. The amount of these complexes is around 5% of the total 
oligonucleotide. There is also a very weak band in lane 9 (x-link 2), so S173C has 
been crosslinked to B l. The distance between the [3-carbon of R172 and the C-5
o
of thymidine B l is 11.32 A, so this reduction in crosslinking could be because the 
thiols are too far away.
Figure 5.12 shows crosslinking between Bl and A171C, R172C and S173C using 
air oxidation. Proteinase K-sensitive bands were observed in all the proteins 
assayed, although more crosslinked complexes were found with R172 (x link 1; 
lane 6 and 7 and R173 (x-link 2; lane 9). These 'xlink-2' bands have slightly 
different mobilities, probably due to the crosslinking to two different cysteine 
mutants. There are also crosslinked species between A171C and B l (lanes 2 and 
3) that appear to have the same mobility as the complexes in the wild-type 
control. The (3-carbon atom of A171 is 12.87 A away from the C-5 of Bl.
124
Figure 5.13 shows crosslinking between Bl and A171C, R172C and S173C, 
using cisplatin. The mutant R172 in lanes 6-8 , shows two crosslinked species (x- 
link 1 and x-link 2). There is also crosslinking between S173C and B l (lane 9).
5.8 Crosslinking of double stranded oligonucleotide with modification at 
position B3
The oligonucleotide B3 has the third thymidine in the consensus TGT modified 
with a thiol group, in the 48 nt bottom strand. The crosslinking agents used on B 1 
oligonucleotide with the cysteine mutant proteins were the same as used for the 
B3 oligonucleotide. Covalent protein-DNA complexes were observed when air 
oxidation and cisplatin were used.
Figure 5.14 shows the crosslinking reaction of A171C, R172C and S173C with 
oligonucleotide B3 with air oxidation. The gel shows that crosslinking between 
S173C and B3 has occurred (see lanes 9 and 10). The band is faint, indicating that 
a very low amount of crosslinked product is present. Less than 5% of the total 
oligonucleotide added is covalently linked to the protein. The cysteine of S173C 
is the closest to the modified base of the three proteins used in this assay, being 
6.31 A away.
Figure 5.15 shows the crosslinking reaction of A171C, R172C and S173C with 
oligonucleotide B3 with cisplatin as the oxidant. Similar results were observed to 
Figure 5.14. A band corresponding to crosslinked complex was observed in lane 
9 and 10 (xlink-1). Thus S173C has formed a covalent complex with 
oligonucleotide B3; the distance between B3 and S173C is 6.31 A. More 
crosslinked complex was observed with cisplatin than with air oxidation.
5.9 Crosslinking of double stranded oligonucleotide with modification at 
position B5
The double stranded site I oligonucleotide with the B5 thymidine modified in the 
bottom strand was used in crosslinking reactions with all of the cysteine mutants.
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Figure 5.14 Crosslinking of double stranded oligonucleotide with
modification at position B3 to A171C, R172C and S173C with 
air oxidation
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A 171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - Undiluted R172C resolvase
7 - 2-fold dilution of R172C resolvase
8 - 4-fold dilution of R172C resolvase
9 - Undiluted S173C resolvase
10 - 2-fold dilution of S173C resolvase 
11-19 - as lane 2-10 + proteinase K
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Figure 5.15 Crosslinking of double stranded oligonucleotide with
modification at position B3 to A171C, R172C and S173C with 
cisplatin oxidation
Lanes 1 - No resolvase (binding buffer)
2 - 16-fold dilution of wild-type resolvase
3 - Undiluted A 171C resolvase
4 - 2-fold dilution of A171C resolvase
5 - 4-fold dilution of A 171C resolvase
6 - Undiluted R172C resolvase
7 - 2-fold dilution of R172C resolvase
8 - 4-fold dilution of R172C resolvase
9 - Undiluted S173C resolvase
10 - 2-fold dilution of S173C resolvase 
11-19 - as lane 2-10 + proteinase K
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Figure 5.16 Crosslinking of double stranded oligonucleotide with
modification at position B5 to A171C and Y176C with cisplatin 
oxidation
Lanes 1 - No resolvase (binding buffer)
2 - 32-fold dilution of wild-type resolvase
3 - 32-fold dilution of SION resolvase
4 - Undiluted A 171C resolvase
5 - 2-fold dilution of A 171C resolvase
6 - 4-fold dilution of A 171C resolvase
7 - Undiluted Y176C resolvase
8 - 2-fold dilution of Y176C resolvase
9 - 4-fold dilution of Y176C resolvase 
10-17 - as lane 2-9 + proteinase K
The best result was obtained with the Y176C mutant as shown in Figure 5.16 (x- 
link 1, x-link 2 and x-link 3, as seen in lane 7). The band x-link 1 represents 
Y176C crosslinked to B5. The distance between the (3-carbon of Y176 and the C-
5 of thymidine B5 is 9.94 A. The more retarded band crosslink 2 is a perhaps due 
to an extra monomer being crosslinked as in Figure 5.18. The very retarded 
species crosslink 3 is probably due to crosslinked, aggregated complexes as it is 
sensitive to proteinase K, and was rather stable to 0.1% SDS, depending on the 
amount of aggregation and the amount of SDS actually present in the gels.
In some of the crosslinking gels, there was a retarded band in the wild-type 
control reactions that was sensitive to proteinase K treatment. As wild-type 
control contains no cysteine residues, this band is not due to disulfide formation 
between protein and DNA, but due to crosslinking by some other method. The 
experiments were repeated using the mutant SION resolvase that lacks the serine 
10 nucleophile (M. Stark, pers. comm.). This should test whether the band in the 
wild-type control represents the oligonucleotide covalently joined to the protein 
via the nucleophilic serine of resolvase's active site. The fact that this band is also 
present in SION crosslinking reactions (Figure 5.16) indicated that crosslinking to 
the wild-type protein was not specifically at serine 10. For the cisplatin gels the 
reaction (Figure 5.17) could account for these bands, but for the other reagents it 
is not obvious what the covalent species are.
The equivalent gels for B l, B3 and B5 using the same proteins that gave 
crosslinked complexes, with no oxidising agents present were run. There were no 
bands present in any of the lanes, except oxidised oligonucleotide. The absence of 
bands in the wild-type control, indicates that the wild-type bands require the 
presence of oxidants and the bands seen with the mutant proteins are real.
The smeary retarded band (xlink 3) in Figures 5.11, 5.12, 5.13 and 5.1
6 could be due to large protein aggregates that are insensitive to SDS present in 
the gel. When the reagent cisplatin was used there were marked bands in the
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wild-type controls. This could be due the cisplatin reacting with guanine in the 
DNA and with a nearby reactive amino group, e.g. lysine at position 177 (Figure 
5.17). X-link (2) could be due to extra protomers being oxidised as in Figure 
5.18.
5.10 Discussion
Initial expectations for levels of crosslinking were unknown. Unfortunately, the 
levels of crosslinking obtained were lower than hoped for.
The two major components required for the disulfide crosslinking approach, the 
novel cysteine mutants (Chapter 3) and the thiol-containing oligonucleotides 
(Chapter 4), were produced during this work.
The evidence for crosslinking is the bands observed on the denaturing SDS Tris- 
glycine gels (Figure 5.10-5.16) that were covalent protein-DNA complexes, 
sensitive to proteinase K treatment, suggesting that the bands did not arise from 
DNA/DNA crosslinking; the disappearance of the crosslinked complexes on 
treatment with proteinase K; and the absence of any protein-DNA adducts when 
the crosslinking reactions were carried out in the absence of oxidants, indicating 
that the crosslinking was dependent on the thiols and being oxidised to sulfides.
The formation of thiol-dependent crosslinks was further confirmed by the 
following; the amount of crosslinking was increased when cysteine mutants and 
thiol-containing oligonucleotides were used, as compared to crosslinking with the 
wild-type protein and unmodified oligonucleotides.
The mutation of important residues in the recognition helix was expected to 
diminish binding to the DNA. However the mutants A171C, S173C and K177C 
were still able to bind to both wild-type and modified site I oligonucleotides, 
although more weakly than wild-type resolvase. The pKa of a cysteine thiol is 
about 9.5, meaning that at pH 9.5 50% of the thiol would be ionised. As the
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Figure 5.17 Additional bands in cisplatin reactions
The cisplatin could crosslink a guanine base to a nearby lysine, as shown 
above.
SH
modified site I
(1)
1. Binding and crosslinking reaction
Figure 5.18 The additional band in crosslinking gels
Species A indicates a disulfide between a modified strand and one dimer of 
cysteine mutant. In B an additional oxidised species may be formed. N 
denotes the N-terminal domain of resolvase and C indicates the C-terminal 
binding domain.
the cysteine thiols may have been negatively charged, which may cause a 
repulsion between it and the similarly ionized thiol present in the oligonucleotide. 
This factor would contribute to the reduced binding that was observed. In order to 
generate more of the protonated thiol species, the crosslinking reactions were 
carried out in Tris buffer at pH 7.5. However, this did not cause a greater amount 
of crosslinking.
Another factor that could contribute to the reduced levels of crosslinking is the 
amount of thiol present in the modified oligonucleotides themselves. There could 
be decreased amount of thiol present due to incomplete deprotection with 
p-mercaptoethanol (Section 5.4). From the alkylation experiment (Figure 5.3), it 
was calculated that around 90% of the free thiol was alkylated, meaning that 10% 
of the oligonucleotides still contained the DNP group. The thiol within the 
oligonucleotides may have been lost or chemically altered and this would reduced 
the amount available for crosslinking.
The type of thiol modification used, replaces the methyl group of thymidine with 
a thiol moiety. Within the pyrimidine ring system of thymidine there is an a -f-  
unsaturated ketone which activates the 6-position and deactivates the 5-position. 
Thus delocalisation of the thiol lone pair throughout the pyrimidine ring renders 
the thiol less nucleophilic, and forms a thione group as shown in Figure 5.19. It 
was hoped that the equilibrium between these two states would be such that any 
tautomerisation from the thione to the thiol would result in disulfide bond 
formation to the thiol from the protein. The thiol form should be stabilised due to 
conjugation in the pyrimidine ring. The thione moiety has a characteristic UV 
absorbance that was not detected (Chapter 2).
The cysteine thiol present in the mutant resolvases and the thiol in the 
oligonucleotides may simply have been too far apart for high levels of 
crosslinking to be achieved. The distances taken from the co-crystal structure 
(Table 4.1), suggested that the two reacting thiols in Y176C and B3 were close
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Figure 5.19 Thiol-thione tautomerisation
The thiol at the 5-position of the pyrimidine ring can exist in two forms, 
the free thiol and the thione conformation.
enough (<5.6 A) to form disulfides. The distances were longer for all the other 
possible combinations of modified oligonucleotide and cysteine thiol. Perhaps the 
thiols did not form close enough interactions to be crosslinked.
In order to determine whether the retarded band present in the binding gels 
(Figure 5.6 and 5.7) contained a covalent disulfide linkage, a 2D gel was run, 
with the normal binding gel in the first dimension and an SDS gel in the second 
dimension. This should cause dissociation of any non-covalent complexes, while 
maintaining the integrity of the covalent complex. Unfortunately the result of the 
gel was inconclusive (data not shown).
Although the site IDNA used in the crosslinking had nearly identical binding 
motifs at each end, there was a noticeable difference in the crosslinking efficiency 
of each half site. All the top strand modifications were in the left hand side of site 
I, whereas the bottom strands were at the right half. All attempts to form 
crosslinks with the top strand-modified oligonucleotides T l, T3 and T4 failed, 
protein-DNA complexes being isolated for bottom strand B l, B3 and B5 
modified oligonucleotides only. It has previously been shown that the left half of 
site II binds more strongly to resolvase (Blake et a l, 1995), and previous work 
indicated that the order of half-site binding affinities, from strongest to weakest, 
were III-L -  II-L > I-R > III-R -  I-L > II-R (Abdel-Meguid et a l, 1984).
When performing the spatial analysis (Table 4.1) of the distances between the p- 
carbon atom of the amino acid to be mutated and the 5-position of the thymidines 
in the region, it was obvious that there were differences in the distances between 
the protein and the bases at each end of the crystallographic site I DNA (Yang 
and Steitz, 1995). The distances between the protein and the DNA at one side of 
the oligonucleotides were marginally smaller than the equivalent contacts at the 
other side. However, as the oligonucleotide in the co-crystal structure (Yang and 
Steitz, 1995) is symmetrical in sequence, it is impossible to say whether the side 
that is closest is relevant to the crosslinking results obtained here.
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The lack of crosslinked complexes with modifications at the left hand side of site 
I DNA may indicate that a stronger interaction occurs at the right side of the 
protein-DNA complex, so introducing modifications there has a greater effect. 
The right end monomer may bind first to the DNA in a strong interaction. Once 
this right side monomer-protein DNA complex is formed a second monomer may 
bind at the left side of the DNA. Once dimerisation is complete, the right end 
which bound first may be held more tightly to the DNA than the left side.
Position 176 is the closest of all the mutated residues to the DNA. It forms both 
hydrophobic and electrostatic interactions with the bases, and in the wild-type 
protein the tyrosine residue is essential for maintenance of the recognition helix. 
Previously it was shown that the mutant Y176C is defective in binding and has 
reduced recombination activity. The presence of crosslinked complexes shows 
that covalent bonds have been formed between the protein and the site I DNA.
Similarly R172 has many important interactions with the DNA, bound to res 
DNA very weakly, and had no full recombination activity. However it did form 
crosslinks with double stranded oligonucleotides containing thiol modifications at 
positions B1 and B3.
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Chapter 6: Investigation of the stereochemical properties 
of Tn3 resolvase
6.1 Introduction
The stereochemical course of the strand exchange reaction involved in site 
specific recombination by the Tn3 resolvase will be determined by making 
reaction substrates that contain phosphorothioates. The number of catalytic steps 
can be inferred from the stereochemistry of a phosphorothioate. For one-step (or 
any odd number of) transesterifications there will be inversion of the chirality, 
and for a two step (or any even number) mechanism the chirality of the phosphate 
will be retained.
The replacement of one non-bridging oxygen atom of a DNA phosphodiester by a 
sulfur atom in the phosphorothioate is a conservative change, as the negative 
charge of the phosphate group is retained, and the size of the sulfur atom is only 
slightly larger than the oxygen atom. The change does, however, make the 
phosphorus centre chiral; that is, there are two diastereoisomeric forms of a 
phosphorothioate linkage (Figure 6.1). Phosphorothioates have been shown to 
possess greater resistance to enzymatic cleavage at the internucleoside linkage, 
and the sulfur atom is more nucleophilic than oxygen.
Use of phosphorothioates in studying protein/DNA interactions has been 
extensive (reviewed in Verma and Eckstein, 1998). Site-specific incorporation of 
phosphorothioates has been used to study reaction mechanisms of restriction 
enzymes such as EcoRl (Connolly et al., 1984) and EcoRV (Grasby and 
Connolly, 1992), HIV integration (Engelman et al., 1991) and site-specific 
recombination (Kitts and Nash, 1988a). In addition, phosphorothioates have been 
used to identify oxygen atoms responsible for or involved in the interaction of 
specific phosphate groups with proteins via incorporation of RP and SP linkages at 
the recognition sites for EcoRl (Kurpiewski et al., 1996) and EcoRV (Thorogood 
et al., 1996).
The phage Mu system was studied using a chiral phosphorothioate to work out 
the number of steps at the strand transfer step, a transesterification reaction
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Figure 6.1 The enantiomeric configurations of a phosphorothioate
(1) The sulfur atom renders the phosphodiester of the intemucleotide 
linkage chiral. The two enantiomeric conformations are indicated above 
as SP and RP. (2) shows the nucleophilic attack at a phosphorus centre 
each attack being equivalent to an inversion of the stereochemistry of that 
phosphorus.
(Mizuuchi and Adzuma, 1991). The preference for R or S phosphorothioates at 
the transesterification reactions, catalysed by Tn 10 transposase (Kennedy et al, 
2000) was also investigated. Phosphorothioates were used to study the 
mechanism of site-specific recombination in phage X (Kitts and Nash, 1988b). 
Substitution of phosphorothioate for phosphate in one strand of the recombination 
site resulted in a block in recombination, leading to accumulation of Holliday 
structures.
EcoRV  restriction endonuclease, acting on a chiral phosphorothioate, shows 
specificity for one (the RP) diastereoisomer; that is, EcoRV only cleaves 
oligonucleotides that contain a Rp phosphorothioate (Grasby and Connolly, 1992).
This selectivity of EcoRV is used here to study the stereochemistry of the 
resolvase strand exchange reaction, which requires the breakage and religation of 
phosphodiester bonds in the DNA backbone. By introducing a phosphorothioate 
and an EcoKV site at the site in the DNA where resolvase cleaves and religates, it 
should be possible to determine the stereochemistry of stand exchange, and hence 
the number of catalytic steps during strand exchange. The currently proposed 
mechanism involves two catalytic steps; that is two nucleophilic steps, the first 
involves nucleophilic attack of the crossover site by serlO of resolvase, forming 
the covalent protein-DNA complex. The second nucleophilic attack occurs via the 
3' hydroxyl from the opposite strand, leading to recombinant products (Figure 
1.16).
6.2 Construction of modified substrates
For X integrase, the phosphorus of the phosphodiester that is cleaved is attached 
to the 3' end in the intermediate, whereas with resolvase the phosphorus is on the 
3' end. The nature of the X int intermediate allowed the use of a strategy (Kitts 
and Nash, 1988a) to characterize the phosphorothioate stereochemistry, by 
digestion of the DNA with nucleases which are specific to either the R or S 
stereoisomers of the phosphorothioate. If the phosphorus 5' of the
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phosphorothioate is labelled, the phosphorothioate refactory to cleavage can be 
detected as a labelled dinucleotide. The nature of the resolvase intermediate 
precludes the use of this strategy.
With X integrase, the 5’ 32P label and the phosphorothioate remain on the same 
nucleotide before and after strand exchange. With Tni resolvase, strand exchange 
joins the left half of one site I in res to the right hand site of the equivalent res 
after strand exchange if the phosphorothioate and the label were at the same site I, 
the recombinant circle would either only be labelled or contain a 
phosphorothioate (not both).
An EcoRV site can be created at the centre of site I, by mutating 3 bp of natural 
site I, such that resolvase and EcoRV both cut the same phosphodiester. This is a 
feasible strategy because both EcoRV and resolvase cleave a phosphodiester after 
an AT dinucleotide at their recognition sequences.
A phosphorothioate would be introduced at the scissile bond using 
oligonucleotides. The substrate would be resolved using Tn3 resolvase. Then 
EcoRV would be used to determine the phosphorothioate chirality in the product 
(see Section 6.1). This approach requires that the recombinant site also contains 
an EcoRV site, so the partner site had to be mutated as well. The natural res 
binding site I was mutated at 3 bp to create an EcoRV site (Figure 6.2.1). A 
modified oligonucleotide (pMSRV) of the same sequence, with a chiral 
phosphorothioate at the centre of site I (Figure 6.2.2) was also made (Section 
3.25).
The resolvase should change the configuration of the phosphorothioate or not, 
depending on how many steps the reaction proceed in, i.e. ( an odd or even 
number). The configuration at the centre of site I in the cleaved intermediate is 
illustrated in Figure 6.3.
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(1) TAATATTTt
natural res site I
ATGATATC
TACTATAGt
‘ EcoRV ’ res site I
(2)
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Figure 6.2 Sequences of the middle of site I of res
(1) The natural palindromic sequence is shown on the left. The 
'EcoRV' site I on the right has 3 bp changed from the natural res site I, 
creating the recognition sequence for EcoRV. The site is was derived from 
pMS53 (M. Burke; Figure 6.5). The arrows indicate the positions where 
resolvase cleaves the DNA. In the 'EcoRV' site I, the cleavage by 
resolvase in the top strand is at the same position as cleavage by EcoRV.
(2) shows the clonable SsfI-£coRI site I oligonucleotide containing an 
EcoRV  site at the centre of the site. The recognition sequence for EcoRV 
is underlined. The top strand 40-mer contains a phosphorothioate (S) 
between the TA as indicated. The bases mutated from wild-type are 
indicated in bold.
oEnz- o- S-
OH O
Sst I -GAT ATC 
-C TATAG-
EcoRl
Enz O'
Q OH
O-
O
Figure 6.3 The configuration at the crossover site of the cleaved intermediate
Illustration of the configuration of the phosphorothioate at the central AT 
of site I, once the strands have been cleaved. Enz = resolvase. The 
radiolabelled phosphate is shown as a blue dot.
The construction of pMSH2 is shown in Figure 6.4. The res site in pMSH2 that 
has an EcoRV site at the centre of the crossover site will be modified with the 
phosphorothioate-containing oligonucleotide, and the DNA will be reconstituted 
into a supercoiled substrate (Section 3.36), radiolabelled with 32P at the EcoRl
32site (Section 3.16). This will ensure that the P goes to the same place as the top 
strand phosphorothioate on resolution (Figure 6.5).
The plasmid pMS53 contains two res sites in direct repeat. One is a wild-type site 
and the other has an EcoRV site at the centre of site I. The modified res sites in 
pMSH2 contain an EcoRV site at the centre of one site I and an "EcoRV half site" 
at the other, so that the resolution product also contains an EcoRV site.
6.3 Resolution of pMSH2
Once the substrate pMSH2 was constructed, it was important to check that the 
resolution product contained an EcoRV site in the small circle. The resolution 
reaction of pMSH2 is shown in Figure 6 .6 . Both wild-type protein and D102Y 
(hyper-reactive mutant; Arnold, 1998) were used to resolve the substrates 
containing the mutated res sites. There is greater resolution with the D102Y 
mutant than with the wild-type protein (Figure 6.6 compare lanes 9 and 2). The 
digestion with Bglll yields a linear 2.4 kbp fragment and a 800 bp supercoiled 
fragment. When the resolution products were cut with EcoRV, a linear 800 bp 
product and a supercoiled 2.4 kbp product were observed. Therefore the EcoRV 
site is in the smaller circle on resolution, as predicted.
6.4 ZscoRV titration of pMSH3
The phosphorothioate-containing 32P labelled oligonucleotides were ligated into 
pMSH2 (Mclllwraith, 1995), yielding pMSF13 as the recombination substrate.
The results of an EcoRV titration of pMSH3 are shown in Figure 6.7. The 
experiment was carried out in duplicate (set A and B) and the resulting intensity 
of the bands were determined by quantitation of the phosphoimage using the 
MacBas program.
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Figure 6.5 Resolution of supercoiled substrate pMSH2
The substrate was designed so that when it is resolved, the chiral 
phosphorothioate and the radiolabel are both in the smaller recombinant 
circle. The radiolabelled phosphate is shown as a blue asterisk.
Figure 6.6 Resolution of pMSH2
R = recombinant, sc = supercoiled, oc = open circle, 1 = linear, nr = non recombinant
The reactions were carried out in MD 10 buffer (50 mM glycine/NaOH pH 10, 5 mM 
EDTA, 5 mM spermidine). Proteins were added to DNA and reacted at 37 °C for 60 
minutes. Size markers are shown on the right.
Lane 1 - pMSH2 + neat wild-type resolvase
2 - pMSH2 + 2-fold dilution of wild-type resolvase
3 - pMSH2 + 4-fold dilution of wild-type resolvase
4 - pMSH2 + 8-fold dilution of wild-type resolvase
5 - pMSH2 + neat D102Y
6 - pMSH2 + 2-fold dilution of D102Y
7 - 1 Kb ladder
8 -13 as lanes 1-6 + BqlW
14 - 1 Kb ladder
15 - 20 as lanes 1-6 + EcoRV
1 2  3 4 5 6 7 8
Figure 6.7 Titration of supercoiled pMSH3 with EcoRV
L = linear, n = nicked, sc = supercoiled
Two radiolabelled bands result when the supercoiled substrate is cut with 
EcoRV. The top band represents nicked plasmid only (the strand with SP 
modification). The top strand is linearised and represents the RP isomer. The 
ratio of nicked to linear is 50%, expected from the chiral phosphorus. The 
unlabelled DNA is fully digested at all concentrations of EcoRV (lanes 1-4).
Lane 1 - pMSH3 + 1 unit of EcoRV
2 - pMSH3 + 5 units of EcoRV
3 - pMSH3 + 10 units of EcoRV
4 - pMSH3 + 20 units of EcoRV
5 - 8 - phosphoimage of 1-4.
Table 6.1 Quantitation of EcoRY digestion
Lane
5A
Lane
5B
Lane
6A
Lane
6B
Lane
7A
Lane
7B
Lane
8A
Lane
8B
Mean
±SD
nicked 32.57 33.29 33.00 37.96 49.81 49.95 42.35 42.45 40.17
±2.61
linear 56.01 55.29 60.00 51.66 50.19 50.05 44.96 57.55 53.21
±2.13
uncut 11.43 11.72 5.88 10.39 5.82 6.01 8.54 
± 1.78
The titration of pMSH3 with EcoRY shows that the DNA is cut as expected. 
Unlabelled pMSH2 was added to the titration in order to compare the results (see 
Figure 6.7, lanes 1-4 contain linear pMSH2). The radiolabelled pMSH3, 
containing the racemic phosphorothioate, gives three products on treatment with 
EcoRY  (see Figure 6.7, lanes 5-8).
The Rp-containing strand and the wild-type strand were cut to completion, 
yielding the linear product. The more retarded band represents nicked substrate, 
where the EcoRY nicked the SP isomer in the wild-type strand. The ratio of linear 
to nicked is 50:50, as predicted for the racemic phosphorothioate. The third band, 
below the linear band may represent residual supercoiled substrate, suggesting 
that the phosphorothioate-containing radiolabelled substrate is cut less efficiently 
than the natural plasmid.
6.5 Resolution of pMSH3
The ratio of diastereoisomers is 50:50, as shown in Figure 6.7. When carrying out 
resolution reactions on pMSH3, a known quantity of cold non-phosphorothioate 
pMSH2 was added, so that both the cold and the labelled reaction products could 
be monitored. All reaction products were run on 1.5% agarose gels (Section 
3.21), then dried and analysed with the phosphoimager (Section 3.29.2).
The results of the first resolution assay with pMSH3 are shown in Figure 6 .8 .
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Figure 6.8 Resolution of pMSH3
R = recombinant, nr = non recombinant, n = nicked, sc = supercoiled, 1 = linear
The reactions were carried out in MD 10 buffer (50 mM glycine/NaOH pH 10, 5 
mM EDTA, 5 mM spermidine). Proteins were added to DNA and reacted at 37 
°C for 60 minutes.
Lane 1 - pMSH3 + dilution buffer
2 - pMSH3 + 2-fold dilution of wild-type resolvase
3 - pMSH3 + undiluted D102Y resolvase
4 - lane 1 + BglU
5 - lane 2 4- BglII
6 - lane 3 + Bglll
7-12 - phosphoimage of lane 1-6
1 2  3 4 5 6 7 8
Figure 6.9 Resolution of pMSH3
R = recombinant, nr = non recombinant, n = nicked, 1 = linear, sc = supercoiled
The reactions were carried out in MD 10 buffer (50 mM glycine/NaOH pH 10, 5 
mM EDTA, 5 mM spermidine). Proteins were added to DNA and reacted at 37 
°C for 60 minutes.
Lane 1 - pMSH3 + undiluted D102Y
2 - lane 1 + BglN
3 - lane 1 + 1 unit EcoRV
4 - lane 1 + 5 units EcoRV
5 -8 phosphoimage of lanes 1 - 4
More resolution occurred with the D102Y mutant than with wild-type resolvase. 
The corresponding phosphoimage shows that the smaller circle remains labelled 
after resolution. There is almost no resolution product from wild-type resolvase, 
indicating that the modifications at the crossover site are inhibiting the reaction.
Figure 6.9 shows a resolution reaction under optimized conditions. The 50:50 
mixture of nicked to linear DNA in the EcoRV digest is very apparent for the 
resolution substrate. However, only approximately 12% recombination occurred, 
so it is impossible to predict the source of the linear labelled product. The 
reaction requires a much higher recombination efficiency before it can be 
deduced whether the linear or nicked band is depleted, as the amount of the 800 
bp linear product increases. This would correlate directly with the preference of 
Tn3 resolvase for RP or SP phosphorothioates.
6.6 Discussion
All attempts to improve the efficiency of the recombination of the modified 
substrate pMSH3 were unsuccessful. Increasing the concentration of enzyme and 
reaction times did not improve recombinational efficiency. It was concluded that 
the phosphorothioate at the crossover site is severely inhibiting the recombination 
reaction, and that any recombination products observed were from a small portion 
of pMSH3 that did not contain any phosphorothioate (i. e. had a natural 
phosphodiester at the point of cleavage). The inefficiency of the reaction was 
probably due to a combination of the mutations in both res sites in the substrate, 
and the phosphorothioate modification. The EcoRV site in the resolution 
substrates alone does not account for the inefficiency, since the cold substrate 
pMSH2 resolved fairly well with wild-type resolvase. The introduction of both 
mutated res site Is in pMSH2, gave no recombination with wild-type resolvase, 
but the substrate was resolved with D102Y. However, the phosphorothioate 
modification in pMSH3 caused a decrease in the efficiency of recombination, 
even with D102Y. Both Rp and SP configurations of the phosphorothioate inhibit
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recombination. The strategy of using EcoRV to determine the phosphorothioate 
stereochemistry is therefore impracticable.
The experiment might be feasible with wild-type substrate with a 
phosphorothioate-modified oligonucleotide (i.e. no EcoRV) sites. A wild-type 
substrate e.g. pMM5 could be modified with a wild-type Sstl-EcoRI site (32P- 
labelled as before). After resolution the recombinant product, containing the 
chiral phosphorothioate could be cut with Psil and radiolabelled. Psil cuts at the 
centre of site I sequence TTAJ/ATT. Following purification of the products an 
enzymatic resolution could be carried out. The nuclease PI cleaves SP 
diastereoisomers of phosphorothioates only and snake venom phosphodiesterase 
cleaves RP diastereoisomers of phosphorothioates only. If the purified 
recombinant product cuts with either of these nucleases and it should be possible 
to determine which isomer was preferentially hydrolysed.
6.7 Future Experiments
Another possible approach to solve this complex problem would be to purify 
chiral phosphorothioate oligonucleotides using HPLC on a chiral column. The 
study of the chirality of the strand transfer step of phage Mu used 24-mer 
oligonucleotides (Mizuuchi and Adzuma, 1991). This strategy proved to be too 
problematic in this work. The phosphorothioate modification is at the centre of a 
48-mer oligonucleotide. Separation of the stereoisomers was therefore very 
difficult. The columns were run at elevated temperatures, but the length of the 
oligonucleotide was such that the subtle differences in chirality were too small to 
detect.
Another approach would be to make the target oligonucleotide out of two shorter 
pieces. T T A -I T(S)A T. The oligo with the phosphorothioate at the 5’ end could 
be separated by the reverse phase method using the trityl group (Mizuuchi and 
Adzuma, 1991). Alternatively, the deprotected form could be purified (Grasby 
and Connolly, 1988). The two pieces would then be religated. This could be done
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32after the P labelling in the final synthetic step, thereby making supercoiled 
plasmid. Or it could be religated as the oligonucleotide, then the religated product 
could be purified.
If EcoRY  is good at discriminating between Rp and Sp phosphorothioates, another 
way to get one stereoisomer would be to cut the double stranded oligonucleotide 
with EcoRY, then purify the uncut DNA. However, only one stereoisomer can be 
obtained in this way.
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Chapter 7: Further Work
7.1 Future Perspectives
Two different approaches were used to study the strand exchange mechanism of 
Tn3 resolvase. The crosslinking approach, would allow us to differentiate 
between different subunits of protein that bind to the three different binding sites, 
by "fixing" a particular subunit to its site. The introduction of a chiral DNA 
substrate at the point of protein-induced cleavage was also used to attempt to 
determine the number of catalytic steps involved in the reaction.
Site-specific crosslinking to Tn3 resolvase using the disulphide approach proved 
to be of limited usefulness. The thiol groups that were introduced, as novel 
cysteine mutants of Tn3 resolvase, gave proteins that had similar binding and 
resolution activity to wild-type protein. However difficulties arose with the thiol- 
containing oligonucleotides and their reactivity. The (protected) thiol-containing 
phosphoramidite that was synthesised was predicted to be reactive enough, 
although chemical degradation might have resulted in less free thiol being 
available to be crosslinked. On the other hand, the mercaptomethyl compound 
was far too reactive, and resulted in the kinetic product of the disulfide (Section 
2.11). An alternative to this would be to use a thiol that was separated from the 
pyrimidine ring by a two carbon chain. This should lead to a reagent of 
intermediate reactivity which may be more able to form disulfides with the 
cysteine thiols. The chemical synthesis that led to the mercaptomethyl analogue 
(Figure 2.8.3) via palladium cross coupling reaction could also be carried out. It 
has been reported that 5-mercaptomethyl uracil was coupled to the sugar portion, 
yielding the desired product. In future this route could be tried, as an alternative 
to the chemistry described in this thesis.
139
Bibliography
S. S. Abdel-Meguid, N. D. F. Grindley, N. S. Templeton and T. A. Steitz, 1984, 
Proc. Natl. Acad. Sci. USA, 81, 2001-2005.
M. Ahmadian and D. E. Bergstrom, 1998, Nucleosides, Nucleotides, 17, 1183- 
1190.
B. Angus and R. G. R. Bacon, 1958, J. Chem. Soc., 774-784.
P. H. Arnold, D. G. Blake, N. D. F. Grindley, M. R. Boocock and W. M. Stark, 
1999, EMBOJ., 18, 1407-1414.
P. Arnold, 1997, PhD thesis
R. W. Armstrong, S. Gupta and F. Whelian, 1989, Tetrahedron Lett., 30, 2057- 
2060.
B. Barbier, M. Charlier and J-C. Maurizot, 1984, Biochemistry, 23, 2933-2939.
T. J. Bardos, M. P. Kotick and C. Szantay, 1966, Tett. Lett., 16, 1759-1764.
T. J. Bardos, R. R. Herr and T. Enkoji, 1955, J. Am. Chem. Soc., 77, 960-963.
B. Bartholomew, G. A. Kassavetis, B. R. Braun and E. P. Geiduschek, 1990, 
EMBO J., 9, 2197-2205.
B. Bartholomew, B. R. Braun, G. A. Kassavetis, and E. P. Geiduschek, 1994, J. 
Biol. Chem., 269, 18090-18095.
S. L. Beaucage and R. P. Iyer, 1993, Tetrahedron, 49, 1925-1963.
H. W. Benjamin and N. R. Cozzarelli, 1986, In proceedings of the Robert A. 
welch Foundation Conferences on Chemical Research, (Welch Foundation, 
Houston), pl07-126.
A. L. Bednarz, M. R. Boocock and D. J. Sherratt, 1990, Genes Dev., 4, 2366- 
2375.
D. E. Bergstrom, P. Beal, J. Jenson and X. Lin, 1991, /. Org. Chem., 56, 5598- 
5602.
B. H. C. Birnhoim and J. Doly, 1979, Nucleic Acids Res., 6 , 1513-1523.
D. G. Blake, 1993, PhD thesis.
D. G. Blake, M. R. Boocock, D. J. Sherratt and W. M. Stark, 1995, Current Biol., 
5, 1036-1046.
E. E. Blatter, Y. W. Ebright and R. E. Ebright, 1992, Nature, 359, 650-652.
140
C. Bleasdale and S. B. Ellwood and B. T. Golding, 1990, J. Chem. Soc., Perkin 
Trans. 1, 803-804.
J. B. Bliska, H. W. Benjamin and N. R. Cozzarelli, 1991, J. Biol. Chem., 226, 
2041-2047.
M. R. Boocock, L. J. Brown and D. J. Sherratt, 1987, In DNA Replication and 
Recombination, T. J. Kelly and R. McMacken, eds. (Alan R. Liss, New York), 
pp703-718.
M. R. Boocock, X. Zhu and N. D. F. Grindley, 1995, EMBO J., 14, 5129-5140.
F. G. Bordwell and H. M. Andersen, 1953, J. Amer. Chem. Soc., 75, 6019-6022.
D. H. Bradley and M. M. Hanna, 1992, Tetrahedron Lett., 33, 6223-6226.
J. L. Brown, 1986, PhD thesis.
L. Campanini, A. Dureault and J. C. Depezay, 1995, Tetrahedron Lett., 36, 8015- 
8018.
G. Chang and M. P. Mertes, J. Org. Chem., 52, 3625-3631.
Y. Chen and R. H. Ebright, 1993, J. Mol. Biol., 230, 453-460.
B. C. F. Chu and L. E. Orgel, 1988, Nucleic Acids Res., 16, 3671-3691.
B. C. F. Chu and L. E. Orgel, 1992, Nucleic Acids Res., 20, 2497-2502.
R. F. R. Church and M. J. Weiss, 1970, J. Org. Chem., 35, 2465-2471.
M. A. Cleary, P. S. Pendergrast and W. Herr, 1997, Proc. Natl. Acad. Sci. USA, 
94, 8450-8455.
R. E. Cline, R. M. Fink and K. Fink, 1959, J. Am. Chem. Soc., 81, 2521-2527.
B. A. Connolly, B. V. L. Potter, F. Eckstein, A. Pingoud and L. Grotjahn, 1984, 
Biochemistry, 23, 3443-3453.
M. Cowart, S. J. Benkovic and H. A. Nash, 1991, J. Mol. Biol., 220, 621-629.
F. J. Dinan, J. Chodkowski, J. P. Barren, D. M. Robinson and D. V. Reinhardt, 
1982,7. Org. Chem., 47, 1769-1772.
Q. Dong, E. E. Blatter, Y. W. Ebright, K. Bister and R. H. Ebright, 1994, EMBO 
J., 13, 200-204.
P. Dumoulin, P. Oertel-Buchheit, M. Granger-Schnarr and M. Schnarr, 1993, 
Proc. Natl. Acad. Sci. USA, 90, 2030-2034.
141
P. Dumoulin, R. H. Ebright, R. Knegtel, R. Kaptein, M. Granger-Schnarr and M. 
Schnarr, 1996, Biochem., 35, 4279-4286.
Y. Endo, K. Shudo and T. Okamoto, 1982, J. Am. Chem. Soc., 104, 6393-6397.
A. Engelman, K. Mizuuchi and R. Craigie, 1991, Cell, 67, 1211-1121.
H. A. Flaschka, A. J. Barnard and P. E. Sturrock, 1969, in Quantitative Analytical 
Chemistry, Short Introduction to Practice, Barnes & Noble, Inc., New York 
R. Gill, F. Heffron and S. Falkow, 1979, Nature, 282, 797-801.
A. Giner-Sorolla and L. Medrek, 1966, J. Med. Chem., 9, 97-101.
A. Giner-Sorolla and L. Medrek, 1978, in "Nucleic Acid Chemistry" Part 1, L. B. 
Townsend and R. S. Tipson, Eds, pp. 83-85.
G. D. Glick, 1991, /. Org. Chem., 1991, 56, 6746-6747.
J. Goodchild, 1990, Bioconj. Chem., 1, 165-187.
J. T. Goodwin and G. D. Glick, 1993, Tett. Lett., 35, 5549-5552.
J. A. Grasby and B. A. Connolly, 1992, Biochemistry, 31, 7855-7861.
N. D. F. Grindley, 1993, Science, 262, 738-740.
N. D. F. Grindley, 1994, In Nucleic Acids and Molecular biology, Vol 8 , eds. F. 
Eckstein and D. M. J. Lilley pp. 236-267.
E. S. Gruff and L. E. Orgel, 1991, Nucleic Acids Res., 19, 6849-6854.
V. S. Gupta, G. L. Bubbar, J. B. Meldrum and J. R. Saunders, 1975, J. Med. 
Chem., 18, 973-976.
M. M. Hanna, S. Dissinger, B. D. Williams and J. E. Colston, 1989,
Biochemistry, 28, 5814-5820.
M. M. Hanna, Y. Zhang, J. C. Reidling, M. J. Thomas and J. Jou, 1993, Nucleic 
Acids Res., 21, 2073-2079.
M. E. Harris, J. M. Nolan, A. Malhotra, J. W. Brown, S. C. Harvey and N. R. 
Pace, 1994, EMBO J., 13, 3953-3963.
G. F. Hatfull and N. D. F Grindley, 1986, Proc. Natl. Acad. Sci. USA, 83, 5429- 
5433.
G. F. Hatfull and N. D. F. Grindley, 1988, In genetic Recombination, R. 
Kucherlapati and G. R. Smith, eds. (American Society forMicrobiology, 
Washington, DC), p357-396
142
M. E. Harris, J. M. Nolan, A. Malhotra, J. W. Brown, S. C. Harvey and N. R. 
Pace, 1994, EMBO J., 13, 3953-3963.
H. Hayakawa, H. Tanaka, K. Obi, M. Itoh and T. Miyasaka, 1987, Tetrahedron 
Lett., 28, 87-90.
B. He, D. L. Riggs and M. M. Hanna, 1995, Nucleic Acids Res., 23, 1231-1238.
F. Heffron, B. J. McCarthy, H. Ohtsubo and E. Ohtsubo, Cell, 18, 1153-1163.
K. Hideg, C. P. Sar, O. H. Hankovszky, T. Tamas and G. Jerkovich, 1992, 
Synthesis, 390-394.
H. Huang, R. Chopra, G. L. Verdine and S. C. Harrison, 1998, Science, 282, 
1669-1675.
R. E. Hughes, G. E. Hatfull, P. Rice, T. A. Steitz and N. D. F. Grindley, 
1990,0?//., 63, 1331-1338.
R. E. Hughes, P. Rice, T. A. Steitz and N. D. F. Grindley, 1993, EMBO J., 12, 
1447-1458.
K. B. Jensen, B. L. Atkinson, M. C. Willis, T. H. Koch and L. Gold, 1995, Proc. 
Natl. Acad. Sci. USA, 92, 12220-12224.
M. Katouzian-Safadi, B. Laine, F. Chartier, J. Cremet, D. Belaiche, P. Sautiere 
and M. Charlier, 1992, Nucleic Acids Res., 19, 4937-4941.
A. K. Kennedy, D. B. Haniford and K. Mizuuchi, 2000, Cell, 101, 295-305.
E. Kilbride, M. R. Boocock and W. M. Stark, 1999, J. Mol. Biol., 1999.
L. Kimzey and W. S. Dynan, 1998, J. Biol. Chem., 273, 13768-13775.
P. A. Kitts and H.A. Nash (a), 1988, Nucl.Acids.Res., 16, 6839-6856.
P. A. Kitts and H. A. Nash (b), 1988, J. Mol. Biol., 1988, 204, 95-107.
N. Kharasch, W. King and T. C. Bruice, 1955, J. Am. Chem. Soc., 11, 931-934.
A. Klippel, G. Mertens, T. Patschinsky and R. Kahmann, EMBO J., 1, 1229- 
1237.
M. P. Kotick, C. Szantay and T. J. Bardos, 1969, J. Org. Chem., 34, 3806-3813. 
M. Kulka, 1956, Can. J. Chem., 34, 1093-1100.
M. R. Kurpiewski, M. Koziolkiewicz, A. Wilk, W. J. Stec and L. Jen-Jacobson, 
Biochemistry, 35, 8846-8854.
143
T. Lagrange, T. K. Kim, G. Orphanides, Y. W. Ebright, R. H. Ebright and D. 
Reinberg, 1996, Proc. Natl. Acad. Sci. USA, 93, 10620-10625.
P. Langen and D. Barwolff, 1975, Acta biol. med. germ.., 34, K7-K10 and 1975, 
German Patent No. 114949.
K. Lee and J. Hayes, 1997, Proc. Natl. Acad. Sci. USA, 94, 8959-8964.
C. H. Lee and Y. H. Kim, 1991, Tetrahedron Lett., 32, 2401-2404.
J. Leonard, B. Lygo and G. Procter, 1989, In Advanced Practical Organic 
Chemistry, Stanley Thornes (pubs)pp. 69-74.
A. E. Leschziner, M. R. Boocock and N. D. F. Grindley, 1995, J. Mol.
Microbiol., 15, 865-870.
T. S. Lin and Y. S. Gao, 1983, J. Med. Chem., 26, 598-601.
T. Lui, E. F. DeRose and G. P. Mullen, 1994, Protein Science, 3, 1286-1295.
T. Lui, D. Lui, E. F. DeRose and G. P. Mullen, 1993, J. Biol. Chem., 268, 16309- 
16315.
J. Liu, M. Sodeoka, W. S. Lane and G. L. Verdine, 1994, Proc. Natl. Acad. Sci. 
USA, 91, 908-912.
M. T. H. Lui, 1986, In Chemistry of Diazirines Vol.II, CRC Press Inc. Boca 
Raton Florida, Florida pp. 77-81.
A. MacDonald, 1999, PhD thesis.
A. M. MacMillan and G. L. Verdine, 1991, Tetrahedron, 47, 2603-2616.
V. A. Maikov, I. Biswas, R. D. Camerini-Otero and P. Hsieh, 1997, J. Biol. 
Chem., 212, 23811-23817.
D. J. Martin and C. C. Greco, 1968, J. Chem. Soc., 1275-1276.
A. Marquet, F. Frappier, G. Guillerm, M. Azoulay, D. Florentin and J. C. Tabet, 
1993,115,2139-2145.
J. Matulic-Adamic and K. A. Watanabe, 1988, Chem. Pharm. Bull., 36, 1554- 
1557.
J. M. Mazzarelli, M. R. Ermacora, R. O. Fox and N. D. F. Grindley, 1993, 
Biochemistry, 32, 2979-2986.
J. D. McGhee and P. H. von Hippel, 1975, Biochemistry, 14, 1281-1285.
144
McGregor, M. V. Rao, G. Duckworth, P. G. Stockley and B. A. Connolly, 1996, 
Nucleic Acids Res., 24, 3173-3180.
M. J. Mcllwraith, 1995, PhD thesis.
M. J. Mcllwraith, M. R. Boocock and W. M. Stark, 1996, J. Mol. Biol., 260, 299- 
303.
M. J. Mcllwraith, M. R. Boocock and W. M. Stark, 1997, J. Mol. Biol., 266, 106- 
121.
K. M. Meisenheimer and T. H. Koch, 1997, Crit. Rev. Biochem. Mol. Biol., 32, 
101-140.
M. J. Melnick and S. M. Weinreb, J. Org. Chem., 1988, 53, 850-854.
K. L. Meyer and M. M. Hanna, 1996, Bioconj. Chem., 7, 401-412.
A. M. Michelson and A. R. Todd, 1955, J. Chem. Soc., 816-823.
K. Mizuuchi and K. Adzuma, 1991, Cell, 66 , 129-140.
L. L. Murley and N. D. F. Grindley, 1998, Cell., 95, 553-562.
T. Nagamachi, P. F. Torrence, J. A. Waters and B. Witkop, 1972, J. Chem. Soc., 
Chem. Comm., 1025-1026.
T. Nagamachi, J. L. Fourrey, P. F. Torrence, J. A. Waters and B. Witkop, 1974, J. 
Med. Chem., 17, 403-406.
N. Naryshkin, A. Revyakin, Y. Kim, V. Mekier and R. H. Ebright, 2000, Cell, 
101, 601-611.
T. T. Nikiforov and B. A. Connolly, 1992, Nucleic Acids Res., 20, 1209-1214.
K. K. Ogilvie, S. L. Beaucage, A. L. Schifman, N. Y. Theriault and K. L. Sadana, 
1978, Can. J. Chem., 56, 2768-2780.
G. Pashev, S. I. Dimitrov and D. Angelov, 1991, Trend. Biochem. Sci., 16, 323- 
326.
P. S. Pendergrast, Y. Chen, Y. W. Ebright and R. E. Ebright, 1992, Proc. Natl. 
Acad. Sci. USA, 89, 10287-10291.
R. R. Reed and N. D. F. Grindley, 1981, Cell, 25, 721-728.
R. R. Reed and C. D. Moser, 1984, Cold Spring Harbour Symp. Quant. Biol., 49, 
245-249.
V. Rimphanitchayakit and N. D. F. Grindley, 1990, EMBO J., 9, 719-725.
145
V. Rimphanitchayakit, G. F. Hatfull and N. D. F. Grindley, 1989, Nucleic Acids 
Res., 17, 1035-1050.
A. Romieu, S. Bellon, D. Gasparutto and J. Cadet, Organic Lett., 2, 1085-1088. 
M. R. Sanderson, P. S. Rice, P. A. Goldman, G. F. Hatfull, N. D. F. Grindley and 
T. A. Steitz, 1990, Cell, 63, 1323-1329.
Y. S. Sanghvi, Z. Guo, H. M. Pfundheller and A. Converso, 2000, Org. Process 
Res. &Dev., 4, 175-181.
J. Sekiguchi and S. Shuman, 1996, EMBO J., 15, 3448-3457.
P. V. Sergiev, I. N. Lavrik, V. A. Wlasoff, S. S. Dokudovskaya, O. A. Dontsova,
A. A. Bogdanov and R. Brimacombe, 1997, RNA, 3, 464-475.
Y. F. Shealy, C. A. O'Dell, G. Arnett and W. M. Shannon, 1986, J. Med. Chem., 
29, 79-84.
D. Sherratt, 1988, In Mobile DNA, D. E. Berg and H. Howe, eds. (American 
Society for Microbiology, Washington, D.C), pp 163-184.
G. T. Shiau, R. F. Schinazi, M. S. Chen and W. H. Prusoff, 1980, J. Med. Chem., 
23, 127-133.
D. Shore, J. Langowski and R. L. Baldwin, 1981, Proc. Natl. Acad. Sci. USA, 78, 
4833-4837.
N. D. Sinha, J. Biemat and H. Koster, 1983, Tetrahedron Lett., 24, 5843-5846.
W. M. Stark, D. J. Sherratt and M. R. Boocock, 1989, Cell, 58, 779-790.
W. M. Stark and M. R. Boocock and D. J. Sherratt, 1989, Trend Genet., 5, 304- 
309.
W. M. Stark, N. D. F. Grindley, G. F. Hatfull and M. R. Boocock, 1991, EMBO 
J., 10, 3541-3548.
W. M. Stark, M. R. Boocock and D. J. Sherratt, 1992, Trends in Genetics, 8 , 432- 
439.
W. M. Stark and M. R. Boocock, 1995, In Mobile Genetic Elements (Frontiers in 
Mol. Biology Series), D. J. Sherratt, ed., (Oxford University Press), p 101-129.
F. W. Studier, A. H. Rosenberg, J. J. Dunn and J. W. Dubendorff, 1990, Methods 
Enzym., 185, 60-89.
J. G. Sutcliffe, 1978, Cold Spring Harbour Symp. Quant. Biol., 43, 77-90.
146
J. J. Tate, J. Persinger and B. Bartholomew, 1998, Nucleic Acids Res., 26, 1421 - 
1426.
L. A. Taylor and R. E. Rose, 1988, Nucleic Acids Res., 16, 358-360.
B. H. Thorogood, J. A. Grasby andB. A. Connolly, 1996, J.Biol.Chem., 1996,
271, 8855-8862.
R. L. Tinker, G. A. Kassavetis and E. P. Geiduschek, EMBO J. 13, 5330-5337.
A. N. Topin, O. M. Gritsenko, M. G. Brevnov, E. S. Gromova and G. A. 
Korschunova, 1998,Nucleotid. Nucleosid., 17, 1163-1175.
P. F. Torrence, J. A. Waters and B. Witkop, 1978, in "Nucleic Acid Chemistry" 
Part 1, L. B. Townsend and R. S. Tipson, Eds, pp. 367-370.
H. Urlaub, V. Kryft, O. Bischof, E. Muller and B. Wittmenn-Liebold, 1995, 
EMBO J., 14, 4578-4588.
G. G. Urquhart, J. W. Gates and R. Connor, 1955, Org. Synth. , 3, 363-365.
S. Verma and F. Eckstein, 1998, Annu. Rev. Biochem., 67, 99-134.
M. A. Watson, 1994 Ph.D thesis
M. A. Watson, M. R. Boocock and W. M. Stark, 1996, J. Mol. Biol., 257, 317- 
329.
S. Weinswieser, 2001, PhD thesis
J. Welsh and C. R. Cantor, Trends Biol. Sci., 1984, 505-508.
D. L. Wong, J. G. Pavlovich and N. O. Reich, 1998, Nucleic Acids Res., 26, 645- 
649.
K. R. Williams and W. H. Konigsberg, 1991, Method. Enzymology, 208, 516-539. 
M. C. Willis, B. J. Hicke, O. C. Unhelbeck, T. R. Cech and T. H. Koch, 1993, 
Science, 262, 1255-1256.
M. C. Willis, K. A. LeCuyer, K. M. Meisenheimer, O. C. Uhlenbeck and T. H. 
Koch, 1994, Nucleic Acids Res., 22, 4947-4952.
L. J. Wilson, M. W. Hager, Y. A. El-Kattan and D. C. Liotta, Synthesis, 1465- 
1479.
Y. Z. Xu, Q. Zheng and P. F. Swann, 1992, Tett. Lett., 33, 5837-5840 and 
Tetrahedron, 48, 1729-1740.
H. Yang and H. A. Nash, 1994, Proc. Natl. Acad. Sci. USA, 91, 12183-12187.
147
W. Yang and T. A. Steitz, 1995, Cell, 82, 193-207.
C. Yanisch-Perron, J. Vieira and J. Messing, 1985, Gene, 33, 103-119.
E. Yuriev, D. Scott and M. M. Hanna, 2000, J. Mol. Recognit., 12, 337-345 
X. Zhao and D. W, Landry, 1993, Tetrahedron, 49, 363-368.
!gM SG O \y i
VNlVERprrYi
148
